A bifunctional chimeric heterocyclic compound and its use as androgen receptor degrader
By designing a bifunctional chimeric heterocyclic compound, the PROTACs mechanism degraded AR-v7 was used to solve the drug resistance of AR signaling pathway inhibitors, effective inhibition of drug-resistant prostate cancer, and good drug abortion was demonstrated Kinetic properties.
Patent Information
- Application Number
- CN202210910651.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-07-30
- Filing Date
- 2022-07-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-07-29
AI Technical Summary
Existing androgen receptor (AR) signaling pathway inhibitors are prone to drug resistance when treating prostate cancer, especially the lack of effective treatment options for drug resistance caused by AR-v7 mutations. Traditional small molecule inhibitors have drug resistance. and adverse reactions.
Develop a bifunctional chimera heterocyclic compound to degrade AR by targeted recognition and binding to androgen receptors using the mechanism of protein degradation of targeted chimera (PROTACs), including the binding of the TB moiety to the target protein and the U moiety to E3 ubiquitin Binding enzymes promote ubiquitination and degradation of target proteins.
Significantly degrading AR-v7, inhibiting the proliferation of drug-resistant prostate cancer cells, demonstrating good metabolic stability and oral pharmacokinetic properties, and providing a new strategy for the treatment of drug-resistant prostate cancer.
Smart Images

Figure CN115677667B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of drug synthesis, specifically relating to a bifunctional chimeric heterocyclic compound and its uses. Background Technology
[0002] With a continuously growing and aging global population, the incidence of prostate cancer continues to rise, and the main treatment currently is androgen deprivation therapy. The androgen receptor (AR) belongs to the nuclear receptor family and is a class of ligand-dependent transcription factors. Aberrant regulation of the AR signaling pathway plays a crucial role in the occurrence and development of prostate cancer; studies have shown that castration-resistant prostate cancer (CRPC) still depends on AR. The androgen receptor contains 918 amino acids and shares a similar structure and function with other nuclear receptors. It consists of three important domains: the DNA-binding domain (DBD), the ligand-binding domain (LBD), and the N-terminal domain (NTD). The DBD and LBD are connected by a hinge region. The LBD, located at the C-terminus of the AR, is the site where AR binds to ligands, determining the specificity of ligand binding to AR. Ligand binding to the LBD activates AR. Currently, two transcriptional activation functional regions have been identified in the AR pathway: activation function 1 (AF1) in the NTD domain and the highly conserved hydrophobic pocket activation function 2 (AF2) in the LBD domain. Prior to 2010, docetaxel-based chemotherapy was the only treatment that could prolong the survival of patients with metastatic CRPC. Since 2011, the FDA has successively approved three inhibitors of the AR signaling pathway: abiraterone acetate and enzalutamide, approved in 2011 and 2012 respectively for the treatment of metastatic castration-resistant prostate cancer, and apalutamide, which was just approved in 2018 for non-metastatic CRPC.
[0003] Although second-generation AR signaling pathway inhibitors abiraterone and enzalutamide have achieved some success in clinical treatment, resistance has emerged. The F876L mutation in the ligand-binding region is a missense mutation that leads to resistance to enzalutamide, causing it to switch from an antagonist to an agonist. Furthermore, AR splicing mutants, especially the AR-v7 mutation lacking the ligand-binding region, are important causes of second-generation resistance. Therefore, there is an urgent clinical need for novel AR signaling pathway inhibitors to treat CRPC.
[0004] Traditional small molecule inhibitors work by binding to target proteins to inhibit their function. However, long-term use of small molecule drugs inevitably leads to drug resistance. Moreover, in order to achieve the desired effect, small molecule compounds need to be maintained at a certain concentration in cells. However, high concentrations of small molecules can cause adverse reactions due to off-target effects. Therefore, finding small molecule compounds that can overcome these shortcomings is of great significance in new drug development.
[0005] In recent years, protein degradation-targeting chimeras (PROTACs) have attracted widespread attention as small molecules capable of inducing the degradation of target proteins. PROTACs are bifunctional molecules comprising a small molecule compound that binds to the target protein (POI), a linker group introduced at an appropriate position, and a small molecule compound that binds to E3 ubiquitinase. As small molecule probes, PROTACs can simultaneously bind to both the target protein and E3 ubiquitinase, thereby promoting the ubiquitination of the target protein, which is then recognized and degraded by the proteasome.
[0006] Over the past decade, many tumor-associated target proteins (including AR, ER, BRD4, ERRα, RIPK2, etc.) have been shown to be regulated and degraded using PROTACs. Furthermore, recent studies have confirmed the catalytic properties of PROTACs, demonstrating that chimeric molecule concentrations can achieve equivalent therapeutic effects at concentrations lower than those required by single inhibitors. Therefore, novel tumor treatment strategies utilizing PROTACs to induce protein degradation can regulate target protein levels through the intracellular ubiquitin-proteasome degradation system, thereby overcoming the limitations of traditional small molecule inhibitors.
[0007] However, treating drug-resistant cancers remains a major challenge in cancer treatment. Existing drug therapies often lead to drug resistance, resulting in patients having no treatment options and increased mortality. AR mutations (including point mutations and splicing mutations) are a significant cause of drug resistance, and inhibitors targeting the primary splicing mutation, AR-v7, as a therapeutic target have been rarely reported. Therefore, developing novel therapies that degrade AR-v7 to treat drug-resistant cancers is crucial. Summary of the Invention
[0008] This invention provides compounds of Formula I, or optical isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or tautomers thereof, or meso compounds thereof, or racemic compounds thereof, or enantiomers thereof, or diastereomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof, or isotopic alternatives thereof:
[0009]
[0010] Where TB is the target recognition / binding part, L is the linking part, and U is the ubiquitin protease recognition / binding part; the three parts are connected by chemical bonds.
[0011] The TB portion mentioned above has the structure shown in equation IA:
[0012]
[0013] Wherein, A represents none, aromatic ring, heteroaromatic ring, non-aromatic heterocycle, non-aromatic carbon ring, bridged ring, spiro ring, fused heterocycle, and fused heteroaromatic ring; the aromatic ring includes a benzene ring; the aromatic heterocycle includes a 5-6 membered heteroaromatic ring; the non-aromatic heterocycle includes a 3-7 membered non-aromatic heterocycle; the non-aromatic carbon ring includes a 3-7 membered non-aromatic carbon ring; the fused heterocycle includes a 5-6 membered heterocycle and a 5-6 membered heterocycle, and the fused heteroaromatic ring includes a 5-6 membered heteroaromatic ring and a 5-6 membered heterocycle, and a 5-6 membered heteroaromatic ring and a 5-6 membered heteroaromatic ring;
[0014] Among them, R 1 R 2 Each group is independently selected from: ⁵ (absent), ⁵ (hydrogen), halogen, cyano, amino, hydroxyl, C1-C6 alkoxy, C1-C6 alkylamine, C1-C6 alkylmercapto, C1-C6 alkylsulfonyl, C1-C6 alkylsulfonyl, C1-C6 alkylcarbonyl, C1-C6 alkylaminocarbonyl, -NR 3 R 4 -CR a R 3 R 4 -NR 3 -CO-R 4 -CO-NR 3 R 4 -NR 3 -SO2-R 4 -SO2-NR 3 R 4 -CO-R 3 -SO-R 3 -SO2-R 3 -CR 3 =CH2, -OR 3 、-SR 3Substituted or unsubstituted C1-C6 alkyl groups, substituted or unsubstituted 3-8 membered cycloalkyl groups, substituted or unsubstituted heterocyclic groups, substituted or unsubstituted fused heterocyclic groups, substituted or unsubstituted spirocyclic groups, substituted or unsubstituted heteroaromatic groups, substituted or unsubstituted phenyl groups; R 1 R 2 They can be connected to form a ring;
[0015] Wherein, the substituent is R a R 3 R 4 The R a ,R 3 ,R 4 Each of the following groups is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 alkylamine, C1-C6 alkylsulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclic, substituted or unsubstituted heteroaromatic, substituted or unsubstituted phenylyl, and sulfonyl; R a R 3 R 4 Any two of them can be linked to form a 3-8 membered ring; the substituents are selected from halogens, amino groups, hydroxyl groups, and hydroxy-substituted C1-6 alkyl groups;
[0016] Among them, G 1 G 2 Each is independently linked to A via a chemical bond; where G 1 Selected from none, -(CH2) y -、-(CH2) m -CR g1 R g2 -、-(CH2) m -CO-, O, S, SO, SO2, NR g1 G 2 Selected from none, -(CH2) n -CR g3 R g4 -、-(CH2) n -O-,O,S,SO,SO2,NR g2 Where y, m, and n are integers from 0 to 3; R g1 R g2 R g3 R g4 Each of the following is independently selected from hydrogen, C1-C6 alkyl, halogen, and hydroxyl; R g1 and R g2 R g3 and R g4 They can be linked into a ring; when both G1 and G2 are absent, X is directly linked to A through a chemical bond.
[0017] Where X is selected from -N- and -NR 5 -, -O-, -S-, -CO-, -SO-, -SO2-, -CONR 5 -、-NR 5 CO-, -CH-, -CHR 5 -、-CR 5 R 5’ -; The R 5 ,R 5’ Each is independently selected from H and C1-C6 alkyl groups;
[0018] Wherein, rings B and C are independently selected from substituted or unsubstituted benzene rings, thiophenes, pyridines, pyrimidines, 5-6 membered heteroaromatic rings, 3-8 membered cycloalkanes, and 3-8 membered heterocycles; the substituents are halogens or cyano groups;
[0019] Among them, B 1 、B 2 Each element is independently selected from H, halogen, C1-C6 alkyl, or B. 1 、B 2 Connect X to form a loop;
[0020] Where Z represents -C-, -CO-, -CH-, -CH2-, -O-, -N-, -S-, -SO-, -SO2-;
[0021] Among them, T 1 、T 2 Each group is independently selected from unsubstituted, hydrogen, hydroxyl, amino, substituted or unsubstituted C1-C6 alkyl, C1-C6 oxaalkyl, C1-C6 azaalkyl, C3-C6 cycloalkyl, acyl, C1-C6 alkoxy, C1-C6 alkylamine, or T groups. 1 T 2 They can be linked together to form a ring; the substituents are hydroxyl or amino groups;
[0022] Among them, L 1 L 2 Each is independently selected from hydrogen, halogen, cyano, amino, hydroxyl, and C1-C6 alkyl groups;
[0023] Wherein, the L part above is the structure shown in formula IL:
[0024]
[0025] Among them, Q, J, Y, W, and V are independently selected from none, -O-, -S-, -SO-, -SO2-, and -NR, respectively. q1 -、-NR j1 -、-C≡C-、-C=C-、-NR q1 CO-, -NRj1 CO-, -CO-, -CONH-, -NR q11 SO2-, -CR q1 R q2 -、-CR y1 R y2 -、-CR w1 R w2 -、-CR v1 R v2 -、-CR j1 R j2 -、-[(OCH2CH2O)2] n5 -、-[(OCH2CH2O)3] n6 -、R c R d Substituted or unsubstituted 3-7 membered cycloalkyl groups, R c R d Substituted or unsubstituted 3-7 membered heterocyclic groups, R c R d Substituted or unsubstituted phenyl, R c R d Substituted or unsubstituted heterocyclic groups, R c R d Substituted or unsubstituted heterocyclic aromatic groups; the R c R d Each of the following is independently selected from H, halogens, C1-3 alkyl groups; or R c R d They can be connected to form a ring;
[0026] Where R q1 R q2 R y1 R y2 R w1 R w2 R v1 R v2 R j1 R j2 Each of the following is independently selected from H, halogen-substituted or unsubstituted C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 oxaalkyl, C1-C6 aziralkyl, C3-C6 oxacycloyl, and C3-C6 azircycloyl;
[0027] Where R q1 and R q2 R y1 and R y2 R w1 and R w2 R v1 and R v2 R j1 and R j2 They can be interconnected to form a ring;
[0028] Where n1, n2, n3, n4, n5, and n6 are each independently selected from integers from 0 to 6;
[0029] Among them, Q and J can freely choose to connect either the TB part or the U part;
[0030] Wherein, the U part above is the structure shown in formula IU:
[0031]
[0032] Where M is selected from -O-, -S-, -CR m -、-NR m -; where R m Selected from H, C 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 Heterocyclic groups,
[0033] The R m1 Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl;
[0034] X m Selected from -CR m2 R m3 -、-OR m2 -、-NR m2 R m3 -, where R m2 ,R m3 Selected independently from H and C respectively 1-6 Alkyl, C 3-6 cycloalkyl, C 3-6 Heterocyclic group, C 1-6 oxane; R m2 ,R m3 They can be connected to form a ring;
[0035] E 1 E 2 Each is independently selected from -CO-, -CS-, and -NR. e1 -, -O-, -S-, -SO2-, -CH2-, -CD2-, -CR e2 R e3 -、 R e1 R e2 R e3 Selected independently from C 1-6 Alkyl, H, halogen, hydroxyl, amino;
[0036] Y 1 Y2 Y 3 Selected independently from H, O, S, and C respectively. 1-3 alkyl;
[0037] J and k are each independently selected from integers between 0 and 3, and j and k are not both 0 at the same time;
[0038] U 1 、U 2 、U 3 、U 4 Selected independently from O, S, N, and -CR g1 -、-CR g2 -、-CR g3 -、-CR g4 -, where R g1 R g2 R g3 R g4 Each group is independently selected from H, halogen, hydroxyl, amino, mercapto, sulfone, sulfoxide, nitro, cyano, CF3, heterocyclic, and C. 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Alkoxy, C 1-6 alkylamine group, C 2-6 alkenyl, C 2-6 Alkyne group.
[0039] Furthermore, the G in the TB moiety of the above compounds 1 G 2 Atoms different from those on A are connected by chemical bonds as shown in formula II-A, or, G in the TB part 1 G 2 The same atom on A is connected by a chemical bond as shown in formula II-B:
[0040]
[0041] Furthermore, in the above compounds: A is a heteroaromatic ring, G 1 G 2 Not absent, the TB moiety of the compound has a structure as shown in Formula III-A:
[0042]
[0043] where k 1 k 2 k 3 k 4 k 5 Each is independently selected from CH or N, but not both of them are CH.
[0044] Furthermore, in the above compounds: G 1For -CH2-, G 2 The compound is -CH2- or -CH2CH2-, and the TB portion has a structure as shown in formula IV-A or IV-B:
[0045]
[0046] where k 1 k 2 k 3 k 4 Each is independently selected from CH or N, but not both of them are CH.
[0047] Furthermore, in the above compounds: A is a heteroaromatic ring, G 2 The compound TB portion has no structure as shown in formula VA:
[0048]
[0049] Among them, G 1 Not non-existent;
[0050] Or the TB portion of the compound may have a structure as shown in formula VB:
[0051]
[0052] Furthermore, in the above compounds: A is a 6-membered aromatic heterocycle, G 2 The compound has none; the TB portion has a structure as shown in formula VI-A.
[0053]
[0054] Among them, G 1 Not non-existent; z 1 z 2 z 3 z 4 z 5 Each is independently selected from CH or N, and not both of them are CH;
[0055] Alternatively, the TB portion of the compound may have a structure as shown in formula VI-B:
[0056]
[0057] Among them, z 1 z 2 z 3 z 4 z 5 Each is independently selected from CH or N, and not both of them are CH.
[0058] Furthermore, in the above compounds: A is a 5-membered aromatic heterocycle, G2 For none:
[0059] The TB portion of the compound has a structure as shown in Formula VII-A:
[0060]
[0061] Among them, G 1 Not non-existent; x 1 x 2 x 3 x 4 Each of the following is independently selected from CH, N, O, or S, and not all of them are CH at the same time;
[0062] Alternatively, the TB portion of the compound may have a structure as shown in formula VII-B:
[0063]
[0064] Where, x 1 x 2 x 3 x 4 Each is independently selected from CH, N, O, or S, and not all of them are CH at the same time.
[0065] Furthermore, in the above compounds: A is a 5-membered aromatic heterocycle and a 6-membered aromatic heterocycle, G 2 The compound TB moiety is absent; it has a structure as shown in Formula VIII-A.
[0066]
[0067] Where, p 1 p 2 p 3 p 4 p 5 p 6 p 7 p 8 Each is independently selected from CH, N, O, or S, and p 1 p 2 p 3 p 4 At least one of them is not CH, p 2 p 3 p 5 p 6 p 7 p 8 At least one of them is not CH.
[0068] Furthermore, in the above compounds: A is absent, G... 1 G 2 For none, R 1 For hydrogen, R2 The compound TB moiety is free, X is -O-, and has the structure shown in Formula IX-A:
[0069]
[0070] Furthermore, the TB portion of the above-mentioned compound... The part has the structure shown below, where X,X 1 ,X 2 Selected independently from -N- and -NR 5 -, -O-, -S-, -CO-, -SO-, -SO2-, -CONR 5 -、-NR 5 CO-, -CH-, -CHR 5 -、-CR 5 R 5’ -; The R 5 ,R 5’ Each is independently selected from H and C1-C6 alkyl groups:
[0071]
[0072]
[0073]
[0074]
[0075]
[0076] Furthermore, the TB portion of the above-mentioned compound... Some have the following structure:
[0077]
[0078] Or hydroxyl group.
[0079] Furthermore, in the TB portion of the above compounds, R 1 ,R 2 Each of the following structures is independently selected from hydrogen, trifluoromethyl, or:
[0080]
[0081] Where q, r, s, and t are each independently selected from integers between 0 and 5;
[0082] Among them, D 1 D 2Selected independently from -O-, -S-, -SO-, -SO2-, and -NR- 6 -、-NCOR 6 -、-NSO2R 7 -、-CR 6 X 1 -、-CR 6 R 7 -; where R 6 R 7 Each of the following is independently selected from H, halogen, hydroxyl, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino, or R. 6 R 7 Connect them into a ring;
[0083] Among them, X 1 For -OR 8 -、-NR 8 R 9 -、-NCOR 8 -、-NSO2R 9 -、-CR 8 R 9 -; where R 8 R 9 Each of the following is independently selected from H, substituted or unsubstituted C1-C6 alkyl, C3-C6 cycloalkyl; or R 8 and R 9 They can be linked together to form a ring; the substituents are hydroxyl or amino groups.
[0084] Furthermore, in the TB portion of the above compounds, R 1 ,R 2 Each of the following is independently selected from hydrogen, trifluoromethyl, or the following structures: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, propoxy, isopropoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, amino, methylamino, ethylamino, propylamino, isopropylamino, cyclopropylamino, cyclobutamino, hydroxyethylamino, 1-hydroxymethylcyclopropylamino, N,N-dimethylamino, N,N-diethylamino, formyl, acetyl, propionyl, isopropionyl, cyclopropionyl, 1-hydroxymethyl, 1 -Hydroxyethyl, 1-hydroxypropyl, 1-hydroxyisopropyl, 1-hydroxycyclopropyl, aminoacyl, N-methylaminoacyl, N-ethylaminoacyl, N,N-dimethylacyl, acrylamide, tetrahydropyrrolylacyl, methoxyacyl, ethoxyacyl, acrylamide, tetrahydropyrrole, piperidine, morpholine, piperazine, N-methylpiperazine, N-ethylpiperazine, N-cyclopropylpiperazine, 2-methylpiperazine, 3-methylpiperazine, 2,2-dimethylpiperazine, 3,3-dimethylpiperazine, 2,3-dimethylpiperazine
[0085]
[0086]
[0087]
[0088] Furthermore, in the TB portion of the above-mentioned compound, R... 1 ,R 2 Each of the following groups is independently selected from the following structures: hydrogen, fluorine, chlorine, bromine, iodine, methyl, amide, substituted or unsubstituted 1,2-diazolyl, 1,3-diazolyl, N-methyl-1,2-diazolyl, N... 1 -1,2,3-triazolyl, N 2 -1,2,3-triazolyl, 1,3,4-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,2-oxazolyl, 1,3-oxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,5-oxadiazolyl, 1,2-thiooxazolyl, 1,3-thiooxazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,5-thiadiazolyl, N 2 -4-Fluoro-1,2,3-triazolyl, N 2 -4-Methyl-1,2,3-triazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, pyridyl, pyridinyl, pyrimidinyl, pyrazinyl; the substituted groups are halogen, hydroxyl, amino, C1-C6 alkoxy, C1-C6 alkylamine, cyano, amide, C1-C6 alkyl, C3-C6 cycloalkyl.
[0089] Furthermore, in the TB portion of the above-mentioned compound, R... 1 ,R 2 Each of the following structures is independently selected: hydrogen, amino, methylamino, dimethylamino, methylthio, methanesulfonyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyridyl, fluorine, iodine, 2-methyl-1,3,4-oxadiazolyl, cyano, 5-methyl-1,2,4-oxadiazolyl, 1-hydroxyethyl, 1-hydroxypropyl, acetyl, propionyl, cyclopropionyl, cyclobutyryl, isopropionyl, 1-hydroxyisopropyl, 1-hydroxyisobutyl, methoxyacyl, ethoxyacyl, 1-hydroxymethyl alkyl, methoxy, ethoxy, cyclopropoxy, aminoacyl, N-methylaminoacyl, 1-methyl-1,2-diazolyl, 1,2-diazolyl, 1,3-diazolyl, 3-methyl-1,2,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 3,5-dimethyl-1,2-oxazolyl, tetrahydropyrrolyl, 1,3,4-thiadiazolyl, 3-methyl-1,2,4-thiadiazolyl, hexahydropyridyl, carboxyl, 1,3-thiazolyl, -NHCN
[0090]
[0091] Wherein, R' is methyl, ethyl or cyclopropyl, and R” is hydrogen or methyl; R”' and R”” are independently selected from: hydrogen, methyl, ethyl, or R”' and R”” are connected to form a 4- to 6-membered heterocycle with or without methyl substitution;
[0092] Preferably, R 1 R 2 Not for
[0093] Furthermore, the TB portion of the above-mentioned compound... Some have the following structure:
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107] Furthermore, the TB portion of the above compounds A portion is selected from any of the following structures:
[0108]
[0109]
[0110]
[0111]
[0112]
[0113] Furthermore, the TB portion of the above compounds Partial structure is shown in equation IC:
[0114]
[0115] Where M0 is -CR a R b - or -SO2-; T1 and T2 are independently selected from -CH- or -N-; X1 and X2 are independently selected from hydrogen or halogen.
[0116] Furthermore, the TB portion of the above compounds Some are selected from the following structure:
[0117]
[0118] Furthermore, the TB moiety in the above compounds is selected from the following structures:
[0119]
[0120]
[0121]
[0122]
[0123]
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146] Furthermore, the L portion in the above compound has the following structure:
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165] Furthermore, the L portion in the above compounds can be any of the following structures:
[0166]
[0167]
[0168]
[0169] Furthermore, the L portion in the above compound has the structure shown in formula XA:
[0170]
[0171] Where n2 is 0 or 1;
[0172] R y1 R y2 Each is independently selected from hydrogen or C1-C3 alkyl groups; R w1 R w2 Each is independently selected from C1 to C3 alkyl groups, either hydrogen- or halogen-substituted or unsubstituted;
[0173] Or R y1 With R y2 The linkage forms a 3- to 4-membered saturated carbon ring; or R w1 With R w2 The linkage forms a 3- to 4-membered saturated carbon ring; or R y2 With R w2 They connect to form 3- to 4-membered saturated carbon rings.
[0174] Furthermore, the aforementioned R y1 R y2 Each is independently selected from hydrogen or methyl; R w1 R w2 Each propyl group is independently selected from hydrogen, methyl, chlorinated, or unsubstituted propyl groups;
[0175] Or R y1 With R y2 Connect to form a 3-membered saturated carbon ring; or Rw1 With R w2 The linkage forms a 3- to 4-membered saturated carbon ring; or R y2 With R w2 They connect to form a 4-membered saturated carbon ring.
[0176] Preferably, the L portion has the following structure:
[0177]
[0178] Furthermore, the U portion in the above compound has the following structure:
[0179]
[0180]
[0181]
[0182]
[0183] Furthermore, in the above formula IU A portion is selected from any of the following structures:
[0184]
[0185] Preferably, U 1 、U 2 、U 3 、U 4 All are CH; or one of them is N or CX0, and the rest are CH, where X0 is a halogen.
[0186] Furthermore, in the above formula IU Part of it has the following structure:
[0187]
[0188] Preferably, R m It can be hydrogen or methyl.
[0189] Furthermore, the U portion in the above compound has the following structure:
[0190]
[0191] Furthermore, the above-mentioned compounds are selected from any of the following compounds:
[0192]
[0193]
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213] The present invention also provides a drug preparation comprising the above-mentioned compound, or its optical isomer, or its solvate, or its pharmaceutically acceptable salt, or its prodrug, or its tautomer, or its meso compound, or its racemic mixture, or its enantiomer, or its diastereomer, or its mixture, or its mixture, or its metabolite, or its isotopic substitute as the active ingredient, plus pharmaceutically acceptable excipients.
[0214] The present invention also provides the use of the above-described compounds, or their optical isomers, or their solvates, or their pharmaceutically acceptable salts, or their prodrugs, or their tautomers, or their meso compounds, or their racemic compounds, or their enantiomers, or their diastereomers, or their mixtures, or their metabolites, or their metabolic precursors, or their isotopic alternatives, in the preparation of protein degradation-targeting chimeras for androgen receptors.
[0215] Furthermore, the aforementioned protein degradation-targeting chimera can target and recognize / bind to androgen receptors.
[0216] Furthermore, the aforementioned protein degradation-targeting chimera can degrade androgen receptors.
[0217] Furthermore, the aforementioned androgen receptors include wild-type and mutant androgen receptors.
[0218] Furthermore, the aforementioned mutant androgen receptors include cleavage mutant androgen receptors and point mutant androgen receptors; preferably, they are cleavage mutant androgen receptors AR-v7.
[0219] Furthermore, the aforementioned protein degradation-targeting chimera is a drug for treating diseases regulated by androgen receptors.
[0220] Furthermore, the aforementioned diseases include cancer, hair loss, acne, or COVID-19.
[0221] Furthermore, the aforementioned cancers are cancers that are positive for androgen receptor expression.
[0222] Furthermore, the aforementioned cancers are drug-resistant cancers.
[0223] Preferably, the cancers mentioned above are prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, endometrial cancer, or salivary gland cancer.
[0224] Experimental results show that the compounds of this invention can target and degrade AR, downregulate AR expression, and have significant degradation activity and inhibitory effect on AR splicing mutation AR-v7. They can effectively inhibit the proliferation of drug-resistant prostate cancer cells and exhibit good metabolic stability and oral pharmacokinetic characteristics. They have good application prospects in the preparation of protein degrading agents targeting androgen receptors and drugs for treating diseases regulated by androgen receptors.
[0225] Regarding the definition of terms used in this invention: Unless otherwise stated, the initial definitions provided for groups or terms herein apply to the groups or terms used throughout this specification; for terms not specifically defined herein, the meanings that a person skilled in the art would give them should be given based on the disclosure and context.
[0226] In this invention, "substitution" means that one, two or more hydrogen atoms in a molecule are replaced by other different atoms or molecules, including one, two or more substitutions on isotopes or ectopic atoms in the molecule.
[0227] In this invention, the minimum and maximum carbon atom content in hydrocarbon groups are indicated by prefixes. For example, the C1-C6 alkyl or C1-6 alkyl refers to C1, C2, C3, C4, C5, and C6 alkyl groups, that is, straight-chain or branched alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl, hexyl, etc. Similarly, C1-C6 alkoxy refers to C1, C2, C3, C4, C5, and C6 alkoxy groups.
[0228] In this invention, "solvate" refers to a compound forming a solvate with a solvent, wherein the solvent includes (but is not limited to): water, ethanol, methanol, isopropanol, propylene glycol, tetrahydrofuran, and dichloromethane.
[0229] In this invention, "pharmaceutically acceptable" means that a carrier, delivery substance, diluent, excipient, and / or the salt formed therefrom is generally chemically or physically compatible with other components constituting a drug dosage form and physiologically compatible with the receptor.
[0230] In this invention, "salt" refers to an acidic and / or basic salt formed by a compound or its stereoisomer with an inorganic and / or organic acid and / or base, including zwitterionic salts (internal salts) and quaternary ammonium salts, such as alkylammonium salts. These salts can be obtained directly during the final separation and purification of the compound. Alternatively, they can be obtained by mixing the compound, or its stereoisomer, with an appropriate amount (e.g., equimolar amounts) of an acid or base. These salts may precipitate in solution and be collected by filtration, or be recovered after solvent evaporation, or be prepared by freeze-drying after reaction in an aqueous medium. The salts described in this invention can be hydrochlorides, sulfates, citrates, benzenesulfonates, hydrobromides, hydrofluoric acids, phosphates, acetates, propionates, succinates, oxalates, malates, succinates, fumarates, maleates, tartrates, or trifluoroacetates of the compound.
[0231] In this invention, "aromatic ring" refers to a monocyclic or fused polycyclic ring with a conjugated π-electron system, such as benzene and naphthalene. The aromatic ring may be fused to other cyclic structures (including saturated and unsaturated rings), but cannot contain heteroatoms such as nitrogen, oxygen, or sulfur, and the point of attachment to the parent compound must be on a carbon atom of a ring with a conjugated π-electron system. "Monocyclic aromatic ring" refers to a monocyclic or fused polycyclic ring with a conjugated π-electron system. Similarly, "aryl" refers to a monocyclic or fused polycyclic group with a conjugated π-electron system, such as phenyl and naphthyl.
[0232] "Heteroaromatic ring" refers to a monocyclic or fused polycyclic ring containing one or more heteroatoms with a conjugated π-electron system. It contains at least one cyclic heteroatom selected from N, O, or S, with the remaining ring atoms being C, and also possesses a fully conjugated π-electron system. Examples include furan, pyrrole, quinoline, thiophene, pyridine, pyrazole, N-alkylpyrrole, pyrimidine, pyrazine, imidazole, tetrazolium, thienopyridyl, etc. The heteroaromatic ring can be fused to an aromatic ring, heterocyclic ring, or alkane ring. "Monocyclic heteroaromatic ring" refers to a monocyclic ring containing one or more heteroatoms with a conjugated π-electron system. Similarly, "heteroaryl" refers to a monocyclic or fused polycyclic group containing one or more heteroatoms with a conjugated π-electron system.
[0233] "Halogen" refers to fluorine, chlorine, bromine, or iodine.
[0234] "Alkyl" is a hydrocarbon group formed by removing one hydrogen atom from an alkane molecule, such as methyl -CH3, -CH3CH2, etc.
[0235] "Alynyl" refers to an aliphatic hydrocarbon group having at least one carbon-carbon triple bond. The alkynyl group can be straight-chain or branched. When the alkynyl group is preceded by a carbon number qualifier, for example, "C..." 2-6 "Alkyne group" refers to a straight-chain or branched alkynyl group with 2-6 carbon atoms.
[0236] "Alkenyl" refers to an aliphatic hydrocarbon group having at least one carbon-carbon double bond. The alkenyl group can be straight-chain or branched. When the alkenyl group is preceded by a carbon number qualifier, for example, "C..." 2-6 "Alkenyl" refers to a straight-chain or branched alkenyl group with 2-6 carbon atoms.
[0237] "Cycloalkanes" refer to saturated or unsaturated cyclic hydrocarbons, while "cycloalkyl" refers to substituents in saturated or unsaturated cyclic hydrocarbons; cyclic hydrocarbons can be monocyclic or polycyclic. For example, "3-8 membered cycloalkyl" refers to cycloalkyl groups with 3 to 8 carbon atoms.
[0238] "Heterocyclic" refers to a saturated or unsaturated cyclic hydrocarbon, and "heterocyclic group" refers to a substituent in a saturated or unsaturated cyclic hydrocarbon. Cyclic hydrocarbons can be monocyclic or polycyclic and carry at least one cyclic heteroatom (including but not limited to O, S, or N). For example, "3- to 8-membered heterocyclic group" refers to a heterocyclic group with a total number of 3 to 8 carbon atoms and heteroatoms.
[0239] "Heterocyclic" refers to a saturated or unsaturated polycyclic cyclic hydrocarbon, and "heterocyclic group" refers to a substituent in a saturated or unsaturated polycyclic cyclic hydrocarbon that carries at least one heteroatom (including but not limited to O, S or N), and in which two rings in the polycyclic cyclic hydrocarbon share two adjacent carbon atoms or heteroatoms.
[0240] "Heterocyclic aromatic ring" refers to a polycyclic structure in which at least one ring of the aforementioned heterocyclic ring is an aromatic ring; "heterocyclic aromatic ring group" refers to a group in which at least one ring of the aforementioned heterocyclic ring group is an aromatic ring.
[0241] "Spiro ring" refers to two multi-component rings sharing a single carbon atom, while "bridged ring" refers to a multi-component ring sharing two or more carbon atoms.
[0242] "Spiroheterocyclic group" is a polycyclic heterocyclic group in which two rings share a carbon atom or heteroatom.
[0243] "Alkyl mercapto" refers to a group formed by connecting a straight-chain or branched alkyl or cycloalkyl group to -S-.
[0244] "Alkylsulfone group" refers to a group formed by connecting a straight-chain or branched alkyl or cycloalkyl group to -SO2-.
[0245] "Alkyl sulfoxide group" refers to a group formed by connecting a straight-chain or branched alkyl or cycloalkyl group to -SO-;
[0246] "Alkyl carbonyl" refers to a group formed by connecting a straight-chain or branched alkyl or cycloalkyl group to -CO-.
[0247] "Alkylaminocarbonyl" refers to a straight-chain or branched alkyl or cycloalkyl group with -NH-CO- or The groups formed by the connection;
[0248] "Alkylamine group" refers to a straight-chain or branched alkyl or cycloalkyl group with -NH- or The groups formed by the connection;
[0249] In this invention, the isotope substitution form of a compound refers to the compound obtained by replacing any one or more atoms in the compound with isotopes.
[0250] Isotope representation: Different nuclides of the same element with the same number of protons but different numbers of neutrons are called isotopes. For example, hydrogen has three isotopes: H protium, D deuterium (also called heavy hydrogen), and T tritium (also called superheavy hydrogen). Unless otherwise specified, hydrogen in this invention is H; carbon has multiple isotopes: 12C, 13C, and 14C. Unless otherwise specified, 12C in this invention is C.
[0251] “Cbz” is a benzyloxycarbonyl protecting group. “Me” is a methyl group.
[0252] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0253] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Detailed Implementation
[0254] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.
[0255] Example 1: N-(4-((4-(2-(4-((8-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)ethoxy)octyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0256]
[0257] Step 1: Synthesis of tert-butyl 4-(2-((8-bromooctyl)oxy)ethyl)piperazine-1-carboxylic acid:
[0258] 4-(2-hydroxyethyl)piperazine-1-carboxylic acid tert-butyl ester (2.3 g, 10 mmol) was dissolved in dry DMF (10 mL). Under nitrogen protection, sodium hydride (800 mg, 20 mmol) was added in portions, and the reaction was carried out for half an hour under ice-water bath conditions. Then, 1,8-dibromooctane (2.7 g, 10 mmol) was added, and the reaction was carried out at room temperature for 3 hours. The reaction solution was poured into water, extracted, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 1.68 g of the product (yield 40%). LC / MS (ESI+) showed calcd for C 19 H 37 BrN2O3([M+H] + )m / z 421, found 421.
[0259] Step 2: Synthesis of tert-butyl 4-(2-(8-(4-(2-(2-(methanesulfonamide)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)ethyl)piperazine-1-carboxylic acid ester:
[0260] 4-(2-((8-bromooctyl)oxy)ethyl)piperazine-1-carboxylic acid tert-butyl ester (420 mg, 1 mmol) was dissolved in DMF (8 mL), and N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (413 mg, 1 mmol) and sodium bicarbonate (252 mg, 3 mmol) were added. The mixture was heated to 90°C and reacted for 15 hours. The reaction solution was poured into water, extracted, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give 600 mg of product (yield 80%). LC / MS (ESI+) calcd for C 40 H 59 N5O7S([M+H)) + )m / z 754, found 754.
[0261] Step 3: Synthesis of N-(4-(4-(2-(4-((8-(2-(piperazin-1-yl)ethoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonylimide:
[0262] 754 mg (1 mmol) of tert-butyl 4-(2-(8-(4-(2-(2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)ethyl)piperazine-1-carboxylic acid ester was dissolved in 40 mL of dichloromethane, and 10 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give 653 mg of product, yield: 99%. LC / MS (ESI+) calcd for C 35 H 51 N5O5S([M+H)) + )m / z 654, found 654.
[0263] Step 4: Synthesis of N-(4-((4-(2-(4-((8-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)ethoxy)octyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide:
[0264] N-(4-(4-(2-(4-((8-(2-(piperazin-1-yl)ethoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonylimide (653 mg, 1 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (276 mg, 1 mmol), and DIPEA (387 mg, 3 mmol) were added sequentially to 15 mL of DMSO, and the mixture was heated to 90 °C and reacted for 36 h. After cooling to room temperature, the product was poured into water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 455 mg of the product was purified, yield: 50%. 1 H NMR(400MHz,Chloroform-d)δ8.55(d,J=5.0Hz,1H),8.15(s,1H),7.68(d,J=8.5Hz,1H),7.27(d,J=2.3Hz ,1H),7.20–7.11(m,3H),7.10–6.99(m,3H),6.88–6.79(m,2H),6.77–6.67(m,2H),5.05(s,2H),4.94(dd,J =12.2,5.2Hz,1H),4.10(p,J=5.7,5.2Hz,2H),3.63(t,J=5.4Hz,2H),3.48(s,6H),3.41(t,J=6.6Hz,2H), 2.93–2.63(m,8H),2.13(ddd,J=10.3,5.0,2.6Hz,1H),1.72(s,2H),1.65–1.40(m,9H).LC / MS(ESI+)calcd for C 48 H 59 N7O9S([M+H)) + )m / z 910, found 910.
[0265] Example 2: N-(4-((4-(2-(4-((7-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)ethoxy)heptyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0266]
[0267] It was prepared using a method similar to that of Example 1. LC / MS (ESI+) calcd for C 47 H 57 N7O9S([M+H)) + )m / z 896, found 896.
[0268] Example 3: N-(4-(4-(2-(4-(4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)-2,7-diazaspiro[3.5]nonane-7-yl)butoxy)butoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0269]
[0270] The target compound was prepared using a synthetic method similar to that of Example 1. 1 H NMR(400MHz,Chloroform-d)δ8.55(d,J=5.1Hz,1H),7.63(d,J=8.3Hz,1H),7.23–7.10(m,3H),7.10–6.99(m,2H),6.87 –6.79(m,2H),6.76(d,J=2.1Hz,1H),6.74–6.68(m,2H),6.49(dd,J=8.3,2.2Hz,1H),5.06(s,2H),4.95–4.90(m,1H),4. 12(tt,J=7.2,3.2Hz,2H),3.72(s,4H),3.48(s,3H),3.40(dt,J=9.5,5.9Hz,4H),2.92–2.70(m,4H),2.63(s,6H),2.44( d,J=8.4Hz,2H),2.17–2.09(m,1H),1.91(t,J=5.5Hz,4H),1.79(q,J=8.3,7.7Hz,2H),1.62(s,10H).LC / MS(ESI+)calcd for C 49 H 59 N7O9S([M+H)) + )m / z 922, found 922.
[0271] Example 4: Synthesis of N-(4-((4-(2-(4-(3-(3-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)-)2,7-diazaspiro[3.5]nonane-7-yl)propoxy)propoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0272]
[0273] The target compound was prepared using a method similar to that in Example 1. 1H NMR(400MHz,Chloroform-d)δ8.56(d,J=5.0Hz,1H),7.64(d,J=8.3Hz,1H),7.21–7.09(m,3H),7.08–7. 00(m,2H),6.86–6.79(m,2H),6.77(d,J=2.1Hz,1H),6.75–6.68(m,2H),6.49(dd,J=8.3,2.2Hz,1H),5.0 8(s,2H),4.93(dd,J=12.2,5.3Hz,1H),4.23–4.11(m,2H),3.73(s,3H),3.52–3.34(m,6H),2.92–2.69( m,4H),2.63(s,6H),2.18–2.08(m,2H),2.01–1.89(m,6H),1.82(s,2H),1.62(s,6H).LC / MS(ESI+)calcd for C 47 H 55 N7O9S([M+H)) + )m / z 894, found 894.
[0274] Example 5: N-(4-((4-(2-(4-((9-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)azacyclobutane-3-yl)piperazin-1-yl)nonyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0275]
[0276] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.18(s,1H),8.68(d,J=5.1Hz,1H),7.64(d,J=8.2Hz,1H),7.24(d,J=5 .1Hz,1H),7.10(d,J=8.3Hz,2H),6.93(dd,J=29.4,8.4Hz,4H),6.78(s,1H),6.63(d,J=8.3Hz,3H),5.14(s,2 H),5.05(dd,J=13.0,5.5Hz,1H),4.17–3.75(m,6H),3.50(s,3H),3.29(t,J=6.1Hz,5H),2.94–2.80(m,1H),2 .22(t,J=7.3Hz,8H),2.00(d,J=12.9Hz,1H),1.59(d,J=36.0Hz,8H),1.41–1.12(m,12H).LC / MS(ESI+)calcd for C 50 H 62 N8O8S([M+H)) + )m / z 935, found 935.
[0277] Example 6: Synthesis of N-(4-((4-(2-(4-((6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl))piperazin-1-yl)methyl)piperidin-1-yl)hexyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0278]
[0279] The target compound was prepared using a method similar to that in Example 1. 1H NMR(400MHz,Chloroform-d)δ8.55(d,J=5.0Hz,1H),7.69(d,J=8.5Hz,1H),7.28(d,J=2.2Hz,1H),7.15(d,J=5.1Hz,1H) ,7.12–7.07(m,2H),7.05(dd,J=8.8,2.3Hz,3H),6.85–6.79(m,2H),6.78–6.68(m,2H),5.07(s,2H),4.99–4.89(m,1H), 4.63(s,2H),4.07(t,J=7.5Hz,2H),3.43(d,J=20.5Hz,6H),3.25(d,J=11.7Hz,2H),2.94–2.68(m,4H),2.55(t,J=5.2Hz ,6H),2.35–2.20(m,6H),2.17–2.09(m,2H),1.87(d,J=11.9Hz,3H),1.62(s,6H),1.37–1.17(m,8H).LC / MS(ESI+)calcd for C 50 H 62 N8O8S([M+H)) + )m / z 935, found 935.
[0280] Example 7: N-(4-((4-(2-(4-((7-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)propoxy)heptyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0281]
[0282] The target compound was prepared using a method similar to that in Example 1. 1H NMR(400MHz,Chloroform-d)δ8.55(d,J=5.0Hz,1H),7.68(dd,J=8.5,4.2Hz,1H),7.28(d,J=2.4Hz,1H ),7.23–7.10(m,3H),7.05(dd,J=7.7,5.7Hz,3H),6.91–6.78(m,2H),6.78–6.64(m,2H),5.05(s,2H),4 .94(dd,J=12.2,5.3Hz,1H),4.10(q,J=7.7Hz,2H),3.57–3.32(m,11H),2.94–2.47(m,12H),2.13(ddd ,J=11.9,9.3,5.6Hz,1H),1.89–1.69(m,4H),1.65-1.50(m,9H),1.40-1.30(m,2H).LC / MS(ESI+)calcd for C 48 H 59 N7O9S([M+H)) + )m / z 910, found 910.
[0283] Example 8: N-(4-((4-(2-(4-((6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)butoxy)hexyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0284]
[0285] The target compound was prepared using a method similar to that in Example 1. 1 H NMR(400MHz,Chloroform-d)δ8.55(d,J=5.1Hz,1H),7.68(dd,J=8.5,4.7Hz,1H),7.29(d,J=3.6Hz,1 H),7.22–7.10(m,3H),7.05(dd,J=7.7,5.7Hz,3H),6.93–6.78(m,2H),6.76–6.62(m,2H),5.06(s,2H ),4.94(dd,J=12.0,5.5Hz,2H),4.10(t,J=7.7Hz,2H),3.56–3.32(m,13H),2.94–2.58(m,10H),2.18 –2.02(m,2H),1.76(tq,J=14.2,6.6Hz,2H),1.60–1.52(m,6H),1.47–1.30(m,5H).LC / MS(ESI+)calcd for C48 H 59 N7O9S([M+H)) + )m / z 910, found 910.
[0286] Example 9: N-(4-((4-(2-(4-((5-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)oxy)pentyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0287]
[0288] Step 1: Synthesis of N-(4-((4-(2-(4-(((5-bromopentyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0289] Compound N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (140 mg, 0.34 mmol) and 1,5-dibromopentane (85 mg, 0.37 mmol) were added to 4 mL of DMF, followed by K₂CO₃ (118 mg, 0.85 mmol) and KI (10 mg, 0.06 mmol). The mixture was stirred at 70 °C for 2 h, cooled to room temperature, and a small amount of water was added to the reaction solution. The mixture was extracted three times with EA, and the organic phases were combined and washed three times with saturated NaCl solution. The mixture was dried over anhydrous sodium sulfate, evaporated to dryness, and purified by column chromatography to obtain the target compound (142 mg, 74% yield). LC / MS (ESI+) calcd for C 26 H 32 BrN3O4S + (M+H + )m / z,564.1;found,564.1.
[0290] Step 2: Synthesis of N-(4-((4-(2-(4-((5-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)oxy)pentyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0291] Compound N-(4-((4-(2-(4-(((5-bromopentyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (70 mg, 0.13 mmol) and 2-(2,6-dioxadiazin-3-yl)-5-hydroxyisoindoline-1,3-dione (35 mg, 0.13 mmol) were added to 3 mL of DMF, followed by the addition of K2CO3 (45 mg, 0.33 mmol) and KI (10 mg, 0.06 mmol). The mixture was stirred at 60 °C for 4 h, cooled to room temperature, and a small amount of water was added to the reaction solution. The mixture was extracted three times with EA, and the organic phases were combined. The organic phases were washed three times with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated to dryness. The target compound was purified by column chromatography to obtain a yellow solid (29 mg, 30% yield). 1 H NMR (400MHz, DMSO-d6) δ11.09(s,1H),9.16(s,1H),8.67(t,J=4.0Hz,1H),7.81(d,J=8.3Hz,1H),7.41(d,J=2.3Hz,1H),7. 32(dd,J=8.3,2.3Hz,1H),7.24(d,J=5.1Hz,1H),7.13–7.07(m,2H),7.01–6.94(m,2H),6.93–6.86(m,2H),6.67–6.60(m,2H ),5.18–5.08(m,3H),4.16(t,J=6.4Hz,2H),3.98(dt,J=18.0,7.6Hz,2H),3.52(d,J=5.6Hz,3H),2.64–2.56(m,1H),2.09–1 .98(m,1H),1.73(ddt,J=23.1,15.8,7.9Hz,4H),1.54(s,6H),1.44(d,J=7.5Hz,2H),1.34–1.10(m,2H).LC / MS(ESI+)calcd for C 39 H 41 N5O9S(M+H + )m / z,756.2;found,756.2.
[0292] Example 10: N-(4-((4-(2-(4-((4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)amino)butoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0293]
[0294] It was prepared using a method similar to that of Example 1. 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),9.16(s,1H),8.67(d,J=5.1Hz,1H),7.55(dd,J=8.6,7.1Hz,1H),7.24(d, J=5.1Hz,1H),7.13–7.05(m,3H),7.03–6.94(m,3H),6.92–6.85(m,2H),6.67–6.61(m,2H),6.57(t,J=6.0Hz,1H) ,5.13(s,2H),5.04(dd,J=12.9,5.4Hz,1H),4.01(t,J=7.4Hz,2H),3.52(s,3H),2.86(ddd,J=17.8,13.8,5.3Hz, 1H),2.56(d,J=17.6Hz,1H),2.04–1.95(m,1H),1.81–1.70(m,2H),1.54(s,9H),1.23(s,2H).LC / MS(ESI+)calcd for C 38 H 40 N6O8S(M+H + )m / z,741.2;found,741.2.
[0295] Example 11: N-(4-((4-(2-(4-(3-(4-((1-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)azacyclobutane-3-yl)methyl)piperidin-4-yl)methyl)piperazin-1-yl)propoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0296]
[0297] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.18(s,1H),8.67(d,J=5.1Hz,1H),7.60(dd,J=17.1,8.3Hz,1H),7.24(d,J=5.1Hz,1H ),7.11(d,J=8.6Hz,2H),6.97(d,J=8.5Hz,2H),6.90(d,J=8.7Hz,2H),6.76(s,1H),6.64(d,J=8.6Hz,3H),5.12(s,2H),5.04( dd,J=12.9,5.4Hz,1H),4.16–3.92(m,5H),3.65(dd,J=8.4,5.6Hz,3H),2.95–2.76(m,5H),2.58(dd,J=10.8,5.5Hz,3H),2.29 (dd,J=17.2,10.0Hz,10H),2.15–1.86(m,8H),1.80(p,J=7.3Hz,3H),1.62(d,J=12.4Hz,2H),1.55(s,6H).LC / MS(ESI+)calcd for C 51 H 63 N9O8S(M+H + )m / z,962.4;found,962.4.
[0298] Example 12: N-(4-(2-(4-((1-((1-((1-((1-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)azacyclobutane-3-yl)methyl)piperidine-4-yl)methyl)piperidine-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0299]
[0300] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, DMSO-d6) δ8.29(d,J=4.9Hz,1H),7.09(dd,J=15.7,8.6Hz,5H),6.87(d,J=9.0Hz,3H),6 .80(d,J=8.5Hz,2H),6.64(td,J=12.9,11.8,6.2Hz,3H),4.90(s,2H),4.32–4.03(m,6H),3.92(t,J= 7.5Hz,3H),2.96(d,J=3.1Hz,3H),2.78(dq,J=17.8,8.5,7.9Hz,10H),2.63(d,J=10.1Hz,4H),2.16– 2.03(m,9H),1.99(dt,J=13.9,7.0Hz,4H),1.88(s,10H),1.78(d,J=10.9Hz,4H).LC / MS(ESI+)calcd for C 55 H 69 N9O8S(M+H + )m / z,1016.5;found,1016.5.
[0301] Example 13: N-(4-((4-(2-(4-((1-(4-(4-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)butyl)pyrrolidine-3-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0302]
[0303] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.18(s,1H),8.69(d,J=5.1Hz,1H),7.55(d,J=8.3Hz,1H),7.26(d,J=5.1Hz, 1H),7.15–7.08(m,3H),6.98(d,J=8.6Hz,2H),6.94(d,J=2.1Hz,1H),6.92–6.88(m,2H),6.84(dd,J=8.4,2.1Hz,1H ),6.66–6.61(m,2H),5.15(s,2H),5.03(dd,J=12.9,5.4Hz,1H),4.05–3.94(m,2H),3.53(s,3H),3.16(q,J=6.1Hz, 3H),2.76–2.53(m,5H),1.99(tt,J=9.9,6.0Hz,2H),1.70–1.37(m,19H),1.23(d,J=3.5Hz,4H).LC / MS(ESI+)calcd forC 47 H 57 N7O9S(M+H + )m / z,896.4; found 896.4
[0304] Example 14: N-(4-(4-(2-(4-((1-(5-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)pentyl)azacyclobutane-3-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0305]
[0306] The target compound was prepared using a method similar to that in Example 1. 1H NMR(400MHz, DMSO-d6)δ11.06(s,1H),8.60(d,J=5.1Hz,1H),7.55(d,J=8.4Hz,1H),7.19–7.04(m,7H),6 .96–6.88(m,3H),6.84(dd,J=8.4,2.1Hz,1H),6.70(d,J=8.7Hz,2H),5.09(s,2H),5.02(dd,J=12.9,5.4 Hz,1H),4.70(p,J=5.7Hz,1H),3.79–3.69(m,2H),3.50(s,3H),3.17(d,J=5.8Hz,4H),3.00–2.79(m,5H) ,2.44(q,J=5.8,5.3Hz,3H),1.98(ddd,J=11.5,6.3,3.7Hz,2H),1.68–1.39(m,16H).LC / MS(ESI+)calcd for C 46 H 55 N7O9S(M+H + m / z, 882.4; found, 882.4
[0307] Example 15: N-(4-(4-(2-(4-((1-(5-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)pentyl)piperidine-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0308]
[0309] The target compound was prepared using a method similar to that in Example 1. 1 H NMR (400MHz, DMSO-d6) δ8.54(d,J=5.1Hz,1H),7.54(d,J=8.3Hz,1H),7.10(dt,J=17.1,7.4H z,7H),6.97–6.87(m,4H),6.82(t,J=10.0Hz,3H),5.04(d,J=6.7Hz,2H),3.26(s,5H),3.15( d,J=4.7Hz,4H),2.89(q,J=7.2Hz,6H),2.76(dd,J=22.8,13.0Hz,4H),2.54(s,6H),2.35(dt ,J=19.4,8.7Hz,6H),1.95(dq,J=23.8,7.1Hz,5H),1.46(p,J=7.0Hz,6H).LC / MS(ESI+)calcd forC 48 H59 N7O9S(M+H + m / z, 910.4; found, 910.4
[0310] Example 16: N-(4-(4-(2-(4-((1-(3-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)propyl)piperidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0311]
[0312] The target compound was prepared using a method similar to that in Example 1. 1 H NMR(400MHz, DMSO-d6)δ8.67(d,J=5.1Hz,1H),7.59–7.44(m,1H),7.24(d,J=5.1Hz,1H),7. 10(d,J=8.4Hz,3H),6.96(t,J=9.0Hz,3H),6.89(d,J=8.2Hz,2H),6.64(d,J=8.3Hz,2H),5. 14(s,2H),3.89(d,J=7.1Hz,3H),3.16(d,J=5.6Hz,3H),2.98–2.83(m,4H),2.61–2.34(m,1 0H),2.09–1.88(m,4H),1.65(t,J=7.2Hz,2H),1.56(d,J=16.9Hz,13H).LC / MS(ESI+)calcd for C 47 H 57 N7O9S(M+H + )m / z,896.4; found 896.4
[0313] Example 17: N-(4-((4-(2-(4-(3-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)amino)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0314]
[0315] Step 1: Synthesis of tert-butyl carbamate (3-(3-(4-(2-(4-(2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)propoxy)carbamate
[0316] N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (206 mg, 0.5 mmol), 3-(3-((tert-butoxycarbonyl)amino)propoxy)propyl methanesulfonate (155 mg, 0.5 mmol), cesium carbonate (325 mg, 1.0 mmol), and sodium iodide (7.5 mg, 0.05 mmol) were sequentially added to 4 mL of DMF. The mixture was heated to 60 °C and reacted overnight. After the reaction was monitored by TLC until complete, it was allowed to cool naturally to room temperature. The mixture was extracted with 4 mL of ethyl acetate, washed with saturated brine (3 x 4 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 125 mg of the target compound (yield: 40%).
[0317] The target compound was prepared in subsequent steps using a method similar to that in Example 1. 1 H NMR (400MHz, CDCl3) δ8.55(d,J=5.1Hz,1H),8.05(s,1H),7.47(dd,J=8.5,7.1Hz,1H),7.19(d,J=5.0Hz,1H),7.17 –7.10(m,2H),7.06(d,J=8.1Hz,2H),6.92(d,J=8.6Hz,1H),6.83(d,J=8.9Hz,2H),6.79–6.65(m,2H),6.48(s,1H), 5.05(s,2H),4.90(dd,J=12.1,5.3Hz,1H),4.28–4.17(m,2H),3.56–3.46(m,5H),3.40(s,2H),3.11(d,J=37.0Hz, 2H),2.91–2.68(m,3H),2.22(t,J=7.7Hz,1H),2.07(dd,J=13.2,6.1Hz,2H),1.96–1.85(m,2H).LC / MS(ESI+)calcd forC 40 H 44 N6O9S([M+H)) + )m / z:785.3; found 785.3.
[0318] Example 18: N-(4-((4-(2-(4-(3-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0319]
[0320] N-(4-((4-(2-(4-(3-(3-aminopropoxy)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (41 mg, 0.075 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (18 mg, 0.075 mmol), and DIPEA (30 mg, 0.23 mmol) were sequentially added to 5 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 11 mg of the target compound (yield: 18%). 1 H NMR (400MHz, CDCl3) δ8.56(d,J=5.1Hz,1H),8.06(s,1H),7.58(d,J=8.3Hz,1H),7.20(d,J=5.1Hz,1H),7.16–7 .10(m,2H),7.10–7.02(m,2H),6.98(d,J=2.2Hz,1H),6.85–6.79(m,2H),6.79–6.74(m,1H),6.74–6.68(m,2H) ,5.06(s,2H),4.91(dd,J=12.1,5.3Hz,1H),4.27–4.17(m,2H),3.55(dt,J=8.3,5.8Hz,4H),3.51(s,3H),3.34 (t,J=6.1Hz,2H),2.89–2.66(m,3H),2.14–2.03(m,3H),1.90(q,J=5.8Hz,3H),1.62(s,6H).LC / MS(ESI+)calcd for C 40 H 44 N6O9S([M+H)) + )m / z:785.3; found 785.3.
[0321] Example 19: N-(4-((4-(2-(4-(3-(3-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)amino)propoxy)propoxy)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0322]
[0323] The target compound was prepared using a method similar to that in Example 17. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.0Hz,1H),8.22(s,1H),7.47(dd,J=8.5,7.1Hz,1H),7.19(d,J=5.1Hz,1H),7.17– 7.11(m,2H),7.08–7.04(m,2H),6.90(d,J=8.6Hz,1H),6.87–6.80(m,2H),6.76–6.67(m,2H),6.44(s,1H),5.05(s, 2H),4.90(dd,J=12.0,5.3Hz,1H),4.27–4.13(m,2H),3.57–3.44(m,11H),3.37(q,J=6.3Hz,2H),2.93–2.64(m,3H) ,2.11(dt,J=10.4,3.5Hz,1H),2.01(p,J=6.3Hz,2H),1.87(dp,J=18.4,6.1Hz,5H),1.61(s,6H).LC / MS(ESI+)calcd forC 43 H 50 N6O 10 S([M+H)) + )m / z:843.3; found 843.3.
[0324] Example 20: N-(4-((4-(2-(4-(3-(3-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)propoxy)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0325]
[0326] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.0Hz,1H),8.13(s,1H),7.57(d,J=8.3Hz,1H),7.19(d,J=5.0Hz,1H),7.16– 7.11(m,2H),7.09–7.02(m,2H),6.93(d,J=2.1Hz,1H),6.86–6.80(m,2H),6.78–6.63(m,3H),5.05(s,2H),4. 91(dd,J=12.1,5.2Hz,1H),4.20(dd,J=8.2,6.3Hz,2H),3.62–3.41(m,11H),3.31(t,J=6.2Hz,2H),2.94–2.6 9(m,3H),2.15–2.07(m,1H),2.07–1.98(m,2H),1.87(dp,J=18.8,6.1Hz,5H),1.62(s,6H).LC / MS(ESI+)calcd for C 43 H 50 N6O 10 S([M+H)) + )m / z:843.3; found 843.3.
[0327] Example 21: N-(4-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0328]
[0329] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.0Hz,1H),8.01(s,1H),7.48(dd,J=8.5,7.1Hz,1H),7.18(d,J=5.0Hz,1H),7.14(d ,J=8.7Hz,2H),7.07(dd,J=7.8,3.5Hz,3H),6.89(d,J=8.5Hz,1H),6.83(d,J=8.8Hz,2H),6.72(d,J=8.6Hz,2H),6.2 6(s,1H),5.05(s,2H),4.93–4.87(m,1H),4.14–4.05(m,2H),3.53–3.36(m,7H),3.30(s,2H),2.89–2.73(m,3H),2.1 1(d,J=5.3Hz,1H),1.75–1.69(m,4H),1.62(s,6H),1.42(d,J=5.0Hz,2H),1.32(d,J=6.4Hz,10H).LC / MS(ESI+)calcd forC 46 H 56 N6O9S([M+H)) + )m / z:869.4; found 869.4.
[0330] Example 22: N-(4-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0331]
[0332] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.1Hz,1H),8.02(s,1H),7.59(d,J=8.3Hz,1H),7.18(d,J=5.1Hz,1H),7.14(d,J=8.8H z,2H),7.09–7.03(m,2H),6.94(d,J=2.1Hz,1H),6.83(d,J=8.8Hz,2H),6.79–6.65(m,3H),5.05(s,2H),4.92(dd,J=12. 0,5.1Hz,1H),4.13–4.02(m,2H),3.63(d,J=6.7Hz,1H),3.51–3.39(m,6H),3.23(t,J=6.5Hz,2H),2.89–2.67(m,3H),2 .15–2.08(m,1H),1.73(dd,J=13.5,6.4Hz,4H),1.62(s,6H),1.43–1.40(m,2H),1.33–1.27(m,10H).LC / MS(ESI+)calcd for C 46 H 56 N6O9S([M+H)) + )m / z:869.4; found 869.4.
[0333] Example 23: N-(4-((4-(2-(4-((7-(3-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)amino)propoxy)propoxy)heptoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0334]
[0335] The target compound was prepared using a method similar to that in Example 17. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.0Hz,1H),8.08(s,1H),7.48(dd,J=8.6,7.1Hz,1H),7.18(d,J=5.1Hz,1H),7.16–7.11(m, 2H),7.11–7.02(m,3H),6.91(d,J=8.5Hz,1H),6.88–6.80(m,2H),6.76–6.67(m,2H),6.43(s,1H),5.05(s,2H),4.90(dd,J=1 2.1,5.3Hz,1H),4.15–4.05(m,2H),3.75(s,1H),3.56–3.48(m,5H),3.48(s,3H),3.38(t,J=6.7Hz,4H),2.92–2.71(m,3H),2 .16–2.08(m,1H),1.96–1.86(m,4H),1.62(s,6H),1.54(s,2H),1.42(d,J=5.1Hz,2H),1.31–1.26(m,6H).LC / MS(ESI+)calcd for C 47 H 58 N6O 10 S([M+H)) + )m / z:899.4; found 899.4.
[0336] Example 24: N-(4-((4-(2-(4-((7-(3-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)propoxy)heptoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0337]
[0338] The target compound was prepared using a method similar to that in Example 1. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.0Hz,1H),8.09(s,1H),7.59(d,J=8.3Hz,1H),7.18(d,J=5.0Hz,1H),7.16–7.10(m,2H),7.10–7.02(m, 2H),6.94(d,J=1.9Hz,1H),6.87–6.80(m,2H),6.71(dd,J=8.1,6.0Hz,3H),5.05(s,2H),4.92(dd,J=12.0,5.1Hz,1H),4.14–4.03(m,2H) ,3.57(t,J=5.4Hz,2H),3.51(dt,J=8.6,6.3Hz,4H),3.40(t,J=6.6Hz,2H),3.32(t,J=6.2Hz,2H),2.91–2.70(m,3H),2.11(dd,J=8.5,6. 0Hz,1H),1.88(dq,J=18.9,6.1Hz,4H),1.62(s,6H),1.56(d,J=6.6Hz,2H),1.42(d,J=5.4Hz,2H),1.32–1.26(m,6H).LC / MS(ESI+)calcd for C 47 H 58 N6O 10 S([M+H)) + )m / z:899.4; found 899.4.
[0339] Example 25: N-(4-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)-N-methylmethanesulfonamide
[0340]
[0341] Step 1: Synthesis of N-methyl-N-(4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0342] N-(4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (328 mg, 1 mmol), iodomethane (142 mg, 1 mmol), and potassium carbonate (276 mg, 2 mmol) were added sequentially to 3 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 248 mg of the target compound, yield: 73%.
[0343] Step 2: Synthesis of N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)-N-methylmethanesulfonamide
[0344] The compound N-methyl-N-(4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (248 mg, 0.73 mmol) was dissolved in 4 mL of dichloromethane, and 2 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction system was concentrated, and the mixture was purified by column chromatography to obtain 136 mg of the target compound, yield: 88%.
[0345] The target compound was prepared in subsequent steps using a method similar to that in Example 1. 1 H NMR (400MHz, CDCl3) δ8.57(d,J=5.0Hz,1H),7.99(s,1H),7.60(d,J=8.2Hz,1H),7.22(d,J=5.0Hz,1H),7.18–7.06(m ,4H),6.95(s,1H),6.87–6.75(m,4H),6.75–6.68(m,1H),5.07(s,2H),4.92(dd,J=12.1,5.2Hz,1H),3.91(t,J=6.5H z,2H),3.54(s,3H),3.49(s,3H),3.44(dt,J=13.2,6.3Hz,4H),3.24(t,J=6.4Hz,2H),2.88–2.67(m,3H),2.12(dd,J =8.4,5.9Hz,1H),1.74(dq,J=13.8,6.7Hz,8H),1.63(s,6H),1.42(d,J=5.0Hz,2H),1.34(s,6H).LC / MS(ESI+)calcd for C 47 H 58 N6O9S([M+H)) + )m / z:883.4; found 883.4.
[0346] Example 26: N-(4-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)acetamide
[0347]
[0348] The target compound was prepared using a method similar to that in Example 1. 1 H NMR (400MHz, CDCl3) δ8.54(d,J=28.7Hz,2H),7.59(d,J=7.7Hz,1H),7.19–7.07(m,4H),6.94(s,1H),6.83(d,J =8.3Hz,2H),6.78(d,J=8.6Hz,2H),6.71(d,J=7.9Hz,1H),5.08(s,2H),4.93(d,J=11.2Hz,1H),3.91(t,J=6.4H z,2H),3.45(dt,J=13.1,6.0Hz,4H),3.24(s,2H),2.81(dt,J=44.5,16.5Hz,3H),2.47(s,3H),2.11(d,J=10.9H z,1H),1.74(dq,J=13.5,6.5Hz,8H),1.63(s,6H),1.34(d,J=6.1Hz,6H),1.30–1.28(m,2H).LC / MS(ESI+)calcd for C 47 H 56 N6O8([M+H)) + )m / z:833.4; found 833.4.
[0349] Example 27: 5-((4-((8-(4-(2-(4-((2-(1,1-dioxyisothiazolidin-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxypiperidin-3-yl)isoindoline-1,3-dione
[0350]
[0351] Step 1: 2-(4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)isothiazolidinyl 1,1-dioxide
[0352] Dissolve 60% sodium hydride (80 mg, 2 mmol) in 10 mL DMF. Add 1,1-dioxoisothiazol (242 mg, 2 mmol) in an ice bath and stir at room temperature for 10 min. Add 2-chloro-4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidine (1.2 g, 2 mmol). Slowly raise the temperature to 70 °C and react overnight. After the reaction is complete as monitored by TLC, quench the reaction with saturated ammonium chloride in an ice bath. Extract three times with 10 mL ethyl acetate, wash with saturated brine (3*4 mL), dry with anhydrous sodium sulfate, concentrate, and purify by column chromatography to obtain 370 mg of the target compound, yield: 27%.
[0353] The target compound was prepared in subsequent steps using a method similar to that in Example 1. 1 H NMR (400MHz, CDCl3) δ8.56(d,J=5.1Hz,1H),8.05(s,1H),7.59(d,J=8.3Hz,1H),7.20(d,J=5.1Hz,1H),7.17–7.06(m,4H),6.94 (d,J=2.0Hz,1H),6.87–6.75(m,4H),6.72(dd,J=8.4,2.0Hz,1H),5.06(s,2H),4.92(dd,J=12.1,5.2Hz,1H),4.05(t,J=6.5Hz,2 H),3.91(t,J=6.5Hz,2H),3.52–3.36(m,6H),3.24(t,J=6.6Hz,2H),2.91–2.68(m,3H),2.50(p,J=7.0Hz,2H),2.14–2.08(m,1H) ,1.73(dt,J=14.3,7.0Hz,6H),1.62(s,6H),1.58(d,J=6.8Hz,2H),1.42(dd,J=6.6,4.1Hz,2H),1.34(s,6H).LC / MS(ESI+)calcd for C 48 H 58 N6O9([M+H)) + )m / z:895.4; found 895.4.
[0354] Example 28: 5-((4-((8-(4-(2-(4-(((2-aminopyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0355]
[0356] Step 1: Synthesis of 4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-amine
[0357] 1.8 g (3 mmol) of 2-chloro-4-((4-(2-(4-(triphenylmethoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidine was dissolved in 5 mL of anhydrous ethanol, and 2.5 mL of ammonia was added. The mixture was then slowly heated to 90 °C overnight under sealed conditions. After the reaction was completed by TLC monitoring, the mixture was extracted three times with 10 mL of ethyl acetate, washed with saturated brine (3*4 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 530 mg of the target compound, yield: 31%.
[0358] The target compound was prepared in subsequent steps using a method similar to that in Example 1. 1 H NMR(400MHz, CDCl3)δ8.65–8.03(m,2H),7.59(d,J=7.3Hz,1H),7.21–7.00(m,6H), 6.78(td,J=19.9,18.3,8.4Hz,7H),4.94(d,J=21.6Hz,3H),3.91(t,J=6.0Hz,2H),3 .45(dt,J=13.1,6.1Hz,4H),3.24(s,2H),2.83(dd,J=36.7,17.3Hz,3H),1.81–1.6 9(m,6H),1.62(s,6H),1.49–1.40(m,4H),1.33(d,J=8.6Hz,6H).LC / MS(ESI+)calcd for C 45 H 54 N6O7([M+H)) + )m / z:791.4;found791.4.
[0359] Example 29: N-(4-((4-(2-(4-(3-(4-((1-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propyl)piperidin-4-yl)methyl)piperazin-1-yl)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0360]
[0361] Step 1: Synthesis of 4-(3-bromopropyl)piperazine-1-carboxylic acid tert-butyl ester
[0362] Piperazine-1-carboxylic acid tert-butyl ester (1.8 g, 10 mmol), 1,3-dibromopropane (1.0 g, 5 mmol), and potassium carbonate (2.76 g, 20 mmol) were added sequentially to 20 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC monitoring, the mixture was extracted with 20 mL of ethyl acetate, washed with saturated brine (3 x 20 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 870 mg of the target compound, yield: 57%.
[0363] Step 2: Synthesis of 4-(3-(4-(2-(4-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)piperazine-1-carboxylic acid tert-butyl ester
[0364] N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (413 mg, 1 mmol), 4-(3-bromopropyl)piperazine-1-carboxylic acid tert-butyl ester (306 mg, 1 mmol), potassium carbonate (276 mg, 2 mmol), and sodium iodide (7.5 mg, 0.05 mmol) were sequentially added to 4 mL of DMF. The mixture was heated to 60 °C and reacted overnight. After the reaction was monitored by TLC until complete, it was allowed to cool naturally to room temperature. The mixture was extracted with 4 mL of ethyl acetate, washed with saturated brine (3*4 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 539 mg of the target compound, yield: 84%.
[0365] Step 3: Synthesis of N-(4-((4-(2-(4-(3-(piperazin-1-yl)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0366] Compound 4-(3-(4-(2-(4-(((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)piperazine-1-carboxylic acid tert-butyl ester (539 mg, 0.84 mmol) was dissolved in 10 mL of dichloromethane, and 5 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 385 mg of the target compound, yield: 85%.
[0367] Step 4: Synthesis of (3-(4-(3-(4-(4-(2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)piperazin-1-yl)methyl)piperidin-1-yl)propyl)tert-butyl carbamate
[0368] The compound N-(4-((4-(2-(4-(3-(piperazin-1-yl)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (385 mg, 0.7 mmol) was dissolved in 10 mL of dichloromethane. Then, (3-(4-formylpiperidin-1-yl)propyl)carbamate tert-butyl ester (190 mg, 0.7 mmol) and glacial acetic acid (4 mg, 0.07 mmol) were added, and the mixture was stirred at room temperature for 10 minutes. Sodium triacetylborohydride (190 mg, 1.4 mmol) was added, and the mixture was stirred overnight at room temperature. After the reaction was complete as monitored by TLC, the reaction mixture was poured into a saturated ammonium chloride solution under ice. The mixture was extracted with dichloromethane (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 190 mg of the target compound (yield: 34%).
[0369] Step 5: Synthesis of N-(4-((4-(2-(4-(3-(3-aminopropyl)piperidin-4-yl)methyl)piperazin-1-yl)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0370] Compound (3-(4-(3-(4-(4-(2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)piperazin-1-yl)methyl)piperidin-1-yl)propyl)tert-butyl carbamate (190 mg, 0.24 mmol)) was dissolved in 10 mL of dichloromethane, and 5 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 124 mg of the target compound, yield: 74%.
[0371] Step 6: Synthesis of N-(4-((4-(2-(4-(3-(4-((1-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propyl)piperidin-4-yl)methyl)piperazin-1-yl)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0372] N-(4-((4-(2-(4-(3-(3-aminopropyl)piperidin-4-yl)methyl)piperazin-1-yl)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (124 mg, 0.18 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (50 mg, 0.18 mmol), and DIPEA (70 mg, 0.54 mmol) were sequentially added to 5 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 18 mg of the target compound. Yield: 11%. 1 H NMR (400MHz, CDCl3) δ8.56(d,J=5.1Hz,1H),7.58(d,J=8.2Hz,1H),7.20(d,J=5.0Hz,1H),7.10(dd,J=25 .5,8.3Hz,4H),6.92(s,1H),6.80(dd,J=21.6,8.4Hz,4H),6.55(s,1H),5.01(s,2H),4.96–4.88(m,1H),4 .17(d,J=8.6Hz,2H),3.48(s,3H),3.34(s,2H),3.20(s,2H),2.92–2.67(m,5H),2.46(s,8H),2.15(d,J= 34.5Hz,6H),1.99(s,4H),1.84(d,J=13.3Hz,2H),1.62(s,6H),1.42(d,J=5.5Hz,4H).LC / MS(ESI+)calcd for C 50 H 63 N9O8S([M+H)) + )m / z:950.5; found 950.5.
[0373] Example 30: N-(4-((4-(2-(4-((8-(6-(2-(2,6-dioxadiazin-3-yl)-1,3-dioxoisoindoline-5-yl)-2,6-diazaspiro[3.3]heptane-2-yl)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0374]
[0375] The target compound was prepared using a method similar to that of Example 29. 1H NMR (400MHz, CDCl3) δ7.66(s,1H),8.54(d,J=5.0Hz,1H),7.62(d,J=8.3Hz,1H),7.16(d,J=5.1Hz,1H) ,7.15–7.01(m,4H),6.95(s,1H),6.87–6.76(m,2H),6.76–6.66(m,2H),6.46(dd,J=8.3,2.1Hz,1H),5. 05(s,2H),4.92(dd,J=12.0,5.3Hz,1H),4.18–3.95(m,6H),3.48(s,7H),2.90–2.67(m,3H),2.62–2.4 2(m,2H),2.16–2.05(m,1H),1.70(d,J=7.5Hz,2H),1.61(s,6H),1.43–1.30(m,4H).LC / MS(ESI+)calcd for C 47 H 55 N7O8S([M+H)) + )m / z:878.4; found 878.4.
[0376] Example 31: N-(6-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrazine-2-yl)methanesulfonamide
[0377]
[0378] Step 1: Synthesis of 2-chloro-6-(chloromethyl)pyrazine
[0379] 2-Chloro-6-methylpyrazine (6 g, 50 mmol) was dissolved in 100 mL of carbon tetrachloride, NCS (6.65 g, 51 mmol) was added, followed by BPO (1.21 g, 5 mmol). The mixture was then refluxed under a nitrogen atmosphere for 24 hours. After the reaction mixture cooled to room temperature, it was filtered, concentrated under reduced pressure, and purified by column chromatography to obtain 2.8 g of the target compound, yield: 35%.
[0380] Step 2: Synthesis of tert-butyl butyl (4-((8-(4-(2-(4-(((6-chloropyrazin-2-yl)methoxy)phenyl)propyl-2-yl)phenoxy)octyl)oxy)butylcarbamate)
[0381] (3-((8-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)octyl)oxy)propyl)tert-butyl carbamate (1.05 g, 2 mmol), 2-chloro-4-(chloromethyl)pyrimidine (320 mg, 2 mmol) and potassium carbonate (552 mg, 4 mmol) were added sequentially to 10 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 400 mg of the target compound, yield: 31%.
[0382] Step 3: Synthesis of tert-butyl carbamate (4-((8-(4-(2-(4-((6-(methylsulfonamido)pyrazin-2-yl)methoxy)phenyl)propyl-2-yl)phenoxy)octyl)oxy)carbamate)
[0383] Compound (4-((8-(4-(2-(4-(((6-chloropyrazin-2-yl)methoxy)phenyl)propyl-2-yl)phenoxy)octyl)oxy)tert-butylcarbamate (400 mg, 0.61 mmol), methanesulfonamide (115 mg, 1.22 mmol), Pd2(dba)3 (55 mg, 0.061 mmol), XantPhos (69 mg, 0.12 mmol), and cesium carbonate (590 mg, 1.8 mmol) were added to 5 mL of dioxane. The reaction system was replaced with a helium atmosphere, and the reaction was carried out overnight at 110 °C. After the reaction was completed as monitored by TLC, the reaction system was filtered with diatomaceous earth, concentrated, and purified by column chromatography to obtain 150 mg of the target compound, yield: 35%.
[0384] Step 4: Synthesis of N-(6-((4-(2-(4-((8-(4-aminobutoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrazin-2-yl)methylsulfonamide
[0385] Compound (150 mg, 0.21 mmol) of tert-butyl carbamate was dissolved in 10 mL of dichloromethane, and 5 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 77 mg of the target compound, yield: 60%.
[0386] Step 5: Synthesis of N-(6-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrazin-2-yl)methanesulfonamide
[0387] N-(6-((4-(2-(4-(((8-(4-aminobutoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrazin-2-yl)methanesulfonamide (77 mg, 0.12 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (33 mg, 0.12 mmol), and DIPEA (60 mg, 0.45 mmol) were sequentially added to 5 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (8 mg target compound, yield: 8%). LC / MS (ESI+) calcd for C 46 H 56 N6O9S([M+H)) + )m / z:869.4; found 869.4.
[0388] Example 32: N-(2-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-4-yl)methanesulfonamide
[0389]
[0390] The target compound was prepared using a method similar to that in Example 31. LC / MS (ESI+) calcd for C 46 H 56 N6O9S([M+H)) + )m / z:869.4; found 869.4.
[0391] Example 33: N-(6-((4-(2-(4-((8-(4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyridin-2-yl)methanesulfonamide
[0392]
[0393] The target compound was prepared using a method similar to that in Example 31. LC / MS (ESI+) calcd for C 47 H 57 N5O9S([M+H)) + )m / z:868.4; found 868.4.
[0394] Example 34: N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)piperidin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0395]
[0396] Step 1: Synthesis of 4-(4-(2-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester
[0397] Compound N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (200 mg, 0.48 mmol) and tert-butyl 4-(p-toluoxy)piperidine-1-carboxylic acid (189 mg, 0.53 mmol) were added to 10 mL of LDM, followed by Cs2CO3 (235 mg, 0.72 mmol) and KI (9 mg, 0.05 mmol). The mixture was stirred at 70 °C for 2 h. The reaction mixture was cooled to room temperature, and a small amount of water was added. The mixture was extracted three times with ethyl acetate. The combined organic phases were washed three times with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated to dryness. Column chromatography was used to purify the compound 4-(4-(2-(4-((2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester (134 mg, 0.22 mmol), yield: 47%. LC / MS (ESI+) calcd for C 31 H 40 N4O6S([M+H)) + )m / z 596.74; found 597.2.
[0398] Step 2: Synthesis of N-(4-((4-(2-(4-(piperidin-4-oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0399] Compound 4-(4-(2-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-carboxylic acid tert-butyl ester (134 mg, 0.22 mmol) was added to 2 mL of 1,4-dioxane and stirred in an ice bath. Then, 2 mL of 4M dioxane hydrochloride solution was added, and the mixture was stirred at room temperature for 15 min. The reaction solution was adjusted to alkaline with saturated NaHCO3 solution, extracted three times with DCM, and the organic phase was washed with saturated NaCl solution. The solution was dried over anhydrous sodium sulfate and evaporated to dryness to give compound N-(4-((4-(2-(4-(piperidin-4-oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (96 mg, 0.19 mmol), yield: 88%. LC / MS (ESI+) calcd for C 26 H 32 N4O4S([M+H)) + )m / z 496.63; found497.1.
[0400] Step 3: Synthesis of N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindololin-5-yl)piperidin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0401] N-(4-((4-(2-(4-(piperidin-4-oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (48 mg, 0.09 mmol) was dissolved in 5 mL of DMSO, and DIPEA (36 mg, 0.28 mmol) and 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (28 mg, 0.10 mmol) were added sequentially. The mixture was heated to 90 °C and reacted overnight under N2 protection. The mixture was cooled to room temperature, quenched with water, extracted three times with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated, and evaporated to dryness. The mixture was then purified by prep-TLC to give compound N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)piperidin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (16 mg, 0.02 mmol), yield: 24%. 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),8.44(d,J=4.9Hz,1H),8.26(s,1H),7.67(d,J=8.5H z,1H),7.41(t,J=7.6Hz,1H),7.16–7.07(m,5H),6.98(d,J=8.2Hz,1H),6.92–6.88(m,3H) ,5.07(dd,J=12.9,5.3Hz,1H),5.00(s,2H),4.60(s,1H),3.79(s,2H),3.14(s,3H),2.88( s,2H),2.04–1.96(m,3H),1.66(d,J=7.8Hz,3H),1.58(d,J=2.6Hz,6H),1.42–1.31(m,2H). LC / MS(ESI+)calcd for C 39 H 40 N6O8S([M+H)) + )m / z752.84; found 753.2.
[0402] Example 35: N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)piperidine-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0403]
[0404] The target compound was prepared using a method similar to that in Example 34. 1 H NMR(400MHz,DMSO-d6)δ11.10(s,1H),8.49(d,J=5.1Hz,1H),8.26(s,1H),7.72–7 .66(m,1H),7.36(d,J=4.5Hz,1H),7.12(t,J=9.4Hz,5H),7.00(d,J=5.4Hz,1H),6 .90(t,J=7.7Hz,3H),5.10(dd,J=13.0,5.3Hz,1H),5.03(s,2H),4.56(s,1H),3.2 0(s,3H),2.60(s,2H),2.06(s,3H),1.81(s,3H),1.58(s,6H),1.45–1.29(m,2H). LC / MS(ESI+)calcd for C 39 H 40 N6O8S([M+H)) + )m / z 752.84; found 753.2.
[0405] Example 36: N-(4-((4-(2-(4-((1-(4-(4-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)butyl)piperidine-4-yl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0406]
[0407] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 47 H 57 N7O9S1([M+H) + )m / z 896.07; found 896.8.
[0408] Example 37: N-(4-((4-(2-(4-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0409]
[0410] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 37 H 39 N6O8S + ([M+H)) + )m / z:727.2; found 727.2. 1 H NMR (400MHz, CDCl3) δ9.09 (s, 1H), 8.60 (d, J = 5.1Hz, 1H), 7.50 (d, J = 8.4Hz, 1H), 7.32 (d, J = 5.0Hz, 1 H),7.14(dd,J=15.0,8.6Hz,4H),6.96(d,J=2.0Hz,1H),6.83(dd,J=17.2,8.6Hz,4H),6.75(d,J=8.1 Hz,1H),5.16–5.03(m,2H),4.92(dd,J=12.0,5.3Hz,1H),4.14–4.02(m,2H),3.60–3.47(m,2H),3.46 (s,2H),2.91(d,J=14.6Hz,1H),2.81–2.69(m,2H),2.63(s,3H),2.12(s,3H),1.64(d,J=2.4Hz,6H).
[0411] Example 38: N-(4-((4-(2-(4-((5-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)pentyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0412]
[0413] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 39 H 43 N6O8S + ([M+H)) + )m / z:755.3; found 755.2. 1 H NMR (400MHz, CDCl3) δ8.62(s,1H),8.60(d,J=5.2Hz,1H),7.60(d,J=8.2Hz,1H),7.28(s,1H),7.14(dd,J=11.7,8.5 Hz,4H),6.97(s,1H),6.84(d,J=8.7Hz,2H),6.79(d,J=8.7Hz,2H),6.74(d,J=8.6Hz,1H),5.09(s,2H),4.93(dd,J= 12.0,5.2Hz,1H),3.96(t,J=6.1Hz,2H),3.45(s,3H),3.27(t,J=6.8Hz,2H),2.94–2.85(m,1H),2.82–2.70(m,2H), 2.22(t,J=7.7Hz,1H),2.12(d,J=7.0Hz,1H),2.01(d,J=7.0Hz,1H),1.83(t,J=6.9Hz,2H),1.73(s,2H),1.63(s,6H)
[0414] Example 39: N-(4-((4-(2-(4-((1r,4r)-4-((4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)-2,7-diazospiro[3.5]nonyl-7-yl)methyl)piperidin-1-yl)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-yl)methanesulfonamide
[0415]
[0416] Step 1: Synthesis of N-(4-((4-(2-(4-((1r,4r)-4-((tert-butyldimethylsiloxy)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide.
[0417] In a 25 mL flask, N-(4-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (300.0 mg, 0.7 mmol), Cs₂CO₃ (354.0 mg, 1.1 mmol), and KI (12.0 mg, 0.07 mmol) were added to 4 mL of DMF. The mixture was heated to 70 °C and stirred overnight. After cooling to room temperature, the mixture was extracted with ethyl acetate and water. The organic layer was washed with saturated brine, dried, and evaporated to dryness. The mixture was then purified by plate filtration. The result was N-(4-((4-(2-(4-((1r,4r)-4-((tert-butyldimethylsiloxy)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (100.0 mg, 0.15 mmol). Yield: 21%.
[0418] Step 2: N-(4-((4-(2-(4-((1r,4r)-4-(hydroxymethyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide.
[0419] In a 25 mL flask, compound N-(4-((4-(2-(4-((1r,4r)-4-((tert-butyldimethylsiloxy)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (100.0 mg, 0.15 mmol) was added to 2 mL of THF, followed by 0.3 mL of TBAF (1 M, 0.3 mmol). The mixture was stirred overnight at room temperature. Extraction was performed with ethyl acetate and water. The organic layer was washed with saturated brine, dried, and evaporated to dryness. The mixture was then purified by plate filtration. The yield was 49%, yielding compound N-(4-((4-(2-(4-((1r,4r)-4-(hydroxymethyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide.
[0420] Step 3: Synthesize N-(4-((4-(2-(4-((1r,4r)-4-formylcyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide.
[0421] In a 25 mL flask, compound N-(4-((4-(2-(4-((1r,4r)-4-(hydroxymethyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (40.0 mg, 0.07 mmol) was added to 2 mL of dichloromethane, followed by the addition of PCC (32.0 mg, 0.14 mmol). The mixture was stirred at room temperature for 2 hours, then extracted with dichloromethane and water. The organic layer was washed with saturated brine, dried, and evaporated to dryness. The resulting product was purified by plate filtration. The yield was 25.0 mg, 0.04 mmol.
[0422] Step 4: Synthesis of N-(4-((4-(2-(4-((1r,4r)-4-((4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)-2,7-diazospiro[3.5]nonyl-7-yl)methyl)piperidin-1-yl)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-yl)methanesulfonamide.
[0423] In a 25 mL flask, N-(4-((4-(2-(4-((1r,4r)-4-formylcyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (25.0 mg, 0.04 mmol), 2-(2,6-dioxadiazin-3-yl)-5-(7-(piperidin-4-ylmethyl)-2,7-diazaspiro[3.5]non-2-yl)isoindol-1,3-dione (22.0 mg, 0.04 mmol), and sodium borohydride acetate (29.0 mg, 0.12 mmol) were added to 2 mL of dichloromethane, followed by the addition of acetic acid (3.0 mg, 0.08 mmol). The mixture was stirred overnight at room temperature, then extracted with dichloromethane and saturated sodium carbonate. The organic layer was washed with saturated brine, dried, and evaporated to dryness to prepare a large-plate purification. The compound N-(4-((4-(2-(4-((1r,4r)-4-((4-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)-2,7-diazaspiro[3.5]nonyl-7-yl)methyl)piperidin-1-yl)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-yl)methanesulfonamide (20 mg, 0.02 mmol) was obtained. The yield was 43%. LC / MS (ESI+) calcd for C 55 H 69 N8O8S + ([M1 / 2+H) +)m / z:501.3;found501.4. 1 H NMR (400MHz, CDCl3) δ8.57(d,J=5.1Hz,1H),7.61(dd,J=17.1,8.0Hz,1H),7.10(dd,J=15.2,8.0Hz,5H), 6.90(d,J=8.5Hz,2H),6.84–6.71(m,3H),6.63(t,J=8.1Hz,1H),5.07(s,3H),3.77–3.67(m,6H),3.29(s, 3H),2.89(dd,J=22.1,9.3Hz,5H),2.64–2.52(m,2H),2.37–2.25(m,4H),2.13(dd,J=20.8,6.7Hz,5H),1 .97(dd,J=22.6,10.7Hz,4H),1.84–1.73(m,7H),1.57(s,6H),1.18–0.99(m,6H),0.86(d,J=11.1Hz,2H).
[0424] Example 40: N-(4-((4-(2-(4-((1-(3-(3-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)propyl)piperidine-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0425]
[0426] The target compound was prepared using a method similar to that of Example 39. LC / MS (ESI+) calcd for C 46 H 56 N7O9S + ([M+H)) + )m / z:882.4; found 882.3.
[0427] Example 41: N-(4-((4-(2-(4-((1-(4-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)butyl)piperidine-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0428]
[0429] The target compound was prepared using a method similar to that of Example 39. LC / MS (ESI+) calcd for C 48 H 60N7O9S + ([M+H)) + m / z:910.4; found 910.3
[0430] Example 42: N-(4-(2-(4-((1-((1r,4r)-4-((2-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)-2,7-diazospiro[3.5]nonyl-7-yl)methyl)cyclohexyl)methyl)piperidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0431]
[0432] The target compound was prepared using a method similar to that of Example 39. LC / MS (ESI+) calcd for C 55 H 69 N8O8S + ([M1 / 2+H) + )m / z:501.2; found 501.4. 1 H NMR (400MHz, DMSO-d6) δ8.58(d,J=5.1Hz,1H),7.61(dd,J=17.2,8.3Hz,1H),7.11(dt,J=14.4,7.8H z,6H),6.90(d,J=8.5Hz,2H),6.83–6.75(m,3H),6.64(d,J=8.3Hz,1H),5.11–5.00(m,3H),3.74(q, J=6.9,6.3Hz,6H),2.89(dd,J=20.7,8.9Hz,5H),2.61–2.52(m,2H),2.37–2.20(m,5H),2.09(dd,J= 20.2,6.7Hz,4H),2.03–1.86(m,5H),1.74(t,J=11.1Hz,10H),1.57(s,6H),1.41(d,J=18.3Hz,4H).
[0433] Example 43: N-(4-((4-(2-(4-((1r,4r)-4-((4-((4-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)methyl)piperidine-1-yl)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0434]
[0435] In a 25 mL flask, N-(4-((4-(2-(4-((1r,4r)-4-formylcyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (14.0 mg, 26.0 μmol) and 2-(2,6-dioxadiazin-3-yl)-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione (11.0 mg, 26.0 μmol) were added to 2 mL of dichloromethane, followed by a catalytic amount of acetic acid. The mixture was stirred overnight at room temperature. The solution was then evaporated under vacuum and purified using silica gel stencils. A yellow solid N-(4-((4-(2-(4-((1r,4r)-4-((4-((4-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoquinoline-5-yl)piperazin-1-yl)methyl)piperidine-1-yl)methyl)cyclohexyl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (11 mg, 11.4 μmol) was obtained in 44% yield. LC / MS (ESI+) calcd for C 52 H 65 N8O8S + ([M+H)) + )m / z:961.5; found 961.5. 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.54(d,J=5.1Hz,1H),7.55(d,J=8.3Hz,1H),7.14–7.05( m,6H),6.95–6.88(m,3H),6.84(d,J=9.2Hz,1H),6.79(d,J=8.3Hz,2H),5.03(d,J=16.1Hz,3H), 3.74(d,J=5.8Hz,2H),3.26(s,3H),3.23–3.11(m,8H),2.95–2.82(m,5H),2.57(s,2H),2.31(d, J=8.4Hz,3H),1.95(dt,J=23.1,9.0Hz,5H),1.79–1.62(m,6H),1.56(s,6H),1.50–1.45(m,4H).
[0436] Example 44: N-(4-(4-(2-(4-((8-(4-)((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)ethanesulfonamide)
[0437]
[0438] The target compound was prepared using a method similar to that of Example 39. LC / MS (ESI+) calcd for C 47 H 59 N6O9S + ([M1 / 2+H) + )m / z:442.2; found 442.1. 1 H NMR (400MHz, CDCl3) δ8.53(d,J=4.8Hz,1H),8.09(s,1H),7.60(d,J=7.8Hz,1H),7.15(dd,J=10.6,6.7Hz, 3H),7.07(d,J=8.1Hz,2H),6.99(s,1H),6.83(d,J=8.3Hz,2H),6.73(d,J=8.4Hz,3H),5.04(s,2H),4.98–4 .88(m,1H),4.09–4.01(m,2H),3.77(q,J=7.2Hz,2H),3.45(dt,J=13.0,6.2Hz,4H),3.24(s,2H),2.94–2. 74(m,3H),2.11(d,J=8.8Hz,1H),1.72(d,J=24.2Hz,6H),1.62(s,6H),1.57(s,2H),1.34(d,J=7.3Hz,11H)
[0439] Example 45: N-(4-((4-(2-(4-((1-((1r,4r)-4-((4-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)piperidine-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0440]
[0441] The target compound was prepared using a method similar to that of Example 39. LC / MS (ESI+) calcd for C 52 H 64 N8O8S + ([M1 / 2+H) + )m / z:481.3; found 481.3. 1H NMR (400MHz, CDCl3) δ8.57(d,J=5.1Hz,1H),7.69(d,J=8.5Hz,1H),7.21(d,J=5.1Hz,1H),7.15(d,J= 8.7Hz,2H),7.07–7.03(m,2H),6.84(d,J=8.6Hz,2H),6.74(d,J=8.6Hz,2H),5.10(s,2H),4.93(dd,J= 12.2,5.3Hz,1H),4.04(d,J=6.9Hz,2H),3.59(s,13H),3.29(s,4H),3.00(q,J=7.3Hz,1H),2.91–2.8 1(m,2H),2.80–2.72(m,2H),2.65(d,J=6.5Hz,2H),1.91–1.81(m,8H),1.62(s,6H),1.12–0.81(m,8H)
[0442] Example 46: N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)azacyclobutane-3-yl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0443]
[0444] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 37 H 36 N6O8S([M+H)) + )m / z:724.2; found 723.3. 1 H NMR(400MHz,Chloroform-d)δ8.99(s,1H),8.21(d,J=7.5Hz,1H),7.90(dd,J=7.4,1.5Hz,1H),7. 51(t,J=7.5Hz,1H),7.22(dd,J=7.5,1.6Hz,1H),7.16(ddd,J=7.7,6.3,1.4Hz,5H),6.93–6.81(m ,4H),5.50(t,J=7.0Hz,1H),5.22–5.06(m,2H),4.73(p,J=7.0Hz,1H),4.09(dd,J=12.4,7.1Hz,2 H),3.97(dd,J=12.5,7.1Hz,2H),3.08(s,3H),2.67–2.52(m,2H),2.25–2.04(m,2H),1.62(s,6H).
[0445] Example 47: Synthesis of N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4-yl)azacyclobutane-3-yl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide:
[0446]
[0447] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 37 H 36 N6O8S([M+H)) + )m / z:724.2; found 723.3. 1 H NMR(400MHz, CDCl3)δ9.12(s,1H),8.21(d,J=7.5Hz,1H),7.70(d,J=7.5Hz,1H),7.39(d,J=1.4Hz,1H),7.21–7.11(m,6H),6.93–6.83(m,4H),5.4 5(t,J=7.0Hz,1H),5.22–5.08(m,2H),4.73(p,J=7.0Hz,1H),4.09–3.87 (m,4H),3.08(s,3H),2.68–2.55(m,2H),2.24–2.02(m,2H),1.62(s,6H).
[0448] Example 48: N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)azacyclobutane-3-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0449]
[0450] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) Calcd for C 38 H 36 N6O8S(M+H + )m / z,738.3;found 738.3.
[0451] Example 49: N-(4-((4-(2-(4-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-4-yl)azacyclobutane-3-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0452]
[0453] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) Calcd for C 38 H 36 N6O8S(M+H + )m / z,738.3;found 738.3.
[0454] Example 50: N-(4-((4-(2-(4-((8-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)amino))butoxy)octyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)cyclopropanesulfonamide
[0455]
[0456] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 48 H 58 N6O9S + ([M+H)) + )m / z:894.4; found 894.3. 1 H NMR (400MHz, CDCl3) δ8.53(d,J=4.8Hz,1H),8.09(s,1H),7.60(d,J=7.8Hz,1H),7.15(dd,J=10.6,6.7Hz, 3H),7.05(d,J=8.1Hz,2H),6.99(s,1H),6.81(d,J=8.3Hz,2H),6.73(d,J=8.4Hz,3H),5.04(s,2H),4.98–4 .88(m,1H),4.09–4.01(m,2H),3.77(q,J=7.2Hz,2H),3.45(dt,J=13.0,6.2Hz,4H),3.24(s,2H),2.94–2. 74(m,3H),2.11(d,J=8.8Hz,1H),1.72(d,J=24.2Hz,6H),1.62(s,6H),1.57(s,2H),1.43(d,J=7.3Hz,11H)
[0457] Example 51: N-(5-((4-(2-(4-((8-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)amino))butoxy)octyl)oxy)phenyl)prop-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0458]
[0459] The target compound was prepared using a method similar to that in Example 34. LC / MS (ESI+) calcd for C 46 H 56 N6O9S + ([M+H)) + )m / z:868.4; found 868.3. 1 H NMR (400MHz, CDCl3) δ8.66(d,J=4.8Hz,1H),8.08(s,1H),7.60(d,J=7.8Hz,1H),7.15(dd,J=10.6,6 .7Hz,3H),7.07(d,J=8.1Hz,2H),6.99(s,1H),6.83(d,J=8.3Hz,2H),6.73(d,J=8.4Hz,3H),5.04(s, 2H),4.98–4.88(m,1H),4.09–4.01(m,2H),3.45(dt,J=13.0,6.2Hz,4H),3.24(s,2H),2.94–2.74(m, 3H),2.11(d,J=8.8Hz,1H),1.72(d,J=24.2Hz,6H),1.62(s,6H),1.57(s,2H),1.34(d,J=7.3Hz,11H)
[0460] Example 52: N-(4-((4-(2-(4-((5-(3-((1-(2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)pyrrolidine-3-yl)methoxy)propoxy)pentyl)oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0461]
[0462] The target compound was prepared using a method similar to that of Example 29. 1H NMR (400MHz, CDCl3) δ8.55(d,J=5.0Hz,1H),8.10(s,1H),7.64(d,J=8.4Hz,1H),7.19(d,J=5.0Hz,1H),7.17–7.10(m, 2H),7.09–7.02(m,2H),6.93(d,J=2.2Hz,1H),6.89–6.79(m,2H),6.78–6.68(m,2H),6.66(dd,J=8.5,2.3Hz,1H),5.05 (s,2H),4.93(dd,J=12.2,5.3Hz,1H),4.14–4.04(m,2H),3.57–3.44(m,10H),3.44–3.36(m,4H),3.21(dd,J=10.2,6.7 Hz,1H),2.92–2.60(m,4H),2.21–2.08(m,2H),1.92–1.69(m,6H),1.40(dq,J=10.0,7.1Hz,2H).LC / MS(ESI+)calcdfor C 47 H 56 N6O 10 S([M+H)) + )m / z:897.4; found 897.4.
[0463] Example 53: N-(4-((4-(2-(4-(2-((2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4-yl)amino)ethoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0464]
[0465] Step 1: Synthesis of 2-((tert-Butoxycarbonyl)amino)ethyl methanesulfonate
[0466] N-Boc-ethanolamine (2000 mg, 12.41 mmol) was weighed into a single-necked round-bottom flask, and dichloromethane (30 mL) was added. The mixture was stirred at room temperature until dissolved and clear. Triethylamine (3767 mg, 37.23 mmol) was then added. After this, the system was transferred to an ice-water bath for cooling and stirring. After 15 min, 10 mL of dichloromethane solution containing methanesulfonyl chloride (1706 mg, 14.89 mmol) was added dropwise. The system was then stirred at room temperature. After 4 h, the reaction was monitored by TLC until complete. The reaction was stopped, and the mixture was extracted with dichloromethane and water. The organic phase was washed with saturated ammonium chloride, then with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the crude product. Column chromatography was used to purify the product, yielding a white solid (2100 mg, 71%).
[0467] Step 2: Synthesis of tert-butyl(2-(4-(2-(4-((2-(methanesulfonyl)pyrimidin-4-yl)methoxy)phenyl)isopropyl-2-yl)phenoxy)ethyl)carbamate
[0468] N-(4-((4-(2-(4-hydroxyphenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (230 mg, 0.56 mmol), 2-((tert-butyloxycarbonyl)amino)ethyl methanesulfonate (90 mg, 0.84 mmol), potassium iodide (93 mg, 0.56 mmol), and cesium carbonate (274 mg, 0.84 mmol) were added to 6 mL of DMF. The system was then evacuated and purged with argon gas three times. After this process, the system was heated to 60 °C and stirred. The next day, TLC monitoring showed that the starting material was consumed, heating was stopped, and the mixture was cooled to room temperature. Ethyl acetate and water were added for extraction. The organic phase was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the crude product. Prep-TLC purification yielded the target product as a white solid (115 mg, 37%). LC / MS (ESI) + calcd for C 28 H 36 N4O6S([M-55)) + )m / z,556.2;found,501.1.
[0469] Step 3: Synthesis of N-(4-((4-(2-(4-(2-aminoethoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0470] 115 mg (0.21 mmol) of tert-butyl(2-(4-(2-(4-((2-(methanesulfonyl)pyrimidin-4-yl)methoxy)phenyl)isopropyl-2-yl)phenoxy)ethyl)carbamate was dissolved in 1 mL of 1,4-dioxane and then cooled and stirred in an ice-water bath. After 10 min, a solution of dioxane containing hydrogen chloride (2 mL) was added. The mixture was then allowed to react at room temperature. After 30 min, TLC monitoring showed that the reaction was complete. The solvent was removed by rotary evaporation, and residual dioxane was repeatedly removed by rotary evaporation using dichloromethane to obtain the hydrochloride salt of the target product as a white solid. This salt was used directly in the next reaction without further purification.
[0471] Step 4: Synthesize compound N-(4-((4-(2-(4-(2-((2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0472] The N-(4-((4-(2-(4-(2-aminoethoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide hydrochloride (0.21 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (88 mg, 0.32 mmol), and sodium bicarbonate (62 mg, 0.74 mmol) from the previous step were added to 5 mL of dry dimethyl sulfoxide. The system was then evacuated and purged with argon gas three times. After this, the system was transferred to an oil bath at 100 °C and stirred. After 4.5 h, TLC showed that the starting material had been largely consumed. The mixture was cooled to room temperature, extracted with ethyl acetate and water, and the organic layer was washed successively with saturated ammonium chloride, water, and saturated brine. The mixture was dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation. Prep-TLC purification yielded the target product as a pale yellow solid (16 mg, 10%). 1H NMR(400MHz,Chloroform-d)δ8.63(d,J=5.0Hz,1H),7.96(s,1H),7.50(dd,J=8.4,7.1Hz,1H) ,7.27(d,J=5.0Hz,1H),7.20–7.03(m,6H),6.86(d,J=8.8Hz,2H),6.71(d,J=8.7Hz,2H),5.13( s,2H),4.87(dd,J=12.1,5.3Hz,1H),4.33(t,J=6.6Hz,2H),3.68(t,J=6.5Hz,2H),3.53(s,3H ),3.11(br,1H),2.89–2.62(m,4H),2.09(ddd,J=8.3,6.5,3.8Hz,1H),1.63(s,6H).LC / MS(ESI + )calcd forC 36 H 36 N6O8S([M+H)) + )m / z,712.2;found,713.2.
[0473] Example 54: N-(4-((4-(2-(4-(4-((4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)butoxy)butoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0474]
[0475] It was prepared using a method similar to that of Example 53. 1H NMR(400MHz,Chloroform-d)δ8.54(d,J=5.0Hz,1H),8.06(s,1H),7.59(d,J=8.3Hz,1H),7.19(d,J=5.1Hz,1H),7.17– 7.11(m,2H),7.09–7.03(m,2H),6.96(d,J=1.9Hz,1H),6.87–6.80(m,2H),6.73(td,J=7.7,6.7,2.1Hz,3H),5.05(s,2 H),4.92(dd,J=12.2,5.3Hz,1H),4.19–4.07(m,2H),3.53–3.36(m,7H),3.22(t,J=6.8Hz,2H),2.92–2.66(m,3H),2.1 5–2.08(m,1H),1.90–1.80(m,3H),1.75(dt,J=13.5,6.6Hz,3H),1.67(dt,J=14.9,6.7Hz,4H),1.62(s,6H).LC / MS(ESI + )calcd forC 42 H 48 N6O9S([M+H)) + )m / z,812.3;found,813.3.
[0476] Example 55: N-(4-((4-(2-(4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4-yl)amino)butoxy)butoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0477]
[0478] It was prepared using a method similar to that of Example 53. 1H NMR (400MHz, Chloroform-d) δ8.54(d,J=5.0Hz,1H),8.11(s,1H),7.47(dd,J=8.5,7.2Hz,1H),7.19(d,J=5.0Hz,1H),7. 15(d,J=8.8Hz,2H),7.10–7.02(m,3H),6.87(d,J=8.6Hz,1H),6.83(d,J=8.8Hz,2H),6.72(d,J=8.7Hz,2H),5.05(s,2H), 4.91(dd,J=12.0,5.3Hz,1H),4.20–4.07(m,2H),3.55–3.39(m,7H),3.28(t,J=6.6Hz,2H),2.92–2.66(m,3H),2.11(dt,J =9.8,3.3Hz,1H),2.01(dd,J=11.9,6.2Hz,1H),1.82(dt,J=14.9,7.8Hz,3H),1.76–1.63(m,6H),1.62(s,6H).LC / MS(ESI + calcd for C 42 H 48 N6O9S([M+H)) + )m / z,812.3;found,813.3.
[0479] Example 56: N-(4-((4-(2-(4-(((1r,4r)-4-(((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)amino)pentyl)oxy)methyl)cyclohexyl)methoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0480]
[0481] Step 1: Synthesis of (((1r,4r)-4-(((5-bromopentyl)oxy)methyl)cyclohexyl)methoxy)(tert-butyl)dimethylsilane
[0482] Weigh 1082 mg (4.19 mmol) of (1r,4r)-4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexyl)methanol into a single-necked round-bottom flask, and add 10 mL of DMF. Stir at room temperature until dissolved and clear. Then, transfer the system to an ice-water bath for cooling and stirring. After 15 min, add 201 mg (5.03 mmol) of sodium hydride and incubate for 10 min. Add 2 mL of DMF solution containing 1,5-dibromopentane (1060 mg, 4.61 mmol). After this, stir the system at room temperature. After 3 h, TLC monitoring showed the starting material had disappeared. Under ice-water bath conditions, a saturated ammonium chloride solution was added to the system to quench the reaction. Then, ethyl acetate and water were added to complete the extraction operation. The organic phase was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the crude product. The target product was obtained as a colorless, transparent, oily liquid (512 mg, 30%) by column chromatography.
[0483] Step 2: Synthesis of 2-(5-(((1r,4r)-4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexyl)methoxy)pentyl)isoindoline-1,3-dione
[0484] Weigh 500 mg (1.23 mmol) of (((1r,4r)-4-(((5-bromopentyl)oxy)methyl)cyclohexyl)methoxy)(tert-butyl)dimethylsilane into a single-necked round-bottom flask, add 12 mL of DMF, and stir at room temperature until dissolved and clear. Add potassium iodide (204 mg, 1.23 mmol) and potassium phthalimide (228 mg, 1.23 mmol) to the system, and perform evacuation and argon purging three times. React the system overnight in an oil bath at 80 °C. The next day, the reaction was monitored by TLC until complete, heating was stopped, and the mixture was cooled to room temperature. Ethyl acetate and water were added for extraction. The organic phase was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the crude product. Column chromatography was used to purify the product to obtain a white solid (428 mg, 74%). LC / MS (ESI) + calcd for C 27 H 43 NO4Si([M+H)) + )m / z,473.3; found,474.3.
[0485] Step 3: Synthesis of 2-(5-(((1r,4r)-4-(hydroxymethyl)cyclohexyl)methoxy)pentyl)isoindoline-1,3-dione
[0486] 2-(5-(((1r,4r)-4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexyl)methoxy)pentyl)isoindoline-1,3-dione (428 mg, 0.90 mmol) was added to 10 mL of THF and stirred at room temperature until dissolved and clear. TBAF·H₂O (706 mg, 2.70 mmol) was added to the system, and the mixture was evacuated under argon gas for three times. The system was stirred overnight at room temperature. The next day, the reaction was monitored by TLC until complete. Ethyl acetate and water were added for extraction. The organic phase was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the crude product. Prep-TLC purification yielded the target product as a white solid (140 mg, 43%).
[0487] Step 4: Synthesis of ((1r,4r)-4-(((5-(1,3-dioxoisoindoline-2-yl)pentyl)oxy)methyl)cyclohexyl)methylmethanesulfonate
[0488] 140 mg (0.39 mmol) of 2-(5-(((1r,4r)-4-(hydroxymethyl)cyclohexyl)methoxy)pentyl)isoindoline-1,3-dione was dissolved in 5 mL of dichloromethane. Triethylamine (52 mg, 0.51 mmol) and DMAP (5 mg, 0.04 mmol) were added to the system, and the mixture was then cooled and stirred in an ice-water bath. After 15 min, methanesulfonyl chloride (49 mg, 0.43 mmol) was added. The reaction was then carried out with stirring at room temperature. After 2.5 h, the starting material disappeared as monitored by TLC. Dichloromethane and water were added to the system to complete the extraction. The mixture was dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the target product as a white solid (171 mg). This product was used directly in the next reaction without further purification.
[0489] Step 5: Synthesis of N-(4-((4-(2-(4-(((1r,4r)-4-(((5-(1,3-dioxopiperidin-2-yl)pentyl)oxy)methyl)cyclohexyl)methoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0490] ((1r,4r)-4-(((5-(1,3-dioxoisoindoline-2-yl)pentyl)oxy)methyl)cyclohexyl)methylmethanesulfonate (171 mg, 0.39 mmol), N-(4-((4-(2-(4-hydroxyphenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (128 mg, 0.31 mmol), potassium carbonate (108 mg, 0.78 mmol), and potassium iodide (98 mg, 0.59 mmol) were added to 5 mL of DMF. The system was evacuated and purged with argon gas three times. The system was then transferred to an oil bath at 75 °C and stirred overnight. The reaction was stopped by TLC after 17 h. After cooling to room temperature, the mixture was extracted with ethyl acetate and water. The organic layer was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation. Prep-TLC purification yielded the target product as an off-white solid (78 mg, 33%). LC / MS (ESI) + calcd for C 42 H 50 N4O7S([M+H)) + )m / z,754.3; found,755.3.
[0491] Step 6: Synthesis of N-(4-((4-(2-(4-(((1r,4r)-4-(((5-aminopentyl)oxy)methyl)cyclohexyl)methoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0492] N-(4-((4-(2-(4-(((1r,4r)-4-(((5-(1,3-dioxopiperidin-2-yl)pentyl)oxy)methyl)cyclohexyl)methoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (78 mg, 0.10 mmol) was dissolved in 5 mL of ethanol, followed by the addition of hydrazine hydrate (54 mg, 1.00 mmol). The system was refluxed in an oil bath at 85 °C. After 2 h, the reactants were consumed by TLC. After the system cooled to room temperature, it was filtered. The filter cake was washed with ethanol in small amounts several times. The filtrates were combined, and the solvent was removed by rotary evaporation to obtain the crude product. Dichloromethane was added to the system, and the mixture was stirred in an ice-water bath. After 30 minutes, the system was filtered again. The filter cake was washed with dichloromethane in small amounts several times. The filtrates were combined, and the solvent was removed by rotary evaporation to obtain the target product as an off-white solid (58 mg, 89%).
[0493] Step 7: Synthesis of N-(4-((4-(2-(4-(((1r,4r)-4-(((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)amino)pentyl)oxy)methyl)cyclohexyl)methoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0494] N-(4-((4-(2-(4-(((1r,4r)-4-(((5-aminopentyl)oxy)methyl)cyclohexyl)methoxy)phenyl)isopropyl-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (58 mg, 0.09 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.11 mmol), and DIPEA (233 mg, 1.80 mmol) were added to 8 mL of dry dimethyl sulfoxide. The system was then evacuated and purged with argon gas three times. After completion, the system was transferred to an oil bath at 90 °C and stirred. The following day, TLC showed that the starting materials had been largely consumed. After cooling to room temperature, ethyl acetate and water were added for extraction. The organic layer was washed successively with saturated ammonium chloride, water, and saturated brine. The mixture was dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation. The target product was obtained as a light yellow solid (15 mg, 18%) by Prep-TLC separation and purification. 1 H NMR(400MHz,Chloroform-d)δ8.56(d,J=4.0Hz,1H),8.07(s,1H),7.60(d,J=7.4Hz,1H),7.23–7.17(m,1H),7.14(d,J=8.3Hz,2H),7 .07(d,J=8.2Hz,2H),6.96(s,1H),6.84(d,J=8.3Hz,2H),6.73(d,J=8.3Hz,3H),5.05(s,2H),4.93(dd,J=11.7,5.1Hz,1H),4.01(d,J =6.6Hz,2H),3.50(s,3H),3.41(t,J=5.6Hz,2H),3.21(d,J=6.0Hz,4H),2.98–2.61(m,4H),2.28–2.19(m,1H),2.17–2.08(m,2H),2. 01(dd,J=11.8,7.2Hz,1H),1.78(t,J=13.0Hz,6H),1.71–1.65(m,2H),1.63(s,6H),1.53–1.44(m,3H),1.10–0.96(m,3H).LC / MS(ESI + )calcd forC 47 H 56 N6O9S([M+H))+ )m / z,880.4;found,881.2.
[0495] Example 57: N-(4-((4-(3-(4-((8-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)pentyl-3-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
[0496]
[0497] The target compound was prepared using a method similar to that in Example 1. LC / MS (ESI) + )calcd forC 48 H 60 N6O9S([M+H)) + )m / z,896.4; found,897.2.
[0498] Example 58: N-(4-((4-(1-(4-((8-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octyl)oxy)phenyl)cyclobutyl)phenoxy)methyl)pyrimidin-2-yl)methylsulfonamide
[0499]
[0500] It was prepared using a method similar to that of Example 1. 1 H NMR(400MHz,Chloroform-d)δ8.62(d,J=15.1Hz,1H),7.59(d,J=8.1Hz,1H),7.25–7.10(m,6H),6.94(s,1H), 6.82(dd,J=19.3,8.6Hz,4H),6.71(d,J=8.0Hz,1H),5.38–5.32(m,1H),5.07(s,2H),4.92(dd,J=12.0,5.1Hz ,1H),3.89(t,J=6.4Hz,2H),3.56–3.31(m,7H),3.24(p,J=6.1Hz,2H),2.94–2.55(m,8H),2.27–2.18(m,1H), 2.16–2.07(m,1H),2.02(dt,J=11.8,6.2Hz,2H),1.94(dt,J=14.8,7.5Hz,3H),1.78–1.56(m,12H).LC / MS(ESI + calcd for C 47 H 56N6O9S([M+H)) + )m / z,879.4; found,880.3.
[0501] Example 59: 2-(2,6-dioxadiazine-3-yl)-4-((3-(4-(2-(4-(2-morpholinidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0502] Step 1: Synthesis of tert-butyl (3-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)propyl)carbamate
[0503] Bisphenol A (11.4 g, 50 mmol), 3-((tert-Butoxycarbonyl)amino)propyl methanesulfonate (12.6 g, 50 mmol), and cesium carbonate (32.5 g, 100 mmol) were added sequentially to 200 mL of DMF. The mixture was heated to 60 °C and reacted overnight. After the reaction was completed by TLC monitoring, it was allowed to cool naturally to room temperature. The mixture was extracted with 200 mL of ethyl acetate, washed with saturated brine (3 x 100 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 11.1 g of the target compound, yield: 58%.
[0504] Step 2: Synthesis of tert-butyl (3-(4-(2-(4-(((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)carbamate
[0505] (3-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)propyl)tert-butyl carbamate (3.85 g, 10 mmol), 2-chloro-4-(chloromethyl)pyrimidine (1.62 g, 10 mmol), and potassium carbonate (2.76 g, 20 mmol) were added sequentially to 30 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 20 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 4.05 g of the target compound, yield: 79%.
[0506] Step 3: Synthesis of tert-butyl carbamate (3-(4-(2-(4-(((2-morpholinid-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)carbamate
[0507] (3-(4-(2-(4-(((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)tert-butyl carbamate (102 mg, 0.2 mmol), morpholine (35 mg, 0.4 mmol), and potassium carbonate (56 mg, 0.4 mmol) were added sequentially to 1 mL of DMF. The mixture was heated to 60 °C and reacted overnight. After the reaction was monitored by TLC until complete, the mixture was allowed to cool naturally to room temperature. The mixture was extracted with 1 mL of ethyl acetate, washed with saturated brine (3 x 1 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 88 mg of the target compound. Yield: 78%.
[0508] Step 4: Synthesis of (3-(4-(2-(4-((2-morpholinidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propane-1-amine
[0509] Compound (3-(4-(2-(4-(((2-morpholinidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)tert-butyl carbamate (88 mg, 0.16 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 52 mg of the target compound, yield: 70%.
[0510] Step 5: Synthesis of 2-(2,6-dioxadiazine-3-yl)-4-((3-(4-(2-(4-(2-morpholinidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0511] (3-(4-(2-(4-(((2-morpholinidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propane-1-amine (52 mg, 0.11 mmol), 2-(2,6-dioxadiazin-3-yl)-4-fluoroisoindoline-1,3-dione (33 mg, 0.12 mmol), and DIPEA (43 mg, 0.33 mmol) were sequentially added to 5 mL of DMSO, and the mixture was heated to 130 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 6 mg of the final product (yield: 7.6%). 1H NMR (400MHz, CDCl3) δ8.33 (s, 1H), 8.14 (s, 1H), 7.46 (t, J = 7.7Hz, 1H), 7.11 (dd, J = 18.1, 7.6Hz,5H),6.92(d,J=8.4Hz,1H),6.83(d,J=8.2Hz,4H),6.77(s,1H),6.46(d,J=5.9Hz,1 H),4.94(s,2H),4.90(d,J=4.5Hz,1H),4.07(t,J=5.6Hz,2H),3.80(d,J=17.9Hz,8H),3.5 0(d,J=6.2Hz,2H),3.00–2.62(m,3H),2.18–2.03(m,3H),1.63(s,6H).LC / MS(ESI+)calcd for C 40 H 42 N6O7([M+H)) + )m / z:719.3; found 719.3.
[0512] Example 60: 2-(2,6-dioxadiazin-3-yl)-4-((3-(4-(2-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0513]
[0514] The target compound was prepared using a method similar to that of Example 59. 1 H NMR(400MHz, CDCl3)δ8.78(s,1H),8.29(d,J=5.0Hz,1H),7.46(dd,J=8.5,7.1Hz,1H),7.16–7.10(m,4H), 7.08(d,J=7.1Hz,1H),6.91(d,J=8.6Hz,1H),6.86–6.79(m,4H),6.71(d,J=5.0Hz,1H),6.45(t,J=5.8Hz, 1H),4.92(s,2H),4.91–4.87(m,1H),4.06(t,J=5.6Hz,2H),3.89(t,J=4.9Hz,4H),3.50(q,J=6.3Hz,2H), 2.91–2.71(m,3H),2.55(t,J=5.2Hz,4H),2.38(s,3H),2.14–2.09(m,3H),1.62(s,6H).LC / MS(ESI+)calcd for C 41 H 45 N7O6([M+H))+ )m / z:732.4; found 732.4.
[0515] Example 61: 5-((4-((8-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0516]
[0517] Step 1: Synthesis of 4-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenol
[0518] Bisphenol A (2.28 g, 10 mmol), 2-chloro-4-(chloromethyl)pyrimidine (0.81 g, 5 mmol), and potassium carbonate (1.38 g, 10 mmol) were added sequentially to 20 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 20 mL of ethyl acetate, washed with saturated brine (3 x 20 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 0.65 g of the target compound, yield: 36%.
[0519] Step 2: Synthesis of 4-(2-(4-((2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenol
[0520] 4-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenol (650 mg, 1.8 mmol), 2-oxa-6-azaspiro[3.3]heptane (200 mg, 2 mmol), and DIPEA (702 mg, 5.4 mmol) were added sequentially to 10 mL of DMSO. The mixture was reacted overnight at 80 °C. After the reaction was completed by TLC, the mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 680 mg of the target compound, yield: 90%.
[0521] The target compound was prepared in subsequent steps using a method similar to that of Example 59. 1H NMR (400MHz, CDCl3) δ8.31(s,1H),8.12(s,1H),7.60(d,J=8.3Hz,1H),7.18–7.08(m,4H),6.95(d,J=2.1Hz,1 H),6.88(s,1H),6.85–6.75(m,4H),6.71(dd,J=8.3,2.1Hz,1H),4.97(s,2H),4.95–4.84(m,5H),4.40(s,4H) ,3.91(t,J=6.5Hz,2H),3.44(dt,J=13.2,6.3Hz,4H),3.24(t,J=6.6Hz,2H),2.88–2.70(m,3H),2.22(t,J=7. 6Hz,1H),1.72(d,J=7.5Hz,4H),1.62(s,6H),1.42(d,J=5.2Hz,4H),1.34(d,J=5.5Hz,8H).LC / MS(ESI+)calcd for C 50 H 60 N6O8([M+H)) + )m / z:873.5; found 873.5.
[0522] Example 62: 5-((3-(3-((7-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)heptyl)oxy)propoxy)propyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0523]
[0524] The target compound was prepared using a method similar to that of Example 59. 1H NMR (400MHz, CDCl3) δ8.30(s,1H),8.13(s,1H),7.60(d,J=8.3Hz,1H),7.17–7.08(m,4H),6.95(d,J=2.1Hz,1H),6.90( s,1H),6.86–6.75(m,4H),6.71(dd,J=8.3,2.2Hz,1H),4.97(s,2H),4.95–4.78(m,5H),4.43(s,4H),3.91(t,J=6.5Hz, 2H),3.58(t,J=5.5Hz,2H),3.52(dt,J=8.4,6.3Hz,4H),3.41(t,J=6.7Hz,2H),3.33(t,J=6.3Hz,2H),2.92–2.72(m,3H ),2.22(t,J=7.6Hz,1H),1.92–1.85(m,4H),1.62(s,6H),1.44–1.40(m,4H),1.30–1.28(m,6H).LC / MS(ESI+)calcdfor C 51 H 62 N6O9([M+H)) + )m / z:903.5; found 903.5.
[0525] Example 63: 2-(2,6-dioxadiazin-3-yl)-5-(4-((8-(4-(2-(2-(3-methylazacyclobutane-1-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)isoindoline-1,3-dione
[0526]
[0527] The target compound was prepared using a method similar to that of Example 59. 1H NMR (400MHz, CDCl3) δ8.28(s,1H),8.10(d,J=11.7Hz,1H),7.59(d,J=7.9Hz,1H),7.11(td,J=16.2 ,7.5Hz,4H),6.94(s,2H),6.86–6.68(m,5H),5.07–4.86(m,3H),4.50(s,2H),3.91(t,J=6.6Hz,3H) ,3.61–3.17(m,7H),2.94–2.74(m,3H),2.38–2.17(m,1H),2.11(t,J=7.6Hz,1H),1.73(dd,J=17.7, 10.4Hz, 6H), 1.63 (s, 6H), 1.39 (d, J=36.1Hz, 10H), 0.86 (q, J=11.1, 8.6Hz, 3H).LC / MS(ESI+)calcd for C 49 H 60 N6O7([M+H)) + )m / z:845.5; found 845.5.
[0528] Example 64: 2-(2,6-dioxadiazine-3-yl)-5-((4-((8-(4-(2-(2-hydroxyethyl)(methyl)amino)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)isoindoline-1,3-dione
[0529]
[0530] The target compound was prepared using a method similar to that of Example 59. 1H NMR (400MHz, CDCl3) δ8.28(s,1H),8.07(s,1H),7.59(d,J=8.3Hz,1H),7.17(d,J=8.7Hz,2H),7.10(t,J=8.3Hz,4H),6.95(d, J=2.1Hz,1H),6.83–6.77(m,4H),6.72(dd,J=8.3,2.2Hz,1H),5.06(s,2H),4.92(dd,J=12.0,5.2Hz,1H),4.02(d,J=26.4Hz, 4H),3.91(t,J=6.5Hz,2H),3.45(dd,J=11.8,6.3Hz,4H),3.37(s,3H),3.24(t,J=6.6Hz,2H),2.91–2.72(m,3H),2.11(dd,J= 12.2,5.8Hz,1H),1.73(dq,J=21.8,7.0Hz,8H),1.63(s,6H),1.43(d,J=3.9Hz,2H),1.34(d,J=5.4Hz,6H).LC / MS(ESI+)calcd for C 48 H 60 N6O8([M+H)) + )m / z:849.5; found 849.5.
[0531] Example 65: 5-((4-((8-(4-(2-(4-(2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)-5,8-dihydropyridin[3,4-d]pyrimidin-7(6H)-yl)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0532]
[0533] Step 1: Synthesis of tert-butyl 2-chloro-5,8-dihydropyridine[3,4-d]pyrimidine-7(6H)-carboxylic acid
[0534] 13 g (42 mmol) of 2,4-dichloro-5,8-dihydropyridine[3,4-d]pyrimidin-7(6H)-carboxylic acid tert-butyl ester was dissolved in 150 mL of anhydrous ethanol. Zinc powder (3.2 g, 50 mmol) and 30 mL of ammonia water were added sequentially to the reaction system. The reaction was carried out overnight at 80 °C. After the reaction was completed by TLC monitoring, the mixture was filtered through diatomaceous earth, 100 mL of water was added, and the mixture was extracted twice with 100 mL of ethyl acetate. The mixture was washed with 0.5 N hydrochloric acid (2 x 50 mL), saturated sodium bicarbonate solution (2 x 50 mL), and saturated brine (2 x 50 mL). The mixture was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 9 g of the target compound, with a yield of 80%.
[0535] Step 2: Synthesis of tert-butyl 2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)-5,8-dihydropyridine[3,4-d]pyrimidine-7(6H)-carboxylic acid
[0536] 2-Chloro-5,8-dihydropyridine[3,4-d]pyrimidin-7(6H)-carboxylic acid tert-butyl ester (1 g, 3.7 mmol), 2-oxa-6-azaspiro[3.3]heptane (380 mg, 3.7 mmol), and DIPEA (1.3 g, 10 mmol) were added sequentially to 10 mL of DMSO. The reaction was carried out overnight at 80 °C. After the reaction was completed by TLC, the mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 1.1 g of the target compound, yield: 90%.
[0537] Step 3: Synthesis of 6-(5,6,7,8-tetrahydropyridine[3,4-d]pyrimidin-2-yl)-2-oxa-6-azaspirocyclic[3.3]heptane
[0538] 1.1 g (3.3 mmol) of tert-butyl 2-(2-oxo-6-azaspiro[3.3]heptan-6-yl)-5,8-dihydropyridine[3,4-d]pyrimidin-7(6H)-carboxylic acid was dissolved in 10 mL of dichloromethane, and 5 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 800 mg of the target compound, yield: 99%.
[0539] Step 4: Synthesis of 6-(7-(4-(2-(4-(4-methoxybenzyl)oxy)phenyl)propane-2-yl)phenyl)-5,6,7,8-tetrahydropyridin[3,4-d]pyrimidin-2-yl)-2-oxo-6-azaspirocyclic[3.3]heptane
[0540] Compound 6-(5,6,7,8-tetrahydropyridin[3,4-d]pyrimidin-2-yl)-2-oxa-6-azaspiro[3.3]heptane (400 mg, 1.7 mmol), 4-(2-(4-((4-methoxybenzyl)oxy)phenyl)propane-2-yl)phenyltrifluoromethanesulfonate (816 mg, 1.7 mmol), Pd(dba)2 (96 mg, 0.17 mmol), XPhos (161 mg, 0.34 mmol), and cesium carbonate (1.1 g, 3.4 mmol) were added to 10 mL of dioxane. The reaction system was replaced with a helium atmosphere, and the reaction was carried out overnight at 110 °C. After the reaction was completed by TLC monitoring, the reaction system was filtered with diatomaceous earth, concentrated, and purified by column chromatography to obtain 700 mg of the target compound, yield: 73%.
[0541] Step 5: Synthesis of 4-(2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)-5,8-dihydropyridin[3,4-d]pyrimidin-7(6H)-yl)phenyl)propane-2-yl)phenol
[0542] Compound 6-(7-(4-(2-(4-(4-methoxybenzyl)oxy)phenyl)propane-2-yl)phenyl)-5,6,7,8-tetrahydropyridin[3,4-d]pyrimidin-2-yl)-2-oxo-6-azaspirocyclic[3.3]heptane (700 mg, 1.2 mmol) was dissolved in 10 mL of dichloromethane, and 5 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed as monitored by TLC, the reaction mixture was concentrated and purified by column chromatography to obtain 190 mg of the target compound, yield: 36%.
[0543] The target compound was prepared in subsequent steps using a method similar to that of Example 59. 1 H NMR (400MHz, CDCl3) δ7.58 (s, 1H), 7.20–7.07 (m, 4H), 6.97 (d, J = 19.3Hz, 2H), 6.88–6.64 (m, 5H) ),4.86(s,2H),4.56(s,2H),4.40(s,2H),3.91(d,J=6.8Hz,2H),3.85(s,2H),3.76(s,2H),3.5 7(s,2H),3.44(dd,J=12.4,6.0Hz,4H),3.24(s,2H),2.94–2.70(m,5H),2.22(t,J=7.6Hz,1H), 1.75(s,8H),1.63(s,6H),1.42(d,J=5.3Hz,2H),1.34(d,J=5.6Hz,6H).LC / MS(ESI+)calcdfor C 52 H63 N7O7([M+H)) + )m / z:898.5; found 898.5.
[0544] Example 66: 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0545] Step 1: Synthesis of tert-butyl carbamate (3-(4-(2-(4-((2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)carbamate
[0546] (3-(4-(2-(4-(((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)tert-butyl carbamate (511 mg, 1 mmol) and sodium methanethiol (144 mg, 2 mmol) were added sequentially to 4 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 4 mL of ethyl acetate, washed with saturated brine (3*4 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 400 mg of the target compound, yield: 76%.
[0547] Step 2: Synthesis of 3-(4-(2-(4-(2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propane-1-amine
[0548] Compound (3-(4-(2-(4-((2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)tert-butyl carbamate (150 mg, 0.28 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 104 mg of the target compound, yield: 88%.
[0549] Step 3: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0550] 3-(4-(2-(4-(2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propane-1-amine (104 mg, 0.24 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (66 mg, 0.24 mmol), and DIPEA (94 mg, 0.72 mmol) were sequentially added to 5 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 70 mg of the target compound was purified, yield: 43%. LC / MS (ESI+) calcd for C 37 H 37 N5O6S([M+H)) + )m / z:680.3; found 680.3.
[0551] Example 67: 2-(2,6-dioxadiazine-3-yl)-5-((3-(4-(2-(4-(4-(2-(methanesulfonyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0552] 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(methylthio)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione (50 mg, 0.07 mmol) was dissolved in 5 mL of dichloromethane, and m-chloroperoxybenzoic acid (24 mg, 0.14 mmol) was added under an ice-salt bath. The reaction was continued under an ice-salt bath for 1 hour. The reaction was monitored by TLC until complete. The reaction was quenched with saturated sodium sulfite while maintaining an ice-salt bath. The mixture was extracted with 5 mL of dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 7 mg of compound 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(4-(4-(2-((methanesulfonyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione was purified. Yield: 14%. 1H NMR(400MHz, CDCl3)δ8.91(d,J=5.1Hz,1H),8.36(s,1H),7.83(d,J=5.1Hz,1H),7.21– 7.11(m,4H),6.97(d,J=2.1Hz,1H),6.89–6.77(m,4H),6.73(dd,J=8.3,2.1Hz,1H),5. 26(s,2H),4.93(dd,J=11.9,5.2Hz,1H),4.09(t,J=5.5Hz,2H),3.46(t,J=6.5Hz,2H), 3.38(s,3H),2.91–2.77(m,3H),2.13(t,J=6.4Hz,3H),1.64(s,6H).LC / MS(ESI+)calcd for C 37 H 37 N5O8S([M+H)) + )m / z:712.2;found 712.2.
[0553] Example 68: 2-(2,6-dioxadiazine-3-yl)-5-((3-(4-(2-(4-((2-methoxypyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0554]
[0555] The target compound was prepared using a method similar to that of Example 66. 1 H NMR (400MHz, CDCl3) δ8.51(d,J=5.0Hz,1H),8.07(s,1H),7.60(d,J=8.3Hz,1H),7.19(dd,J= 5.0,0.8Hz,1H),7.17–7.11(m,4H),6.97(d,J=2.2Hz,1H),6.87–6.79(m,4H),6.74(dd,J=8. 3,2.2Hz,1H),5.06(d,J=0.7Hz,2H),4.94(d,J=5.3Hz,1H),4.13–4.05(m,2H),4.02(s,3H), 3.46(q,J=6.2Hz,2H),2.94–2.70(m,3H),2.16–2.07(m,3H),1.63(s,6H).LC / MS(ESI+)calcd for C 37 H 37 N5O7([M+H)) + )m / z:664.3; found 664.3.
[0556] Example 69: 2-(2,6-dioxadiazine-3-yl)-5-((3-(4-(2-(4-((2-ethoxypyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0557]
[0558] The target compound was prepared using a method similar to that of Example 66. 1 H NMR (400MHz, CDCl3) δ8.50(s,1H),8.08(s,1H),7.60(d,J=8.2Hz,1H),7.15(dd,J=8.7,2.3Hz, 5H),6.97(d,J=1.8Hz,1H),6.83(dd,J=11.6,8.6Hz,4H),6.78–6.71(m,1H),5.05(s,2H),4.93 (dd,J=12.1,5.2Hz,1H),4.44(q,J=7.0Hz,2H),4.09(t,J=5.4Hz,2H),3.46(t,J=6.3Hz,2H),2 .92–2.72(m,3H),2.18–2.07(m,3H),1.63(s,6H),1.44(t,J=7.0Hz,3H).LC / MS(ESI+)calcdfor C 38 H 39 N5O7([M+H)) + )m / z:678.3; found 678.3.
[0559] Example 70: 5-((3-(4-(2-(4-((2-cyclopropoxypyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0560]
[0561] The target compound was prepared using a method similar to that of Example 66. 1H NMR (400MHz, CDCl3) δ8.54(s,1H),8.07(s,1H),7.60(d,J=8.3Hz,1H),7.22(s,1H),7.15(dd,J= 8.7,2.1Hz,4H),6.98(d,J=2.0Hz,1H),6.91–6.77(m,4H),6.78–6.70(m,1H),5.06(s,2H),4.93 (dd,J=12.0,5.2Hz,1H),4.36(d,J=3.6Hz,1H),4.09(t,J=5.4Hz,2H),3.46(t,J=6.4Hz,2H),2. 94–2.67(m,3H),2.12(q,J=6.7,6.1Hz,3H),1.63(s,6H),0.88–0.81(m,4H).LC / MS(ESI+)calcd for C 39 H 39 N5O7([M+H)) + )m / z:690.3; found 690.3.
[0562] Example 71: 2-(2,6-dioxadiazine-3-yl)-5-((3-(4-(2-(4-((2-morpholinidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0563]
[0564] The target compound was prepared using a method similar to that of Example 61. 1 H NMR(400MHz, CDCl3)δ8.31(d,J=5.0Hz,1H),8.13(s,1H),7.60(d,J=8.3Hz,1H), 7.21–7.05(m,4H),6.97(d,J=2.1Hz,1H),6.89–6.78(m,4H),6.78–6.71(m,2H),4 .98–4.89(m,3H),4.08(t,J=5.5Hz,2H),3.97–3.63(m,8H),3.45(d,J=7.5Hz,2H ),2.92–2.66(m,3H),2.13(p,J=7.6,7.0Hz,3H),1.63(s,6H).LC / MS(ESI+)calcd for C 40 H 42 N6O7([M+H)) + )m / z:719.3; found 719.3.
[0565] Example 72: 2-((2,6-dioxadiazin-3-yl)-5-(3-(4-(2-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0566]
[0567] The target compound was prepared using a method similar to that of Example 61. 1 H NMR (400MHz, CDCl3) δ8.28(d,J=5.0Hz,1H),7.58(d,J=8.3Hz,1H),7.17–7.08(m,4H),6.96 (d,J=2.2Hz,1H),6.81(t,J=8.6Hz,4H),6.74–6.66(m,2H),4.91(s,2H),4.89(d,J=5.7Hz, 1H),4.07(t,J=5.5Hz,2H),3.85(t,J=5.0Hz,4H),3.43(q,J=6.2Hz,2H),2.94–2.67(m,3H) ,2.49(t,J=5.1Hz,4H),2.34(s,3H),2.12(q,J=5.8Hz,3H),1.62(s,6H).LC / MS(ESI+)calcd for C 41 H 45 N7O6([M+H)) + )m / z:732.4; found 732.4.
[0568] Example 73: 5-((3-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0569]
[0570] The target compound was prepared using a method similar to that of Example 61. 1H NMR (400MHz, CDCl3) δ8.33(s,1H),8.10(s,1H),7.60(d,J=7.2Hz,1H),7.14(s,4H),6.98(s,1H),6.82(s,4H),6.76(s,1H),4.94 (d,J=29.0Hz,7H),4.64–4.18(m,4H),4.09(s,2H),3.47(s,2H),2.96–2.69(m,3H),2.13(s,3H),1.64(s,6H).LC / MS(ESI+)calcd for C 41 H 42 N6O7([M+H)) + )m / z:731.3;found 731.3.
[0571] Example 74: 5-((3-(4-(2-(4-((2-aminopyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0572]
[0573] The target compound was prepared using a method similar to that of Example 61. 1 H NMR(400MHz, CDCl3)δ8.75(s,1H),8.30(s,1H),7.55(dd,J=27.3,8.3Hz,1H),7.20–7.02(m,4H),6.99–6.86(m,2H),6.87–6.67(m,5H),5.05– 4.84(m,3H),4.15–3.98(m,2H),3.48(dt,J=19.3,6.7Hz,2H),2.95–2.67(m,3H),2.16–2.05(m,3H),1.62(d,J=2.7Hz,6H).LC / MS(ESI+)calcd forC 36 H 36 N6O6([M+H)) + )m / z:649.3; found 649.3.
[0574] Example 75: 5-(((1r,3r)-3-(4-(2-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0575]
[0576] Step 1: Synthesis of ((1r,3r)-3-(4-(2-(4-(((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl
[0577] ((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propyl-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl ester (400 mg, 1 mmol), 2-chloro-4-(chloromethyl)pyrimidine (162 mg, 1 mmol), and potassium carbonate (276 mg, 2 mmol) were added sequentially to 5 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 20 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 180 mg of the target compound, yield: 34%.
[0578] Step 2: Synthesis of ((1r,3r)-3-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0579] ((1r,3r)-3-(4-(2-(4-(((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl ester (180 mg, 0.34 mmol), 2-oxa-6-azaspiro[3.3]heptane (35 mg, 0.34 mmol) and DIPEA (90 mg, 0.7 mmol) were added sequentially to 2 mL of DMSO. The reaction was carried out overnight at 80 °C. After the reaction was completed by TLC monitoring, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3*5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 120 mg of the target compound, yield: 60%.
[0580] Step 3: Synthesis of (1r,3r)-3-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutamine
[0581] Compound ((1r,3r)-3-(4-(2-(4-((2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (120 mg, 0.2 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction system was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 60 mg of the target compound, yield: 62%.
[0582] Step 4: Synthesis of 5-(((1r,3r)-3-(4-(2-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0583] (1r,3r)-3-(4-(2-(4-((2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutamine (60 mg, 0.12 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.12 mmol), and DIPEA (52 mg, 0.4 mmol) were added sequentially to 5 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 20 mg of the target compound was purified, yield: 22%. 1 H NMR (400MHz, CDCl3) δ8.46(s,1H),8.39(s,1H),7.59(d,J=8.1Hz,1H),7.12(dd,J= 8.5,4.9Hz,4H),6.96–6.77(m,4H),6.69(t,J=8.6Hz,3H),4.90(d,J=34.4Hz,7H),4 .49(p,J=7.0Hz,1H),4.31(s,4H),3.74(q,J=7.4Hz,1H),3.10(dt,J=13.1,6.8Hz, 2H),2.94–2.64(m,3H),2.08(p,J=7.7,7.3Hz,3H),1.62(s,6H).LC / MS(ESI+)calcd for C 42 H 42N6O7([M+H)) + )m / z:743.3;found743.3.
[0584] Example 76: 5-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0585]
[0586] The target compound was prepared using a method similar to that of Example 75. 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.33(d,J=4.9Hz,1H),7.59(d,J=8.3Hz,1H),7.44(d,J=6.4Hz,1H),7.15–7.03(m ,4H),6.89(dd,J=9.2,2.3Hz,3H),6.82(dd,J=8.3,2.1Hz,1H),6.76(dd,J=9.8,3.5Hz,3H),5.04(dd,J=13.0,5.3Hz,1H ),4.95(s,2H),4.71(s,4H),4.48(p,J=7.1Hz,1H),4.19(s,4H),3.77(q,J=7.4Hz,1H),3.14–2.98(m,2H),2.87(ddd,J= 17.3,14.0,5.4Hz,1H),2.68–2.51(m,2H),2.02(d,J=7.7Hz,1H),1.95(d,J=9.9Hz,2H),1.57(s,6H).LC / MS(ESI+)calcd for C 42 H 42 N6O7([M+H)) + )m / z:743.3; found 743.3.
[0587] Example 77: 5-((3-(4-(2-(4-((2-(2-oxo-7-azaspirocyclic[3.5]non-7-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0588]
[0589] The target compound was prepared using a method similar to that of Example 61. 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.33(d,J=4.9Hz,1H),7.56(d,J=8.4Hz,1H),7.20(t,J=5.5Hz,1H),7 .16–7.06(m,4H),6.98(d,J=2.1Hz,1H),6.94–6.76(m,5H),6.65(d,J=5.0Hz,1H),5.03(dd,J=12.9,5.4Hz,1 H),4.94(s,2H),4.34(s,4H),4.07–3.98(m,2H),3.74–3.61(m,4H),3.32(d,J=9.2Hz,2H),2.87(ddd,J=17.4 ,14.0,5.4Hz,1H),2.63–2.51(m,2H),2.03–1.94(m,3H),1.83–1.72(m,4H),1.57(s,6H).LC / MS(ESI+)calcd for C 43 H 46 N6O7([M+H)) + )m / z:759.4; found 759.4.
[0590] Example 78: 5-((3-(4-(2-(4-((2-(2-oxo-7-azaspirocyclic[3.5]non-7-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0591]
[0592] The target compound was prepared using a method similar to that of Example 75. 1H NMR (400MHz, CDCl3) δ8.29(d,J=4.8Hz,1H),8.15(d,J=5.5Hz,1H),7.62(dd,J=8.2,2.2Hz,1H),7.13(dd ,J=8.9,5.8Hz,4H),6.89(dd,J=9.5,2.0Hz,1H),6.83(d,J=8.4Hz,2H),6.76–6.66(m,4H),4.97–4.88(m, 3H),4.86(s,1H),4.50(s,4H),4.21(s,1H),3.78(t,J=5.5Hz,4H),3.18–3.05(m,1H),2.92–2.64(m,4H) ,2.40(dd,J=12.2,6.3Hz,1H),2.16–2.06(m,2H),1.91(t,J=5.5Hz,4H),1.63(s,6H).LC / MS(ESI+)calcd for C 44 H 46 N6O7([M+H)) + )m / z:771.4;found771.4.
[0593] Example 79: 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(4-((2-(7-methyl-2,7-diazaspiro[4.4]nonyl-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0594]
[0595] Step 1: Synthesis of 3-aminocyclobutane-1-ol trifluoroacetate
[0596] The compound 3-hydroxycyclobutamine-1-tert-butoxycarbonylamino (3.6 g, 20 mmol) was dissolved in 40 mL of dichloromethane, and 20 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 1 hour. After the reaction was completed as monitored by TLC, the reaction system was concentrated to obtain 4.1 g of crude target compound.
[0597] Step 2: Synthesis of 2-(3-hydroxycyclobutyl)isoindoline-1,3-dione
[0598] Crude 3-aminocyclobutane-1-ol trifluoroacetate (4.1 g), phthalic anhydride (3 g, 20 mmol), and triethylamine (10 g, 100 mmol) were sequentially added to 50 mL of toluene. The mixture was reacted overnight at 100 °C. After the reaction was completed by TLC monitoring, the reaction solution was concentrated, 50 mL of water was added, and the mixture was extracted with ethyl acetate (2 x 50 mL), washed with saturated brine (2 x 50 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 3 g of the target compound. The overall yield of the two steps was 69%.
[0599] Step 3: Synthesis of 2-(3-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione
[0600] Compound 2-(3-hydroxycyclobutyl)isoindoline-1,3-dione (3 g, 13.8 mmol), bisphenol A (3.1 g, 13.8 mmol), and triphenylphosphine (4 g, 15 mmol) were dissolved in 50 mL of tetrahydrofuran. DIAD (3 g, 15 mmol) was added under ice bath conditions, and the mixture was stirred for half an hour while maintaining the ice bath. The reaction was then carried out overnight at 65 °C. After the reaction was completed as monitored by TLC, the reaction solvent was concentrated, and the crude target compound was purified by column chromatography to obtain 12 g of crude compound.
[0601] Step 4: Synthesis of 2-(3-(4-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione
[0602] The crude product 2-(3-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione, 2-chloro-4-(chloromethyl)pyrimidine (2.2 g, 13.8 mmol) and potassium carbonate (4.1 g, 30 mmol) were added sequentially to 100 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the product was extracted with 100 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 3.1 g of the target compound. The overall yield of the two steps was 41%.
[0603] Step 5: Synthesis of 7-(4-(2-(4-(4-(3-(1,3-dioxoisoindoline-2-yl)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-yl)-2,7-diazaspirocyclic[4.4]non-2-carboxylic acid tert-butyl ester
[0604] 2-(3-(4-(2-(4-(((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione (500 mg, 0.9 mmol), 2,7-diazaspirocyclic[4.4]nonane-2-carboxylic acid tert-butyl ester (226 mg, 1 mmol) and DIPEA (260 mg, 2 mmol) were added sequentially to 10 mL of DMSO. The reaction was carried out overnight at 80 °C. After the reaction was completed by TLC, the mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3*10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 488 mg of the target compound, yield: 73%.
[0605] Step 6: Synthesis of 2-(3-(4-(2-(4-((2-(2,7-diazaspiro[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione
[0606] 288 mg (0.38 mmol) of 7-(4-(2-(4-(4-(3-(1,3-dioxoisoindoline-2-yl)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-yl)-2,7-diazaspiro[4.4]non-2-carboxylic acid tert-butyl ester was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction system was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3*10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 204 mg of the target compound, yield: 83%.
[0607] Step 7: Synthesis of 2-(3-(4-(2-(4-((2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione
[0608] Compound 2-(3-(4-(2-(4-((2-(2,7-diazaspiro[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione (204 mg, 0.32 mmol) was dissolved in 5 mL of dichloromethane, paraformaldehyde (270 mg, 3 mmol) was added, followed by glacial acetic acid (2 mg, 0.03 mmol), and the mixture was stirred at room temperature for 10 minutes. Sodium triacetylborohydride (135 mg, 0.64 mmol) was added, and the mixture was stirred overnight at room temperature. After the reaction was complete as monitored by TLC, the reaction mixture was poured into a saturated ammonium chloride solution under ice. The mixture was extracted with dichloromethane (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 140 mg of the target compound (yield: 66%).
[0609] Step 8: Synthesis of 3-(4-(2-(4-((2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutamine
[0610] Compound 2-(3-(4-(2-(4-((2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione (140 mg, 0.21 mmol) was dissolved in 5 mL of anhydrous ethanol, and hydrazine hydrate (32 mg, 1 mmol) was added. The mixture was stirred at 80 °C for 2 hours. After the reaction was completed by TLC monitoring, the reaction system was concentrated and purified by column chromatography to obtain 92 mg of the target compound, yield: 83%.
[0611] Step 9: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(4-((2-(7-methyl-2,7-diazaspiro[4.4]nonyl-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0612] 3-(4-(2-(4-((2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutamine (92 mg, 0.17 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (50 mg, 0.17 mmol), and DIPEA (70 mg, 0.5 mmol) were sequentially added to 5 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 15 mg of the target compound was obtained, yield: 11%. 1 H NMR (400MHz, CDCl3) δ8.29 (d, J=5.0Hz, 1H), 7.62 (dd, J=8.3, 2.2Hz, 1H), 7.12 (dt, J=8 .7,1.9Hz,4H),6.90(dd,J=9.7,2.2Hz,1H),6.87–6.79(m,2H),6.75–6.63(m,4H),4.93 (s,2H),4.91(s,2H),3.68–3.50(m,4H),3.20–3.05(m,1H),2.91–2.61(m,7H),2.46(s ,3H),2.38(dd,J=13.4,6.3Hz,1H),2.15–1.94(m,8H),1.62(s,6H).LC / MS(ESI+)calcd for C 45 H 49 N7O6([M+H)) + )m / z:784.4; found 784.4.
[0613] Example 80: 2-(2,6-dioxadiazin-3-yl)-5-((3-(4-(2-(2-(hexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0614]
[0615] It was prepared using a method similar to that of Example 79. 1H NMR (400MHz, DMSO-d6) δ8.35 (d, J=5.0Hz, 1H), 7.65–7.40 (m, 2H), 7.11 (t, J= 8.6Hz,4H),6.94–6.65(m,6H),5.03(dd,J=13.0,5.4Hz,1H),4.95(s,2H),4. 56–4.39(m,1H),3.82–3.52(m,5H),3.10–2.71(m,8H),2.69–2.51(m,2H),2. 42(s,2H),1.96(q,J=20.1,15.4Hz,3H),1.57(s,6H).LC / MS(ESI+)calcdfor C 43 H 45 N7O6([M+H)) + )m / z:756.4; found 756.4.
[0616] Example 81: 5-(((1r,3r)-3-(4-(2-(4-((2-(2,7-diazaspirocyclic[4.4]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0617]
[0618] The target compound was prepared using a method similar to that of Example 79. 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.35(d,J=5.0Hz,1H),7.57(dd,J=12.2,6.9Hz,2H),7.11(t,J= 8.6Hz,4H),6.94–6.68(m,6H),5.03(dd,J=12.9,5.4Hz,1H),4.94(s,2H),4.88–4.80(m,1H),4.16(d, J=24.8Hz,1H),3.52(dd,J=27.8,10.2Hz,4H),3.30–3.10(m,6H),2.88(dd,J=22.4,9.5Hz,1H),2.70– 2.53(m,2H),2.47–2.31(m,3H),1.98(dqt,J=20.4,13.1,7.3Hz,5H),1.57(s,6H).LC / MS(ESI+)calcd for C 44 H 47 N7O6([M+H)) + )m / z:770.4; found 770.4.
[0619] Example 82: 5-(((1r,3r)-3-(4-(2-(4-((2-(2,6-diazaspirocyclic[3.3]heptane-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0620]
[0621] The target compound was prepared using a method similar to that of Example 79. 1 H NMR (400MHz, DMSO-d6) δ8.35(d,J=5.4Hz,1H),7.66–7.39(m,2H),7.10(d,J=8.4Hz,4H),6.96–6.61(m,7H),4.94(s,2H),4.84(d,J=8.2Hz,1 H),4.47(s,1H),4.15(d,J=29.4Hz,8H),2.88(dd,J=20.5,11.3Hz,2H),2.63(d,J=30.5Hz,2H),1.98(s,3H),1.56(s,6H).LC / MS(ESI+)calcd forC 42 H 43 N7O6([M+H)) + )m / z:742.3; found 742.3.
[0622] Example 83: 5-(((1r,3r)-3-(4-(2-(4-((2-(2,6-diazaspiro[3.4]octyl-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0623]
[0624] The target compound was prepared using a method similar to that of Example 79. 1H NMR (400MHz, DMSO-d6) δ11.04(s,1H),8.34(d,J=5.0Hz,1H),7.63(t,J=5.6Hz,1H),7.58(d,J=8.3Hz,1H),7.10(t,J=8. 1Hz,4H),6.93–6.83(m,3H),6.84–6.67(m,4H),5.03(dd,J=12.9,5.4Hz,1H),4.94(d,J=4.1Hz,2H),4.89(s,1H),4.13( dp,J=12.6,5.5Hz,1H),4.03–3.85(m,4H),3.49(q,J=8.5,7.7Hz,4H),2.87(ddd,J=17.5,14.0,5.4Hz,1H),2.64–2.51( m,2H),2.43(dt,J=10.7,6.2Hz,3H),2.23(t,J=6.9Hz,2H),2.13–1.89(m,2H),1.56(d,J=5.6Hz,6H).LC / MS(ESI+)calcd for C 43 H 45 N7O6([M+H)) + )m / z:756.4; found 756.4.
[0625] Example 84: 5-(((1s,3s)-3-(4-(2-(4-((2-(2,7-diazaspiro[3.5]non-7-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0626]
[0627] The target compound was prepared using a method similar to that of Example 79. 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.34(d,J=4.9Hz,1H),7.58(d,J=8.3Hz,1H),7.50(d,J=6.6Hz,1H),7.10(t,J=8. 7Hz,4H),6.90–6.87(m,2H),6.82(dd,J=8.5,2.1Hz,1H),6.76(dd,J=9.5,2.8Hz,2H),6.67(d,J=4.9Hz,1H),5.03(dd,J =12.9,5.4Hz,1H),4.94(s,2H),4.48(p,J=6.9Hz,1H),3.95–3.44(m,9H),3.13–2.98(m,2H),2.87(ddd,J=18.1,14.0,5 .6Hz,1H),2.65–2.51(m,2H),1.97(td,J=11.5,11.0,4.1Hz,3H),1.77(t,J=5.7Hz,4H),1.57(s,6H).LC / MS(ESI+)calcd for C 44 H 47 N7O6([M+H)) + )m / z:770.4; found 770.4.
[0628] Example 85: 5-(((1s,3s)-3-(4-(2-(4-((2-(2,7-diazaspiro[3.5]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0629]
[0630] The target compound was prepared using a method similar to that of Example 79. 1H NMR (400MHz, DMSO-d6) δ8.33(d,J=5.0Hz,1H),7.58(d,J=8.3Hz,1H),7.48(d,J=6.6Hz,1H),7.10(t,J= 8.6Hz,4H),6.94–6.85(m,3H),6.82(dd,J=8.5,2.1Hz,1H),6.74(dd,J=13.4,6.7Hz,3H),5.03(dd,J=1 2.9,5.4Hz,1H),4.94(s,2H),4.48(p,J=7.1Hz,1H),3.78(s,4H),3.10–2.99(m,2H),2.95–2.79(m,5H) ,2.69–2.51(m,2H),1.96(p,J=9.7,8.9Hz,3H),1.82(d,J=5.7Hz,4H),1.57(s,6H).LC / MS(ESI+)calcd for C 44 H 47 N7O6([M+H)) + )m / z:770.4; found 770.4.
[0631] Example 86: 5-(((1s,3s)-3-(4-(2-(4-((2-(2,6-diazaspirocyclic[3.3]-((2-(2,6-heptane-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0632]
[0633] The target compound was prepared using a method similar to that of Example 79. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.35(d,J=5.0Hz,1H),7.58(d,J=8.3Hz,1H),7.48(d,J=6.5Hz ,1H),7.10(t,J=8.6Hz,4H),6.96–6.67(m,7H),5.03(dd,J=12.8,5.4Hz,1H),4.95(s,2H),4.48(p,J =6.9Hz,1H),4.18(d,J=17.4Hz,8H),3.78(p,J=7.7Hz,1H),3.04(ddd,J=11.3,8.6,5.8Hz,2H),2.95 –2.80(m,1H),2.61–2.52(m,2H),1.96(td,J=19.1,16.0,8.1Hz,3H),1.57(s,6H).LC / MS(ESI+)calcd for C 42 H 43 N7O6([M+H)) + )m / z:742.3; found 742.3.
[0634] Example 87: 5-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-7-azaspiro[3.5]non-7-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0635]
[0636] The target compound was prepared using a method similar to that of Example 76. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.33(d,J=5.0Hz,1H),7.58(d,J=8.4Hz,1H),7.45(d,J=6.4Hz,1H), 7.17–7.05(m,4H),6.96–6.85(m,3H),6.82(dd,J=8.4,2.1Hz,1H),6.79–6.69(m,2H),6.67(d,J=5.0Hz,1H) ,5.03(dd,J=12.9,5.4Hz,1H),4.95(s,2H),4.48(p,J=7.1Hz,1H),3.86–3.74(m,3H),3.58–3.42(m,6H),3 .18–3.00(m,2H),2.92–2.81(m,1H),2.69–2.52(m,2H),2.00–1.83(m,7H),1.57(s,6H).LC / MS(ESI+)calcd for C 44 H 46 N6O7([M+H)) + )m / z:771.4;found771.4.
[0637] Example 88: 5-(((1s,3s)-3-(4-(2-(4-((2-(6-oxa-2-azaspiro[3.4]octyl-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0638]
[0639] The target compound was prepared using a method similar to that of Example 76. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.34(d,J=5.0Hz,1H),7.58(d,J=8.3Hz,1H),7.47(d,J=6.4Hz,1 H),7.10(t,J=8.5Hz,4H),6.94–6.85(m,3H),6.79–6.69(m,3H),5.04(dd,J=12.9,5.3Hz,1H),4.95(s,2 H),4.48(p,J=7.0Hz,1H),4.00(s,4H),3.85–3.66(m,5H),3.09–3.00(m,2H),2.87(ddd,J=17.4,14.0,5 .4Hz,1H),2.63–2.51(m,2H),2.14(t,J=6.9Hz,2H),2.04–1.94(m,3H),1.57(s,6H).LC / MS(ESI+)calcd for C 43 H 44 N6O7([M+H)) + )m / z:757.3; found 757.3.
[0640] Example 89: 5-(((1s,3s)-3-(4-(2-(4-((2-(7-oxa-2-azaspiro[3.5]non-2-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0641]
[0642] The target compound was prepared using a method similar to that of Example 76. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.33(d,J=5.0Hz,1H),7.58(d,J=8.3Hz,1H),7.45(d,J=6.4Hz,1H),7.10(t,J=8. 4Hz,4H),6.93–6.85(m,3H),6.82(dd,J=8.4,2.1Hz,1H),6.79–6.73(m,2H),6.72(d,J=5.0Hz,1H),5.04(dd,J=12.9,5.4 Hz,1H),4.94(s,2H),4.48(p,J=7.0Hz,1H),3.78(s,5H),3.54(t,J=5.2Hz,4H),3.10–3.01(m,2H),2.87(ddd,J=17.4,1 4.1,5.5Hz,1H),2.57(dd,J=19.3,6.3Hz,2H),1.99–1.91(m,3H),1.72(t,J=5.2Hz,4H),1.57(s,6H).LC / MS(ESI+)calcd for C 44 H 46 N6O7([M+H)) + )m / z:771.4; found 771.4.
[0643] Example 90: 5-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)-6-fluoroisoindoline-1,3-dione
[0644]
[0645] The target compound was prepared using a method similar to that of Example 76. 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),8.33(d,J=5.0Hz,1H),7.59(d,J=10.2Hz,1H),7.20(dd,J=6.8,2.5 Hz,1H),7.14–7.07(m,4H),7.05(d,J=7.2Hz,1H),6.93–6.83(m,2H),6.81–6.71(m,3H),5.06(dd,J=12.8 ,5.4Hz,1H),4.95(s,2H),4.71(s,4H),4.45(p,J=7.0Hz,1H),4.19(s,4H),3.85(p,J=7.5Hz,1H),3.07–2 .82(m,3H),2.64–2.51(m,2H),2.13(q,J=9.1Hz,2H),2.06–1.99(m,1H),1.57(s,6H).LC / MS(ESI+)calcd for C 42 H 41 FN6O7([M+H)) + )m / z:761.3; found 761.3.
[0646] Example 91: 3-(5-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxoisoindoline-2-yl)piperidine-2,6-dione
[0647]
[0648] Step 1: Synthesis of 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione
[0649] Methyl 4-bromo-2-(bromomethyl)benzoate (3 g, 10 mmol), 3-amino-2,6-piperidinidone hydrochloride (1.65 g, 10 mmol), and DIPEA (2.6 g, 20 mmol) were dissolved in 30 mL of acetonitrile and reacted overnight at 60 °C. The mixture was allowed to cool naturally to room temperature and then stirred in an ice bath for 1 hour. The precipitated solid was filtered and washed with a small amount of cold acetonitrile to give 1.8 g of the target compound, yield: 56%.
[0650] Step 2: Synthesis of 3-(5-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxoisoindololin-2-yl)piperidine-2,6-dione
[0651] Compounds (1s,3s)-3-(4-(2-(4-((2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutamine (73 mg, 0.15 mmol), 3-(5-bromo-1-oxoisoindoline-2-yl)piperidine-2,6-dione (48 mg, 0.15 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (12 mg, 0.015 mmol), and cesium carbonate (100 mg, 0.3 mmol) were added to 2 mL of dioxane. The displacement reaction system was under a helium atmosphere, and the reaction was carried out overnight at 110 °C. After the reaction was monitored to be complete by TLC, the reaction system was filtered with diatomaceous earth, concentrated, and purified by column chromatography to obtain 8 mg of the target compound, yield: 7%. LC / MS (ESI+) calcd for C 42 H 44 N6O6([M+H)) + )m / z:729.3; found 729.3.
[0652] Example 92: 3-(6-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxoisoindoline-2-yl)piperidine-2,6-dione
[0653]
[0654] Step 1: Synthesis of methyl 5-bromo-2-(bromomethyl)benzoate
[0655] Methyl 5-bromo-2-methylbenzoate (2.2 g, 10 mmol) was dissolved in 20 mL of carbon tetrachloride, NBS (1.8 g, 10 mmol) was added, followed by BPO (242 mg, 1 mmol). The mixture was then refluxed under a nitrogen atmosphere for 24 hours. After the reaction mixture cooled to room temperature, it was filtered, concentrated under reduced pressure, and purified by column chromatography to obtain 2.4 g of the target compound, yield: 80%.
[0656] Subsequent steps involved preparing the target compound using a method similar to that in Example 91. LC / MS (ESI+) calcd for C 42 H 44 N6O6([M+H)) + )m / z:729.3; found 729.3.
[0657] Example 93: 3-(5-((1r,3r)-3-(4-(2-(4-((6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxoisoindoline-2-yl)piperidine-2,6-dione
[0658]
[0659] 5-((1r,3r)-3-(4-(2-(4-((6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione (35 mg, 0.05 mmol) was dissolved in 2 mL of glacial acetic acid, and zinc powder (64 mg, 1 mmol) was added. The reaction was carried out at 60 °C for 2 hours, and the starting material was monitored by TLC until it was completely consumed. The reaction was cooled to room temperature, filtered through diatomaceous earth, and the solution was concentrated in glacial acetic acid. Saturated sodium bicarbonate was added to make the reaction weakly alkaline. Extraction was performed repeatedly with 5 mL of ethyl acetate. The organic phases were combined, washed with saturated brine, dried, and concentrated. The resulting solution was dissolved in 2 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added. Triethylsilane (12 mg, 0.1 mmol) was added, and the mixture was stirred overnight at room temperature. LC-MS was used to monitor complete consumption of the hydroxyl compounds, at which point the reaction was stopped. Dichloromethane and most of the trifluoroacetic acid were directly concentrated. Saturated sodium bicarbonate was added to make the system weakly alkaline. Extraction was performed repeatedly with 5 mL of ethyl acetate. The organic phases were dried, combined, concentrated, and purified by column chromatography. 11 mg of compound 3-(5-((1r,3r)-3-(4-(2-(4-((6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxoisoindololin-2-yl)piperidin-2,6-dione was purified, yield: 32%. 1 HNMR(400MHz, CDCl3)δ10.46(s,1H),8.18(s,1H),7.91(s,1H),7.78(m,3H),7.07(m,7H),6.85(m,2H ),6.59(m,2H),5.00(m,1H),4.76(s,1H),4.11(m,4H),2.47(m,8H),1.56(s,6H).LC / MS(ESI+)calcd for C 39 H 37 N7O5([M+H)) + )m / z:684.3; found 684.3.
[0660] Example 94: 3-(6-(((1r,3r)-3-(4-(2-(4-((6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxoisoindoline-2-yl)piperidine-2,6-dione
[0661]
[0662] The target compound was obtained during the preparation of Example 93. 1 H NMR (400MHz, CDCl3) δ10.14(s,1H),8.18(s,1H),7.89(s,1H),7.76(s,2H),7.61(t,J=6.4Hz ,1H),7.37(d,J=8.7Hz,1H),7.10(dd,J=8.6,4.5Hz,2H),7.06–6.87(m,4H),6.82(dd,J=8.4, 4.4Hz,2H),6.57(dd,J=8.6,4.5Hz,2H),5.08–4.96(m,1H),4.83(s,1H),4.38–3.93(m,4H), 2.69(d,J=14.2Hz,3H),2.57(s,2H),2.11(d,J=64.6Hz,3H),1.53(s,6H).LC / MS(ESI+)calcd for C 39 H 37 N7O5([M+H)) + )m / z:684.3; found 684.3.
[0663] Example 95: 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(2-(4-((5-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0664]
[0665] Step 1: Synthesis of 3-(4-(2-(4-((1r,3r)-3-(1,3-dioxoisoindoline-2-yl)cyclobutoxy)phenyl)propane-2-yl)phenoxy)-5-fluoropyridine nitrile
[0666] 60% sodium hydride (88 mg, 2.2 mmol) was dissolved in 10 mL of DMF. 2-((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione (854 mg, 2 mmol) was added under ice bath conditions. The mixture was stirred at room temperature for 10 min, and then 3,5-difluoropyridine nitrile (280 mg, 2 mmol) was added. The mixture was slowly heated to room temperature and reacted for 2 hours. After the reaction was complete as monitored by TLC, the reaction was quenched with saturated ammonium chloride under ice bath conditions. The mixture was extracted three times with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 470 mg of the target compound (yield: 43%).
[0667] Step 2: Synthesis of 3-(4-(2-(4-((1r,3r)-3-aminocyclobutoxy)phenyl)propane-2-yl)phenoxy)-5-fluoropyridinecarboxylate salt
[0668] Compound 3-(4-(2-(4-((1r,3r)-3-(1,3-dioxoisoindoline-2-yl)cyclobutoxy)phenyl)propane-2-yl)phenoxy)-5-fluoropyridine nitrile (460 mg, 0.84 mmol) was dissolved in 5 mL of methanol, and concentrated hydrochloric acid (1 mL, 12 mmol) was added. The reaction was carried out overnight at 90 °C. After the reaction was completed by TLC monitoring, the solvent was directly concentrated to give 380 mg of the target compound, yield: 95%.
[0669] Step 3: Synthesis of 3-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)-5-fluoropyridinecarboxylic acid
[0670] Compound 3-(4-(2-(4-((1r,3r)-3-aminocyclobutoxy)phenyl)propane-2-yl)phenoxy)-5-fluoropyridine carboxylate (380 mg, 0.8 mmol) was dissolved in 10 mL of methanol, and 3 mL of sodium bicarbonate aqueous solution (2 M) was added. The mixture was stirred at room temperature for 10 minutes. Then, Boc anhydride (218 mg, 1 mmol) was added. After the reaction was monitored by TLC until complete, a saturated sodium bicarbonate solution was added to the reaction system to quench the reaction, and stirring was continued for 10 minutes. The mixture was extracted with ethyl acetate (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 190 mg of the target compound (yield: 44%).
[0671] Step 4: Synthesis of ((1r,3r)-3-(4-(2-(4-((2-(2-acetylhydrazine-1-carbonyl)-5-fluoropyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0672] Compound 3-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)-5-fluoropyridinecarboxylic acid (190 mg, 0.35 mmol) was dissolved in 2 mL of dichloromethane. DIPEA (90 mg, 0.7 mmol) and HATU (133 mg, 0.35 mmol) were added, and the mixture was stirred at room temperature for 10 minutes. Acetylhydrazine (51 mg, 0.7 mmol) was then added, and the reaction was carried out at room temperature for 6 hours. After the reaction was complete as monitored by TLC, a saturated ammonium chloride solution was added to the reaction system under ice bath conditions to quench the reaction. The mixture was extracted with dichloromethane, washed with saturated brine, and the organic phase was concentrated. The purified organic phase was then separated by column chromatography to obtain 138 mg of the target compound, with a yield of 67%.
[0673] Step 5: Synthesis of ((1r,3r)-3-(4-(2-(4-((5-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0674] Compound ((1r,3r)-3-(4-(2-(4-((2-(2-acetylhydrazine-1-carbonyl)-5-fluoropyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (138 mg, 0.23 mmol)) was dissolved in 5 mL of dichloromethane, and triethylamine (50 mg, 0.46 mmol) and p-toluenesulfonyl chloride (88 mg, 0.46 mmol) were added. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC monitoring, the reaction system was concentrated and purified by column chromatography to obtain 110 mg of the target compound, yield: 83%.
[0675] Step 6: Synthesis of (1r,3r)-3-(4-(2-(4-((5-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutamine
[0676] (1r,3r)-3-(4-(2-(4-((5-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (110 mg, 0.19 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 42 mg of the target compound, yield: 46%.
[0677] Step 7: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(2-(4-((5-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0678] (1r,3r)-3-(4-(2-(4-((5-fluoro-2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutamine (42 mg, 0.09 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (25 mg, 0.09 mmol), and DIPEA (40 mg, 0.3 mmol) were added sequentially to 10 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 12 mg of the target compound. Yield: 18%. 1 H NMR (400MHz, CDCl3) δ8.35 (s, 1H), 8.09 (s, 1H), 7.62 (d, J = 7.9Hz, 1H), 7.28 (d, J = 8. 5Hz,2H),7.13(d,J=8.2Hz,2H),7.03(t,J=8.7Hz,3H),6.88(s,1H),6.71(d,J=8.1Hz ,3H),4.92(dd,J=11.9,5.1Hz,1H),4.87(s,1H),4.22(s,1H),2.93–2.68(m,5H),2.6 5(s,3H),2.42(d,J=11.0Hz,2H),2.16–2.07(m,1H),1.67(s,6H).LC / MS(ESI+)calcd for C 40 H 35 FN6O7([M+H)) + )m / z:731.3;found 731.3.
[0679] Example 96: 2-(2,6-dioxadiazol-3-yl)-5-(((1r,3r)-3-(4-(2-(4-((5-(5-methyl-1,3,4-oxadiazol-2-yl)oxazol-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0680]
[0681] Step 1: Synthesis of ethyl 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)oxazol-5-carboxylic acid
[0682] 60% sodium hydride (44 mg, 1.1 mmol) was dissolved in 5 mL of DMF. 2-((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)cyclobutyl)isoindoline-1,3-dione (427 mg, 1 mmol) was added under ice bath conditions. The mixture was stirred at room temperature for 10 min, and then ethyl 2-bromooxazol-5-carboxylate (218 mg, 1 mmol) was added. The mixture was slowly heated to room temperature and reacted for 2 hours. After the reaction was complete as monitored by TLC, the reaction was quenched with saturated ammonium chloride under ice bath conditions. The mixture was extracted three times with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 402 mg of the target compound (yield: 75%).
[0683] Step 2: Synthesis of 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)oxazol-5-carboxylic acid
[0684] Ethyl 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)oxazol-5-carboxylic acid (402 mg, 0.75 mmol) was dissolved in 4 mL of acetonitrile, 2 mL of water was added, followed by triethylamine (150 mg, 1.5 mmol) and lithium bromide (258 mg, 3 mmol). The reaction was carried out overnight at 90 °C. After the reaction was completed by TLC monitoring, the pH was adjusted to less than 7 with 0.5 N hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic phases were combined, dried, concentrated, and purified by column chromatography to obtain 146 mg of the target compound, yield: 38%.
[0685] Step 3: Synthesis of ((1r,3r)-3-(4-(2-(4-((5-(2-acetylhydrazine-1-carbonyl)oxazol-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0686] Compound 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)oxazol-5-carboxylic acid (146 mg, 0.29 mmol) was dissolved in 2 mL of dichloromethane. DIPEA (80 mg, 0.6 mmol) and HATU (114 mg, 0.3 mmol) were added, and the mixture was stirred at room temperature for 10 minutes. Acetylhydrazine (45 mg, 0.6 mmol) was then added, and the reaction was carried out at room temperature for 6 hours. After the reaction was complete as monitored by TLC, a saturated ammonium chloride solution was added to the reaction system under ice bath conditions to quench the reaction. The mixture was extracted with dichloromethane, washed with saturated brine, and the organic phase was concentrated. The purified organic phase was then separated by column chromatography to obtain 112 mg of the target compound, with a yield of 68%.
[0687] Step 4: Synthesis of ((1r,3r)-3-(4-(2-(4-((5-(5-methyl-1,3,4-oxadiazol-2-yl)oxazol-2-yl)oxy)phenyl)propyl-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0688] Compound ((1r,3r)-3-(4-(2-(4-((5-(2-acetylhydrazine-1-carbonyl)oxazol-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl ester (112 mg, 0.2 mmol) was dissolved in 5 mL of dichloromethane, and triethylamine (40 mg, 0.4 mmol) and p-toluenesulfonyl chloride (76 mg, 0.4 mmol) were added. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC monitoring, the reaction system was concentrated and purified by column chromatography to obtain 108 mg of the target compound, yield: 98%.
[0689] Step 5: Synthesis of (1r,3r)-3-(4-(2-(4-((5-(5-methyl-1,3,4-oxadiazol-2-yl)oxazol-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutamine-1-amine
[0690] 108 mg (0.19 mmol) of tert-butyl carbamate ((1r,3r)-3-(4-(2-(4-((5-(5-methyl-1,3,4-oxadiazol-2-yl)oxazol-2-yl)oxy)phenyl)propyl-2-yl)phenoxy)cyclobutyl)carbamate)tert-butyl)carbamate))2 mL dichloromethane was dissolved in 2 mL dichloromethane, and 1 mL trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 32 mg of the target compound, yield: 38%.
[0691] Step 6: Synthesis of 2-(2,6-dioxadiazol-3-yl)-5-(((1r,3r)-3-(4-(2-(4-((5-(5-methyl-1,3,4-oxadiazol-2-yl)oxazol-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0692] (1r,3r)-3-(4-(2-(4-((5-(5-methyl-1,3,4-oxadiazol-2-yl)oxazol-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutylamine-1-amine (32 mg, 0.07 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (20 mg, 0.07 mmol), and DIPEA (40 mg, 0.3 mmol) were added sequentially to 10 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (3 mg target compound, yield: 6%). 1 H NMR (400MHz, CDCl3) δ7.99 (s, 1H), 7.64 (d, J = 8.1Hz, 1H), 7.30 (d, J = 8.4Hz, 3H),7.24(s,1H),7.14(d,J=8.4Hz,2H),6.90(s,1H),6.71(d,J=8.6Hz,3H) ,4.95–4.86(m,2H),4.25(s,1H),2.91(s,1H),2.74(d,J=18.8Hz,3H),2.56 (s,3H),2.41(s,2H),2.12(d,J=9.2Hz,2H),1.67(s,6H).LC / MS(ESI+)calcd for C 38 H 34 N6O8([M+H)) + )m / z:703.3; found 703.3.
[0693] Example 97: 5-(4-(2-(4-((1r,3r)-3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-2-carboxynitrile)
[0694]
[0695] Step 1: Synthesis of 5-(4-(2-(4-((1r,3r)-3-aminocyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-2-carboxynitrile
[0696] 100 mg (0.2 mmol) of tert-butyl carbamate ((1r,3r)-3-(4-(2-(4-(((2-cyanopyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 52 mg of the target compound, yield: 65%. Step 2: Synthesis of 5-(4-(2-(4-((1r,3r)-3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindololin-5-yl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-carboxynitrile)
[0697] 5-(4-(2-(4-((1r,3r)-3-aminocyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidin-2-carboxynitrile (52 mg, 0.13 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (38 mg, 0.13 mmol), and DIPEA (52 mg, 0.4 mmol) were sequentially added to 10 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 20 mg of the target compound was purified, yield: 23%. LC / MS (ESI+) calcd for C 37 H 32 N6O6([M+H)) + )m / z:657.3; found657.3.
[0698] Example 98: 6-(4-(2-(4-((1r,3r)-3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyridazine-3-carboxynitrile)
[0699]
[0700] Step 1: Synthesis of ((1r,3r)-3-(4-(2-(4-(((6-cyanopyridin-3-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl
[0701] ((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propyl-2-phenoxy)cyclobutyl)carbamate tert-butyl ester (200 mg, 0.5 mmol), 6-chloropyridin-3-carboxynitrile (70 mg, 0.5 mmol), and cesium carbonate (326 mg, 1 mmol) were added sequentially to 5 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 162 mg of the target compound, yield: 65%.
[0702] The target compound was then prepared using a method similar to that in Example 97.
[0703] LC / MS(ESI+)calcd for C 37 H 32 N6O6([M+H)) + )m / z:657.3; found 657.3.
[0704] Example 99: 2-(2,6-dioxadiazine-3-yl)-5-((1r,3r)-3-(4-(1-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0705]
[0706] Step 1: Synthesis of tert-butyl carbamate ((1r,3r)-3-(4-(1-(4-(((2-cyanopyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutyl)carbamate
[0707] The compound ((1r,3r)-3-(4-(1-(4-hydroxyphenyl)ethyl)phenoxy)cyclobutyl)carbamate tert-butyl ester (383 mg, 1 mmol), 5-fluoropyrimidin-2-carboxynitrile (123 mg, 1 mmol), cuprous iodide (19 mg, 0.1 mmol), 2-pyridinecarboxylic acid (24 mg, 0.2 mmol), and potassium phosphate (424 mg, 2 mmol) were placed in a 25 mL round-bottom flask, and 5 mL of dimethyl sulfoxide was added. The system was replaced with an argon atmosphere, and the reaction was carried out overnight at 90 °C. After the reaction was completed by TLC monitoring, the reaction was cooled to room temperature, filtered through diatomaceous earth, and extracted with ethyl acetate after adding 5 mL of water. The organic phases were combined, washed with saturated brine, concentrated, and purified by column chromatography to obtain 340 mg of the target compound, yield: 70%.
[0708] Step 2: Synthesis of ((1r,3r)-3-(4-(1-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutyl)tert-butyl carbamate
[0709] Compound ((1r,3r)-3-(4-(1-(4-(((2-cyanopyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutyl)carbamate tert-butyl ester (340 mg, 0.7 mmol) was dissolved in 10 mL of anhydrous ethanol, and hydroxylamine (46 mg, 1.4 mmol) was added. The reaction was carried out at 70 °C for 2 hours. TLC monitoring showed complete consumption of the starting material, and the anhydrous ethanol was directly concentrated. Ethyl acetate was then added, followed by washing with water and saturated brine. The organic phases were combined and concentrated, and the resulting product was dissolved in 5 mL of pyridine. Acetyl chloride (109 mg, 1.4 mmol) was added under ice bath conditions, and the reaction was carried out at 100 °C for 3 hours. After the reaction was completed as monitored by TLC, most of the pyridine was concentrated, followed by washing with 0.5 N hydrochloric acid, extraction with ethyl acetate, washing with water and saturated brine, and combining the organic phases. The mixture was dried, concentrated, and purified by column chromatography to obtain 115 mg of the target compound, yield: 30%.
[0710] Step 3: Synthesis of (1r,3r)-3-(4-(1-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutane-1-amine)
[0711] (1r,3r)-3-(4-(1-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutyl)carbamate tert-butyl ester (115 mg, 0.21 mmol) was dissolved in 2 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added under ice bath conditions. The mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. The mixture was extracted with dichloromethane / methanol (10:1) (3 x 10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 33 mg of the target compound, yield: 36%.
[0712] Step 4: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(1-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0713] (1r,3r)-3-(4-(1-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)ethyl)phenoxy)cyclobutane-1-amine (33 mg, 0.074 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (22 mg, 0.074 mmol), and DIPEA (40 mg, 0.3 mmol) were added sequentially to 10 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 15 mg of the target compound. Yield: 29%. 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.73(s,2H),7.59(d,J=8.3Hz,1H),7.53(d,J=5.5Hz,1 H),7.34(d,J=8.5Hz,2H),7.21–7.14(m,4H),6.85(s,1H),6.83–6.71(m,3H),5.04(dd,J=12. 9,5.4Hz,1H),4.91–4.81(m,1H),4.15(d,J=8.4Hz,2H),2.94–2.80(m,1H),2.69(s,3H),2.63 –2.51(m,3H),2.47–2.39(m,2H),2.19–1.86(m,2H),1.56(d,J=7.2Hz,3H).LC / MS(ESI+)calcd forC 38 H 33 N7O7([M+H)) + )m / z:700.3; found 700.3.
[0714] Example 100: 5-((1r,3r)-3-(4-(2-(4-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(1-methyl-2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0715]
[0716] 5-(((1s,3s)-3-(4-(2-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione (70 mg, 0.09 mmol) was dissolved in 2 mL of LDMF, potassium carbonate (28 mg, 0.2 mmol) was added, and methyl iodoform (15 mg, 0.1 mmol) was added under ice bath conditions. The reaction was carried out at room temperature for one hour. After the reaction was monitored by TLC until complete, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3*5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 40 mg of compound 5-((1r,3r)-3-(4-(2-(4-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(1-methyl-2,6-dioxanil-3-yl)isoindoline-1,3-dione, yield: 59%. 1 HNMR (400MHz, DMSO-d6) δ8.33(d,J=5.0Hz,1H),7.59(d,J=8.3Hz,1H),7.48(d,J=1.9Hz,1H),7.12–7.08( m,4H),6.92–6.86(m,3H),6.82(dd,J=8.3,2.0Hz,1H),6.80–6.72(m,3H),5.10(dd,J=13.0,5.3Hz,1H),4. 95(s,2H),4.71(s,4H),4.49(t,J=6.9Hz,1H),4.19(s,4H),3.77(d,J=7.2Hz,1H),3.08–3.02(m,2H),3.00 (s,3H),2.92(d,J=12.5Hz,1H),2.54(d,J=5.3Hz,2H),2.02–1.94(m,3H),1.57(s,6H).LC / MS(ESI+)calcd for C 43 H 44 N6O7([M+H)) + )m / z:757.3; found 757.3.
[0717] Example 101: (S)-3-(5-((1r,3S)-3-(4-(2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxindoline-2-yl)piperidine-2,6-dione
[0718]
[0719] Step 1: Synthesis of tert-butyl (S)-5-amino-4-((benzyloxy)carbonyl)amino)-5-oxovalerate
[0720] (S)-2-((benzyloxy)carbonyl)amino)-5-(tert-butoxy)-5-oxovaleric acid (10 g, 30 mmol) was dissolved in 100 mL of dioxane. Di-tert-butyl dicarbonate (10.4 g, 48 mmol) and pyridine (4.5 g, 60 mmol) were added sequentially to the reaction system, replacing the atmosphere with helium. The reaction was carried out at 0 °C for 30 minutes. Ammonium bicarbonate (7.1 g, 90 mmol) was added while maintaining the temperature at 0 °C, and the reaction was continued overnight at room temperature. After the reaction was complete as monitored by TLC, the reaction was quenched with water. The mixture was extracted twice with 100 mL of ethyl acetate, washed with 0.5 N hydrochloric acid (2 x 50 mL), saturated sodium bicarbonate solution (2 x 50 mL), and saturated brine (2 x 50 mL). The mixture was dried over anhydrous sodium sulfate, concentrated, and slurried with ethyl acetate to give 8.2 g of the target compound (yield: 83%).
[0721] Step 2: Synthesis of tert-butyl (S)-4,5-diamino-5-oxopentanoate
[0722] (S)-5-amino-4-((benzyloxy)carbonyl)amino)-5-oxovalerate tert-butyl ester (8.1 g, 24 mmol) was dissolved in 150 mL of methanol, and 800 mg of 10% palladium on carbon was added. The reaction system was replaced with hydrogen gas using a hydrogen balloon, and the mixture was stirred overnight at room temperature. After the reaction was completed by TLC monitoring, the reaction system was concentrated, and the mixture was purified by column chromatography to obtain 4.7 g of the target compound, yield: 97%.
[0723] Step 3: Synthesis of ((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0724] Compound ((1r,3r)-3-(4-(2-(4-(((2-cyanopyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl ester (2 g, 4 mmol) was dissolved in 30 mL of anhydrous ethanol. Hydroxylamine (270 mg, 8 mmol) was added, and the reaction was carried out at 70 °C for 2 hours. TLC monitoring showed complete consumption of the starting material, and the anhydrous ethanol was directly concentrated. Ethyl acetate was then added, followed by washing with water and saturated brine. The organic phases were combined, concentrated, and dissolved in 20 mL of pyridine. Acetyl chloride (630 mg, 8 mmol) was added under ice bath conditions, and the reaction was carried out at 100 °C for 3 hours. After the reaction was completed as monitored by TLC, most of the pyridine was concentrated, followed by washing with 0.5 N hydrochloric acid, extraction with ethyl acetate, washing with water and saturated brine, and combining the organic phases. The mixture was dried, concentrated, and purified by column chromatography to obtain 1.4 g of the target compound, with a yield of 63%.
[0725] Step 4: Synthesis of (1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutamine-1-amine
[0726] 1.4 g (2.5 mmol) of tert-butyl carbamate ((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate)tert-butyl)carbamate) was dissolved in 20 mL of dichloromethane. 10 mL of trifluoroacetic acid was added under ice bath conditions, followed by stirring at room temperature for 0.5 hours. After the reaction was complete as monitored by TLC, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. Extraction was performed with dichloromethane / methanol (10:1) (3 x 20 mL), washing with saturated brine, drying over anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain 1.02 g of the target compound, yield: 88%.
[0727] Step 5: Synthesis of 5-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isobenzofuran-1(3H)-one
[0728] Compound (1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutylamine-1-amine (300 mg, 0.65 mmol), 5-bromophthalide (152 mg, 0.71 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (54 mg, 0.065 mmol), and cesium carbonate (425 mg, 1.3 mmol) were added to 5 mL of dioxane. The reaction system was replaced with a helium atmosphere, and the reaction was carried out overnight at 110 °C. After the reaction was completed as monitored by TLC, the reaction system was filtered with diatomaceous earth, concentrated, and purified by column chromatography to obtain 79 mg of the target compound, yield: 21%.
[0729] Step 6: Synthesis of 2-(hydroxymethyl)-4-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)benzoic acid
[0730] 79 mg (0.13 mmol) of 5-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isobenzofuran-1(3H)-one was added to 1 mL of THF, followed by 1 mL of methanol and 0.2 mL (1 mmol) of 5 N sodium hydroxide solution. The mixture was heated to 40 °C and reacted for half an hour. After the reaction was completed by TLC monitoring, it was allowed to cool naturally to room temperature. The pH was adjusted to acidic with 0.5 N dilute hydrochloric acid, extracted with ethyl acetate, washed with saturated brine (3*4 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 70 mg of the target compound, yield: 89%.
[0731] Step 7: Synthesis of methyl 2-(hydroxymethyl)-4-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)benzoate
[0732] Compound 2-(hydroxymethyl)-4-((1r,3r)-3-(4-(2-(4-(((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)benzoic acid (70 mg, 0.11 mmol) was dissolved in 1 mL of dichloromethane. Trimethylsilyldiazomethane (0.5 mL, 0.5 mmol) was added under ice bath conditions, and the mixture was stirred at room temperature for 0.5 hours. After the reaction was complete as monitored by TLC, the solvent was directly concentrated, and the solution was purified by column chromatography to obtain 55 mg of the target compound, yield: 80%.
[0733] Step 8: Synthesis of methyl 2-(bromomethyl)-4-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)benzoate
[0734] 55 mg (0.09 mmol) of methyl benzoate 2-(hydroxymethyl)-4-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)benzoate was dissolved in 1 mL of dichloromethane. Triphenylphosphine (47 mg, 0.18 mmol) and carbon tetrabromide (60 mg, 0.18 mmol) were added, and the mixture was stirred at room temperature for 0.5 hours. After the reaction was completed by TLC monitoring, the solvent was directly concentrated, and the target compound was purified by column chromatography to obtain 27 mg of the target compound, yield: 44%.
[0735] Step 9: Synthesis of (S)-5-amino-4-(5-((1r,3S)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxindoline-2-yl)-5-oxoglutaric acid tert-butyl ester
[0736] Methyl 2-(bromomethyl)-4-((1r,3r)-3-(4-(2-(4-(((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)benzoate (27 mg, 0.04 mmol) was dissolved in 1 mL of acetonitrile, and (S)-4,5-diamino-5-oxovalerate tert-butyl ester (8 mg, 0.04 mmol) was added. DIPEA (10 mg, 0.08 mmol) was added, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 18 mg of the target compound was purified, yield: 56%.
[0737] Step 10: Synthesis of (S)-3-(5-((1r,3S)-3-(4-(2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-1-oxindoline-2-yl)piperidine-2,6-dione
[0738] Methyl benzoate (18 mg, 0.02 mmol) was dissolved in 1 mL of acetonitrile, and p-toluenesulfonic acid (17 mg, 0.1 mmol) was added. The mixture was heated to 80 °C and reacted overnight. The reaction mixture was monitored by TLC until the starting material was completely consumed. After natural cooling to room temperature, the reaction was quenched with water. The mixture was extracted with 5 mL of ethyl acetate, washed with saturated brine (3 x 5 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (2 mg of compound). Yield: 14%. LC / MS (ESI+) calcd for C 39 H 37 N7O6([M+H)) + )m / z:700.3; found 700.3; 98%ee from chiral SFC analysis.
[0739] Example 102: 2-(2,6-dioxadiazin-3-yl)-5-fluoro-6-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0740]
[0741] (1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutylamine-1-amine (100 mg, 0.22 mmol), 2-(2,6-dioxadiazin-3-yl)-5,6-difluoroisoindoline-1,3-dione (65 mg, 0.22 mmol) and DIPEA (86 mg, 0.66 mmol) were added sequentially to 10 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After naturally cooling to room temperature, extract with 5 mL of ethyl acetate, wash with saturated brine (3*5 mL), dry with anhydrous sodium sulfate, concentrate, and purify 21 mg of compound 2-(2,6-dioxadiazol-3-yl)-5-fluoro-6-((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione, yield: 13%. 1 H NMR(400MHz,DMSO-d6)δ11.08(s,1H),8.74(s,2H),7.62(d,J=10.2Hz,1H),7.33–7.28 (m,2H),7.28–7.24(m,1H),7.18–7.12(m,4H),6.92(d,J=7.1Hz,1H),6.80–6.74(m,2H) ,5.06(dd,J=12.8,5.4Hz,1H),4.88(s,1H),4.23(d,J=5.3Hz,1H),2.92–2.82(m,1H), 2.69(s,3H),2.63–2.52(m,5H),2.00(d,J=7.3Hz,2H),1.63(s,6H).LC / MS(ESI+)calcd for C 39 H 34 FN7O7([M+H)) + )m / z:732.3;found732.3.
[0742] Example 103: 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(1-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0743]
[0744] Step 1: Synthesis of ((1r,3r)-3-(4-(1-(4-((6-cyanopyridin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)tert-butyl carbamate
[0745] ((1r,3r)-3-(4-(1-(4-hydroxyphenyl)cyclopentyl)phenoxy)cyclobutyl)carbamate tert-butyl ester (423 mg, 1 mmol), 6-chloropyridine-3-carboxynitrile (140 mg, 1 mmol), and cesium carbonate (652 mg, 2 mmol) were added sequentially to 10 mL of DMF. The reaction was carried out overnight at room temperature. After the reaction was completed by TLC, the mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 484 mg of the target compound, yield: 92%.
[0746] Step 2: Synthesis of ((1r,3r)-3-(4-(1-(4-((6-acetyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)tert-butyl carbamate
[0747] Compound ((1r,3r)-3-(4-(1-(4-(((6-cyanopyridin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)carbamate tert-butyl ester (484 mg, 0.92 mmol) was dissolved in 10 mL of anhydrous tetrahydrofuran. Magnesium methyl bromide (5 mL, 5 mmol) was added under ice bath conditions, and the mixture was stirred at room temperature for 0.5 hours. After the reaction was complete as monitored by TLC, 0.5 N hydrochloric acid was added, and the mixture was stirred at room temperature for 10 minutes. The mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 450 mg of the target compound (yield: 90%).
[0748] Step 3: Synthesis of ((1r,3r)-3-(4-(1-(4-((6-(1-hydroxyethyl)pyridazine-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)tert-butyl carbamate
[0749] Compound ((1r,3r)-3-(4-(1-(4-(((6-acetyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)carbamate tert-butyl ester (450 mg, 0.8 mmol) was dissolved in 10 mL of methanol. Sodium borohydride (152 mg, 4 mmol) was added under ice bath conditions, and the mixture was stirred at room temperature for 3 hours. After the reaction was monitored by TLC until complete, the reaction was quenched with saturated ammonium chloride solution. The mixture was extracted with 10 mL of ethyl acetate, washed with saturated brine (3 x 10 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 380 mg of the target compound, yield: 85%.
[0750] Step 4: Synthesis of 1-(6-(4-(1-(4-((1r,3r)-3-aminocyclobutoxy)phenyl)cyclopentyl)phenoxy)pyridazin-3-yl)ethane-1-ol
[0751] (1r,3r)-3-(4-(1-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)tert-butyl carbamate (380 mg, 0.7 mmol) was dissolved in 10 mL of dichloromethane. 5 mL of trifluoroacetic acid was added under ice bath conditions, followed by stirring at room temperature for 0.5 hours. After the reaction was complete as monitored by TLC, the reaction mixture was poured into a saturated sodium bicarbonate solution under ice bath conditions to make the system alkaline. Extraction was performed with dichloromethane / methanol (10:1) (3 x 10 mL), washing with saturated brine, drying over anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain 276 mg of the target compound (yield: 88%).
[0752] Step 5: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(1-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0753] 1-(6-(4-(1-(4-((1r,3r)-3-aminocyclobutoxy)phenyl)cyclopentyl)phenoxy)pyridazin-3-yl)ethane-1-ol (276 mg, 0.62 mmol), 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (171 mg, 0.62 mmol), and DIPEA (390 mg, 3 mmol) were sequentially added to 30 mL of DMSO, and the mixture was heated to 90 °C and reacted overnight. After cooling to room temperature, the mixture was extracted with 30 mL of ethyl acetate, washed with saturated brine (3 x 30 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 114 mg of the target compound (yield: 26%). 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),7.79(d,J=9.2Hz,1H),7.58(d,J=8.4Hz,1H),7.52(d,J=5.4Hz,1H),7.43–7.3 1(m,3H),7.29–7.19(m,2H),7.11–7.03(m,2H),6.86(s,1H),6.76(dd,J=19.0,8.6Hz,3H),5.59(d,J=4.7Hz,1H),5.0 3(dd,J=12.9,5.4Hz,1H),4.95–4.79(m,2H),4.13(d,J=4.7Hz,1H),2.87(ddd,J=17.3,14.0,5.5Hz,1H),2.61–2.51( m,3H),2.42(q,J=6.6Hz,2H),2.27(s,4H),2.04–1.95(m,1H),1.62(s,4H),1.39(d,J=6.5Hz,3H).LC / MS(ESI+)calcd for C 40 H 39 N5O7([M+H)) + )m / z:702.3; found 702.3.
[0754] Example 104: 5-((1r,3r)-3-(4-(1-(4-((6-acetylpyridin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0755]
[0756] 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(1-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione (60 mg, 0.085 mmol) was dissolved in 2 mL of dichloromethane, and Dys-Martin oxidant (106 mg, 0.25 mmol) was added. The reaction was carried out at room temperature for 3 hours, and the reaction was monitored by TLC until complete. The mixture was filtered through diatomaceous earth, the filtrate was concentrated, and 34 mg of compound 5-((1r,3r)-3-(4-(1-(4-((6-acetyridazin-3-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione was purified by column chromatography, yield: 57%. 1HNMR(400MHz,DMSO-d6)δ11.06(s,1H),8.14(d,J=9.2Hz,1H),7.55(dt,J=14.5,6.8Hz,3H),7.47–7.35 (m,2H),7.35–7.22(m,2H),7.24–7.09(m,2H),6.86(s,1H),6.77(dd,J=15.2,8.8Hz,3H),5.03(dd,J=1 2.9,5.4Hz,1H),4.93–4.78(m,1H),4.13(d,J=5.1Hz,1H),2.86(d,J=12.1Hz,1H),2.67(s,3H),2.62–2 .51(m,3H),2.43(p,J=6.0Hz,2H),2.28(s,4H),2.05–1.92(m,1H),1.63(s,4H).LC / MS(ESI+)calcdfor C 40 H 37 N5O7([M+H)) + )m / z:700.3; found 700.3.
[0757] Example 105: 2-(2,6-dioxadiazin-3-yl)-5-(1r,3r)-3-(4-(4-(6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)tetrahydro-2H-pyran-4-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0758]
[0759] The target compound was prepared using a method similar to that of Example 103. 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.57(s,2H),7.59(d,J=8.3Hz,1H),7.52(d,J=5.4Hz,1H),7.43–7.31(m ,2H),7.24(d,J=8.5Hz,2H),7.07–6.95(m,2H),6.85(s,1H),6.78(t,J=8.8Hz,3H),5.22(d,J=5.5Hz,1H),5.0 3(dd,J=12.9,5.4Hz,1H),4.86(s,1H),4.79(q,J=6.3Hz,1H),4.13(s,1H),3.58(t,J=5.0Hz,4H),2.96–2.80( m,1H),2.54(s,4H),2.39(d,J=31.0Hz,6H),1.99(d,J=12.3Hz,1H),1.40(d,J=6.6Hz,3H).LC / MS(ESI+)calcd for C 40 H 39 N5O8([M+H)) + )m / z:718.3; found 718.3.
[0760] Example 106: 5-((1r,3r)-3-(4-(4-(((6-acetylpyridazin-3-yl)oxy)phenyl)tetrahydro-2H-pyran-4-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0761]
[0762] The target compound was prepared using a method similar to that of Example 105. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),8.69(s,2H),7.59(d,J=8.4Hz,1H),7.52(d,J=5.4Hz,1H),7.45–7.37(m ,2H),7.30–7.23(m,2H),7.18–7.11(m,2H),6.86(s,1H),6.77(d,J=8.9Hz,3H),5.03(dd,J=13.0,5.4Hz,1H),4 .91–4.80(m,1H),4.18–4.09(m,1H),3.59(d,J=5.3Hz,4H),3.17(d,J=5.2Hz,1H),2.96–2.79(m,1H),2.64(s, 3H),2.60–2.53(m,2H),2.43(d,J=5.5Hz,2H),2.37(d,J=5.9Hz,4H),2.00(d,J=7.8Hz,2H).LC / MS(ESI+)calcd for C 40 H 37 N5O8([M+H)) + )m / z:716.3; found 716.3.
[0763] Example 107: 5-(3-(4-(2-(2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)-2-(2,6-dioxadiopterin-3-yl)isoindoline-1,3-dione
[0764]
[0765] Step 1: Synthesis of N-Boc-3-methanesulfonyloxypiperidine
[0766] N-Boc-3-hydroxypiperidine (1.00 g, 5 mmol) was dissolved in 10 mL of dichloromethane, and triethylamine (2.01 g, 20 mmol) was added. The mixture was placed in an ice-water bath, and methanesulfonyl chloride (851 mg, 7.5 mmol) was added. The mixture was heated to room temperature and reacted for 2 h. After the reaction of the starting material was monitored by TLC until complete, saturated ammonium chloride aqueous solution was added to quench the reaction. The mixture was extracted with 10 mL of dichloromethane, and the organic phases were combined, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 1.50 g of crude N-Boc-3-methanesulfonyloxypiperidine.
[0767] Step 2: Synthesis of 3-(4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester
[0768] N-Boc-3-methanesulfonyloxypiperidine (350 mg crude, 0.78 mmol) and 4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenol (100 mg, 0.26 mmol) were dissolved in 5 mL of DMF, and Cs₂CO₃ (167 mg, 0.51 mmol) was added. The reaction was carried out overnight at 100 °C. The reaction was quenched with water, extracted with 10 mL of ethyl acetate, and the organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by prep-TLC to give compound 3-(4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester (50 mg), yield 34%. LC / MS (ESI+) calcd for C 34 H 43 N3O5([M+H)) + )m / z 574.3; found 574.3.
[0769] Step 3: Synthesis of 2-(1-ethoxyvinyl)-4-((4-(2-(4-(piperidin-3-oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidine
[0770] 3-(4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester (50 mg, 0.08 mmol) was dissolved in 4 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added dropwise under ice bath conditions. After the addition, the reaction was continued to be stirred under ice bath conditions for 1 h. After the reaction was complete as monitored by TLC, the pH was adjusted to alkaline with saturated sodium carbonate aqueous solution, and the mixture was extracted with dichloromethane / methanol at a ratio of 10:1. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give compound 2-(1-ethoxyvinyl)-4-((4-(2-(4-(piperidine-3-oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidin (40 mg), yield: 95%. LC / MS (ESI+) calcd for C 29 H 35 N3O3([M+H)) + )m / z 474.3; found 474.3.
[0771] Step 4: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-(3-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)isoindoline-1,3-dione
[0772] Dissolve 2-(1-ethoxyvinyl)-4-((4-(2-(4-(piperidin-3-oxy)phenyl)propane-2-yl)phenoxy)methyl)pyrimidine (40 mg, 0.085 mmol) in 5 mL DMSO, add 3 drops of DIPEA, 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.11 mmol), and react overnight at 90 °C. The extract was quenched with water, extracted three times with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated, and evaporated to dryness. The compound was purified by prep-TLC to give 2-(2,6-dioxadiidine-3-yl)-5-(3-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)isoindol-1,3-dione (34 mg), yield: 54%. LC / MS (ESI+) calcd for C 42 H 43 N5O7([M+H)) + )m / z 730.3; found 730.3.
[0773] Step 5: Synthesis of 5-(3-(4-(2-(2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)-2-(2,6-dioxadioperidin-3-yl)isoindoline-1,3-dione
[0774] 2-(2,6-dioxadiazin-3-yl)-5-(3-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)isoindoline-1,3-dione (34 mg, 0.046 mmol) was dissolved in 2 mL of acetone, and 2 mL of 2N HCl aqueous solution was added. The reaction was carried out at room temperature for 2 hours. After the reaction was completed by TLC, 10 mL of water was added, and the mixture was extracted three times with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by prep-TLC to obtain the product 5-(3-(4-(2-(2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione (8 mg, yellow solid), yield: 25%. 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),9.01(d,J=5.1Hz,1H),7.77(d,J=5.1Hz,1H),7.62(d,J=8.5Hz,1H),7.26(dd,J=5.4 ,2.3Hz,1H),7.22–7.17(m,1H),7.17–7.12(m,2H),7.09(d,J=8.6Hz,2H),6.96(d,J=8.8Hz,2H),6.82(dd,J=8.9,2.4Hz,2H ),5.26(s,2H),5.06(dd,J=12.8,5.4Hz,1H),4.48(s,1H),3.83(d,J=13.3Hz,1H),3.60(s,1H),3.56–3.40(m,2H),2.95–2 .81(m,1H),2.67(s,3H),2.63–2.52(m,2H),2.00(dd,J=14.9,7.1Hz,3H),1.83(s,1H),1.72(d,J=8.8Hz,1H),1.58(s,6H).
[0775] LC / MS(ESI+)calcd for C 40 H 39 N5O7([M+H)) + m / z:702.3; found 702.3.
[0776] Example 108: Synthesis of 5-(4-((4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
[0777]
[0778] The target compound was prepared using a method similar to that in Example 107. 1H NMR(400MHz,Chloroform-d)δ8.92(d,J=5.1Hz,1H),8.12(s,1H),7.71(dd,J=22.0,6.8Hz,2H),7. 30(s,1H),7.20–7.03(m,4H),6.83(dd,J=27.9,8.4Hz,4H),5.25(s,2H),4.94(dd,J=12.2,5.3Hz,1 H),4.00(d,J=13.0Hz,2H),3.82(d,J=6.2Hz,2H),3.03(t,J=12.8Hz,2H),2.79(d,J=11.0Hz,3H), 2.23–2.10(m,2H),1.99(t,J=11.3Hz,3H),1.64(s,6H),1.43(d,J=16.0Hz,4H).LC / MS(ESI+)calcd for C 41 H 41 N5O7([M+H)) + )m / z 716, found 716.
[0779] Example 109: Synthesis of 5-((2-(4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)ethyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0780]
[0781] The target compound was prepared using a method similar to that in Example 107. 1 H NMR(400MHz,Chloroform-d)δ8.92(d,J=5.1Hz,1H),8.13(s,1H),7.74(d,J=5.1Hz, 1H),7.63(d,J=8.3Hz,1H),7.16(dd,J=8.8,3.1Hz,4H),7.03(d,J=2.2Hz,1H),6.92– 6.75(m,5H),5.25(s,2H),4.93(dd,J=12.1,5.2Hz,1H),4.23–4.12(m,2H),3.63(t, J=5.1Hz,2H),2.94–2.65(m,6H),2.17–2.08(m,1H),1.64(s,6H).LC / MS(ESI+)calcd for C 37 H 35 N5O7([M+H)) + )m / z 662, found 662.
[0782] Example 110: Synthesis of 5-(((trans)-3-(4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0783]
[0784] The target compound was prepared using a method similar to that in Example 107. 1 H NMR(400MHz,Chloroform-d)δ8.92(d,J=5.1Hz,1H),8.08(s,1H),7.74(dt,J=5.1,0.9Hz,1H),7.62(d,J=8.2 Hz,1H),7.21–7.09(m,4H),6.91–6.82(m,3H),6.69(dq,J=7.1,3.2,2.6Hz,3H),5.25(d,J=0.8Hz,2H),4.93( dd,J=12.2,5.2Hz,1H),4.85(td,J=6.9,3.5Hz,1H),4.22(td,J=7.8,3.9Hz,1H),2.94–2.74(m,6H),2.73–2. 67(m,2H),2.40(dt,J=12.9,6.1Hz,2H),2.12(ddd,J=13.2,5.8,2.9Hz,1H),1.64(s,6H).LC / MS(ESI+)calcd for C 39 H 37 N5O7([M+H)) + )m / z 688, found 688.
[0785] Example 111: Synthesis of 5-(((trans)-3-(4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)(methyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0786]
[0787] The target compound was prepared using a method similar to that in Example 107. 1H NMR(400MHz,Chloroform-d)δ9.01–8.85(m,1H),8.19(s,1H),7.80–7.72(m,1H),7.67 (d,J=8.4Hz,1H),7.22–7.07(m,5H),6.88(td,J=6.0,2.8Hz,3H),6.71(d,J=8.5Hz,2H) ,5.25(s,2H),4.94(dd,J=12.0,5.2Hz,1H),4.74(d,J=6.7Hz,1H),4.61(p,J=7.8Hz,1H ),3.06(s,3H),2.95–2.51(m,10H),2.19–2.08(m,1H),1.65(s,6H).LC / MS(ESI+)calcd for C 40 H 39 N5O7([M+H)) + )m / z 702, found 702.
[0788] Example 112: Synthesis of 5-((3-((4-(2-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0789]
[0790] The target compound was prepared using a method similar to that of Example 59. 1 H NMR(400MHz,Chloroform-d)δ8.30(d,J=5.3Hz,2H),7.60(d,J=8.2Hz,1H),7.14(t,J=8.4Hz,4H),6.96–6.76(m,6H),6.68(td,J=8.5,2.1Hz,1H),4.91( d,J=34.5Hz,8H),4.32(s,4H),3.93(t,J=8.7Hz,2H),2.95–2.42(m,6H),2.1 6–2.10(m,1H),1.91–1.77(m,2H),1.64(d,J=4.8Hz,6H).LC / MS(ESI+)calcd for C 43 H 44 N6O7([M+H)) + )m / z 757, found 757.
[0791] Example 113: Synthesis of 5-(3-(4-(2-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)propoxy)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0792]
[0793] 4-(2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl methanesulfonate (554 mg, 1 mmol), 2-(2,6-dioxadiazin-3-yl)-5-hydroxyisoindoline-1,3-dione (274 mg, 1 mmol), and sodium bicarbonate (252 mg, 3 mmol) were added sequentially to 15 mL of DMF, and the mixture was heated to 75 °C and reacted for 16 h. After naturally cooling to room temperature, the product was poured into water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 439 mg of the product was purified, yield: 60%. 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),8.33(d,J=5.0Hz,1H),7.83(d,J=8.3Hz,1H),7.45(d,J=2.3Hz,1H),7.3 7(dd,J=8.3,2.3Hz,1H),7.09(dd,J=8.9,2.5Hz,4H),6.94–6.80(m,4H),6.74(d,J=5.0Hz,1H),5.11(dd,J=12 .9,5.4Hz,1H),4.94(s,2H),4.71(s,4H),4.32(t,J=6.2Hz,2H),4.19(s,4H),4.10(t,J=6.2Hz,2H),2.89(s,1 H),2.73(s,1H),2.64–2.54(m,1H),2.20(q,J=6.2Hz,2H),2.10–1.99(m,1H),1.56(s,6H).LC / MS(ESI+)calcd for C 41 H 41 N5O8([M+H)) + )m / z 732, found 732.
[0794] Example 114: Synthesis of N-(2-(4-(2-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)ethyl)-2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-carboxamide
[0795]
[0796] The target compound was obtained using a similar method. 1 H NMR (400MHz, DMSO-d6) δ11.16(s,1H),9.12(t,J=5.4Hz,1H),8.45–8.27(m,3H),8.03(d,J=7.7Hz,1H),7. 10(d,J=8.5Hz,5H),6.87(dd,J=8.6,6.1Hz,4H),6.74(d,J=5.0Hz,1H),5.19(dd,J=12.8,5.3Hz,1H),4.9 4(s,2H),4.71(s,4H),4.15(d,J=29.8Hz,6H),3.66(q,J=5.7Hz,2H),2.89(ddd,J=17.0,14.1,5.2Hz,1H) ,2.59(td,J=15.6,14.9,4.1Hz,2H),2.08(ddt,J=12.3,7.1,4.3Hz,1H),1.56(s,6H).LC / MS(ESI+)calcd for C 41 H 40 N6O8([M+H)) + )m / z 745, found 745.
[0797] Example 115: Synthesis of 5-(((trans)-3-(4-(2-(4-((2-(cyclopropanecarbonyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0798]
[0799] Step 1: Synthesis of (1r,3r)-3-(4-(2-(4-((2-cyanopyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate:
[0800] 4-(chloromethyl)pyrimidin-2-carbamate (153 mg, 1 mmol) and tert-butyl((1r, 3r)-3-(4-(2-(4-hydroxyphenyl)propyl-2-phenoxy)cyclobutyl)carbamate (397 mg, 1 mmol) were dissolved in DMF (8 mL), and potassium carbonate (276 mg, 2 mmol) was added. The mixture was reacted at room temperature for 15 hours. The reaction solution was poured into water, extracted, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 413 mg of the product (80% yield). LC / MS (ESI+) calcd for C30 H 34 N4O4([M+H)) + )m / z 515, found 515.
[0801] Step 2: Synthesis of tert-butyl ((1r,3r)-3-(4-(2-(4-(2-(cyclopropylcarbonyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate:
[0802] (1r, 3r)-3-(4-(2-(4-(((2-cyanopyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (514 mg, 1 mmol) was dissolved in dry THF (10 mL), and the mixture was reacted in an ice-water bath under nitrogen protection with a THF solution of cyclopropylmagnesium bromide (10 mL, 5 mmol) for 10 minutes. The reaction mixture was then extracted in cold 0.5 N dilute hydrochloric acid, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 398 mg of the product (70% yield). LC / MS (ESI+) calcd for C 33 H 39 N3O5([M+H)) + )m / z 558, found 558.
[0803] Step 3: Synthesis of tert-butyl ((1r,3r)-3-(4-(2-(4-(2-(cyclopropyl(hydroxy)methyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate:
[0804] tert-butyl ((1r, 3r)-3-(4-(2-(4-(2-(cyclopropylcarbonyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (557 mg, 1 mmol)) was dissolved in 15 mL of methanol. Sodium borohydride (114 mg, 3 mmol) was added in portions over an ice-water bath, and the reaction was allowed to proceed for half an hour after the addition was complete. The reaction mixture was poured into water, extracted, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 502 mg of the product (90% yield). LC / MS (ESI+) showed calcd for C 33 H 41 N3O5([M+H)) + )m / z 560, found 560.
[0805] Subsequent steps were similar to those in Example 107 to prepare 5-((1r,3r)-3-(4-(2-(2-(cyclopropyl(hydroxy)methyl)pyrimidin-4-ylmethoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanil-3-yl)isoindole-1,3-dione. LC / MS (ESI+) calcd for C 41 H 41 N5O7([M+H)) + )m / z 716, found 716.
[0806] Step 6: Synthesis of 5-((1r, 3r)-3-(4-(2-(4-(2-(cyclopropanecarbonyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione:
[0807] 5-((1r,3r)-3-(4-(2-(2-(cyclopropyl(hydroxy)methyl)pyrimidin-4-ylmethoxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanil-3-yl)isoindole-1,3-dione (715 mg, 1 mmol) was dissolved in 30 mL of DCM. The mixture was placed in an ice-water bath, and Dysmartin oxidant (640 mg, 1.5 mmol) was added in portions. The mixture was allowed to return to room temperature for 16 hours. The solution was poured into a saturated sodium sulfite aqueous solution, filtered through a diatomaceous earth liner, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 356 mg of the product was purified, yield: 50%. LC / MS (ESI+) calcd for C 41 H 39 N5O7([M+H)) + )m / z 714, found 714.
[0808] Example 116: Synthesis of 5-(((trans)-3-(4-(2-(4-((6-(cyclopropyl(hydroxy)methyl)pyridin-2-yl)methoxy)phenyl)propyl-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0809]
[0810] The target compound was prepared using a method similar to that in Example 115. 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),7.81(t,J=7.7Hz,1H),7.56(dd,J=25.0,6.9Hz,2H),7.39(dd,J=20.2,7. 7Hz,2H),7.11(dd,J=8.7,4.8Hz,4H),6.99–6.64(m,6H),5.32(d,J=4.7Hz,1H),5.18–4.98(m,3H),4.86(p,J=6 .1Hz,1H),4.15(dt,J=9.8,4.7Hz,2H),2.88(ddd,J=17.5,14.2,5.5Hz,1H),2.64–2.51(m,3H),2.42(dq,J=12. 5,8.1,6.3Hz,3H),2.06–1.91(m,1H),1.57(s,6H),1.18–1.07(m,1H),0.37(t,J=7.5Hz,4H).LC / MS(ESI+)calcd for C 42 H 42 N4O7([M+H)) + )m / z715, found 715.
[0811] Example 117: Synthesis of 5-(((trans)-3-(4-(2-(4-((6-(cyclopropanecarbonyl)pyridin-2-yl)methoxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0812]
[0813] 5-(((trans)-3-(4-(2-(4-(((6-(cyclopropyl(hydroxy)methyl)pyridin-2-yl)methoxy)phenyl)propyl-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione (714 mg, 1 mmol)) was dissolved in 30 mL of DCM. The mixture was placed in an ice-water bath, and Dysmartin oxidant (640 mg, 1.5 mmol) was added in portions. The mixture was allowed to return to room temperature for 16 hours. The solution was poured into a saturated sodium sulfite aqueous solution, filtered through a diatomaceous earth liner, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 356 mg of the product was purified, yield: 50%. LC / MS (ESI+) calcd for C 42 H 40 N4O7([M+H)) + )m / z 713, found 713.
[0814] Example 118: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-(((trans)-3-(4-(2-(4-((2-(1-hydroxyethyl)pyrimidin-5-yl))oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0815]
[0816] Step 1: Synthesis of tert-butyl ((1r,3r)-3-(4-(2-(4-((2-cyanopyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate:
[0817] Tert-butyl ((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propyl-2-phenoxy)cyclobutyl)carbamate (397 mg, 1 mmol) and 2-cyano-5-bromopyrimidine (183 mg, 1 mmol), CuI (26 mg, 0.2 mmol), pyridinedicarboxylic acid (33 mg, 0.2 mmol), and potassium phosphate (424 mg, 2 mmol) were dissolved in DMSO (8 mL), purged three times with nitrogen, and heated to 90°C for 5 hours. The reaction mixture was poured into water, extracted, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 400 mg of the product (80% yield). LC / MS (ESI+) showed calcd for C 29 H 32 N4O4([M+H)) + )m / z 501, found 501.
[0818] Step 2: Synthesis of tert-butyl ((1r,3r)-3-(4-(2-(4-(((2-acetylpyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate:
[0819] tert-butyl ((1r,3r)-3-(4-(2-(4-(((2-cyanopyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (500 mg, 1 mmol)) was dissolved in THF (10 mL) and reacted in an ice-water bath under nitrogen protection with a THF solution of methyl magnesium bromide (10 mL, 5 mmol) for 10 minutes. The reaction mixture was then extracted in cold 0.5 N dilute hydrochloric acid. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 360 mg of the product (70% yield). LC / MS (ESI+) calcd for C 30 H 35 N3O5([M+H)) + )m / z 518, found 518.
[0820] Step 3: Synthesis of tert-butyl ((1r,3r)-3-(4-(2-(4-(2-(1-hydroxyethyl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate:
[0821] tert-butyl ((1r,3r)-3-(4-(2-(4-(((2-acetylpyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (517 mg, 1 mmol)) was dissolved in 15 mL of methanol. Sodium borohydride (114 mg, 3 mmol) was added in portions over an ice-water bath, and the reaction was allowed to proceed for half an hour after the addition was complete. The reaction mixture was poured into water, extracted, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and column chromatography was performed to give 470 mg of the product (90% yield). LC / MS (ESI+) calcd for C 30 H 37 N3O5([M+H)) + )m / z 520, found 520.
[0822] Subsequent steps four and five were similar to the last two steps of Example 1 to prepare the target compound. Yield: 25%. 1 H NMR(400MHz,Chloroform-d)δ8.46(s,2H),8.30(s,1H),7.61(d,J=8.2Hz,1H),7.25(d ,J=2.2Hz,1H),7.18–7.09(m,2H),6.99–6.92(m,2H),6.88(d,J=2.1Hz,1H),6.77–6.65 (m,3H),5.02–4.82(m,3H),4.21(td,J=7.7,3.9Hz,1H),2.93–2.65(m,5H),2.40(dt,J= 13.8, 5.9Hz, 2H), 2.11 (td, J = 9.3, 8.6, 5.4Hz, 1H), 1.67 (s, 6H), 1.57 (d, J = 6.6Hz, 3H). LC / MS(ESI+)calcd for C 38 H 37 N5O7([M+H)) + )m / z 676, found 676.
[0823] Example 119: Synthesis of 5-(((trans)-3-(4-(2-(4-(((2-acetylpyrimidin-5-yl)oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0824]
[0825] 2-(2,6-dioxadiazin-3-yl)-5-(((trans)-3-(4-(2-(4-(((2-(1-hydroxyethyl)pyrimidin-5-yl))oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)isodihydroindole-1,3-dione (675 mg, 1 mmol)) was dissolved in 30 mL of DCM. The mixture was placed in an ice-water bath, and Dysmartin oxidant (640 mg, 1.5 mmol) was added in portions. The mixture was allowed to return to room temperature for 16 hours. The solution was poured into a saturated sodium sulfite aqueous solution, filtered through a diatomaceous earth liner, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography. 510 mg of the product was purified, yield: 80%. 1 H NMR(400MHz,Chloroform-d)δ8.54(s,2H),8.15(s,1H),7.62(d,J=8.3Hz,1H),7.33 –7.28(m,2H),7.20–7.08(m,2H),7.05–6.97(m,2H),6.90(d,J=2.1Hz,1H),6.72(dd ,J=8.8,2.5Hz,3H),4.99–4.82(m,2H),4.22(td,J=7.8,4.0Hz,1H),2.93–2.66(m,8 H),2.42(dt,J=12.9,6.2Hz,2H),2.16–2.08(m,1H),1.68(s,6H).LC / MS(ESI+)calcd for C 38 H 35 N5O7([M+H)) + )m / z 674, found 674.
[0826] Example 120: 3-(7-(((trans)-3-(4-(2-(4-((6-(5-methyl-1,3,4-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl))oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-4-oxoquinazoline-3(tetrahydro)-yl)piperidin-2,6-dione
[0827]
[0828] Step 1: Synthesis of 2-amino-N-(2,6-dioxadiazin-3-yl)-4-fluorobenzamide
[0829] 2-Amino-4-fluorobenzoic acid (155 mg, 1 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (166 mg, 1 mmol) were dissolved in 6 mL of DMF, and DIEA (387 mg, 3 mmol) and HATU (380 mg, 1 mmol) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water, extracted, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and slurried to give 160 mg of product (yield: 60%). LC / MS (ESI+) calcd for C 12 H 12 FN3O3([M+H) + )m / z 266, found 266.
[0830] Step 2: Synthesis of 3-(7-fluoro-4-oxazolidine-3(4H)-yl)piperidine-2,6-dione
[0831] 2-Amino-N-(2,6-dioxadiazin-3-yl)-4-fluorobenzamide (265 mg, 1 mmol) and TsOH (172 mg, 1 mmol) were dissolved in 5 mL of trimethyl orthoformate and reacted at 120 °C for 2 hours. After cooling, EA and methanol were added and stirred to give 138 mg of product, yield: 50%. LC / MS (ESI+) calcd for C 13 H 10 FN3O3([M+H) + )m / z 276, found 276.
[0832] The target compound was prepared in a manner similar to that of Example 116. 1 HNMR(400MHz,DMSO-d6)δ11.06(s,1H),8.52(d,J=2.8Hz,1H),8.21–8.10(m,2H),7.82(d,J=8.7Hz,1H),7 .51(dd,J=8.8,2.9Hz,1H),7.38–7.27(m,2H),7.22–7.05(m,5H),6.78(t,J=9.6Hz,3H),6.44(d,J=2.2Hz ,1H),5.33(s,1H),4.88(h,J=6.0,5.5Hz,1H),4.06(dd,J=26.5,6.5Hz,1H),2.81(q,J=14.3Hz,1H),2.59 (s,5H),2.53(d,J=7.6Hz,2H),2.45(q,J=5.7Hz,2H),2.17–2.02(m,1H),1.63(s,6H).LC / MS(ESI+)calcd for C 40 H37 N7O6([M+H)) + )m / z 712, found 712.
[0833] Example 122: Synthesis of 5-(((trans)-3-(4-(4-((5-(dihydro-1,2,3-triazol-2-yl)pyrimidin-2-yl)oxy)phenoxy)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0834]
[0835] The target compound was prepared using a method similar to that of Example 228. 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),9.23(s,2H),8.23(s,2H),7.67–7.50(m,2H),7.33–7.20(m,2H),7.06–6.81(m,8H),5.04(dd,J=13.0,5 .4Hz,1H),4.96–4.82(m,1H),4.17(s,1H),2.93–2.80(m,1H),2.57(d,J=17.3Hz,3H),2.46(d,J=5.9Hz,2H),1.99(s,2H).LC / MS(ESI+)calcd forC 35 H 28 N8O7([M+H)) + )m / z 673, found 673.
[0836] Example 123: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-(((trans)-3-(4-(2-(4-((6-(1-hydroxyethyl)pyridin-3-yl))oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0837]
[0838] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1H NMR (400MHz, Chloroform-d) δ8.33–8.20 (m, 2H), 7.62 (d, J = 8.3Hz, 1H), 7.41 (dd, J = 8. 6,2.7Hz,1H),7.32(d,J=8.6Hz,1H),7.25–7.20(m,2H),7.18–7.10(m,2H),6.96–6.86 (m,3H),6.77–6.66(m,3H),5.00–4.81(m,4H),4.22(s,1H),2.93–2.65(m,5H),2.47–2 .34(m,2H),2.14–2.10(m,1H),1.66(s,6H),1.53(d,J=6.5Hz,3H).LC / MS(ESI+)calcd for C 39 H 38 N4O7([M+H)) + )m / z 675, found 675.
[0839] Example 124: Synthesis of 5-((((trans)-3-(4-(2-(4-(((6-acetylpyridin-3-yl)oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-oxoperidin-3-yl)isoindoline-1,3-dione
[0840]
[0841] The target compound was prepared according to a method similar to that of Example 119. Yield: 80%. LC / MS (ESI+) calcd for C 39 H 36 N4O7([M+H)) + )m / z 673,found 673.
[0842] Example 125: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-(((trans)-3-(4-(2-(4-((6-(1-hydroxyethyl)pyridazin-3-yl))oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0843]
[0844] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1H NMR(400MHz,Chloroform-d)δ8.20(s,1H),7.60(t,J=8.9Hz,2H),7.22(d,J=8.7Hz,2H),7.12(d d,J=28.8,8.3Hz,4H),6.93–6.85(m,1H),6.70(dd,J=8.3,4.7Hz,3H),5.10(d,J=6.6Hz,1H),4. 99–4.80(m,2H),4.21(s,1H),2.99(s,2H),2.91–2.75(m,2H),2.69(td,J=9.4,6.8,3.8Hz,2H), 2.40(p,J=5.7Hz,2H),2.14–2.09(m,1H),1.67(s,6H),1.56(d,J=6.3Hz,3H).LC / MS(ESI+)calcd for C 38 H 37 N5O7([M+H)) + )m / z 676,found 676.
[0845] Example 126: Synthesis of 5-(((trans)-3-(4-(2-(4-(((6-acetyridazin-3-yl)oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0846]
[0847] The target compound was prepared according to a method similar to that of Example 119. Yield: 80%. 1 H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.16(d,J=9.2Hz,1H),7.56(td,J=10.9,6.9Hz,3H),7 .37–7.27(m,2H),7.22–7.13(m,4H),6.90–6.71(m,4H),5.03(dd,J=12.9,5.4Hz,1H),4.88(p ,J=6.1Hz,1H),4.15(d,J=5.0Hz,1H),2.89(s,2H),2.73(d,J=0.6Hz,2H),2.68(s,3H),2.57– 2.52(m,2H),2.45(dd,J=7.3,4.7Hz,1H),2.04–1.95(m,1H),1.65(s,6H).LC / MS(ESI+)calcd for C 38 H 35N5O7([M+H]+)m / z 674, found 674.
[0848] Example 127: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-(((cis)-3-(4-(2-(4-((2-(1-hydroxyethyl)pyrimidin-5-yl))oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0849]
[0850] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.58(s,2H),7.59(d,J=8.3Hz,1H),7.46(d,J=6.4Hz,1H),7.32–7.20 (m,2H),7.19–7.09(m,2H),7.07–6.97(m,2H),6.90(d,J=2.0Hz,1H),6.86–6.73(m,3H),5.24(d,J=5.5Hz,1 H),5.04(dd,J=12.9,5.4Hz,1H),4.86–4.73(m,1H),4.57–4.41(m,1H),3.86–3.67(m,1H),3.00(s,3H),2.9 4–2.81(m,1H),2.63–2.52(m,1H),2.08–1.87(m,3H),1.61(s,6H),1.41(d,J=6.6Hz,3H).LC / MS(ESI+)calcd for C 38 H 37 N5O7([M+H)) + )m / z 676, found 676.
[0851] Example 128: Synthesis of 5-(((cis)-3-(4-(2-(4-(((2-acetylpyrimidin-5-yl)oxy)phenyl)prop-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0852]
[0853] The target compound was prepared according to a method similar to that of Example 119. Yield: 80%. 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.70(s,2H),7.59(d,J=8.3Hz,1H),7.46(d,J =6.4Hz,1H),7.37–7.25(m,2H),7.22–7.08(m,4H),6.95–6.73(m,4H),5.04(dd,J=12 .9,5.4Hz,1H),4.50(t,J=6.9Hz,1H),3.78(d,J=7.3Hz,1H),3.13–2.98(m,2H),2.95 –2.77(m,1H),2.69–2.51(m,5H),2.04–1.88(m,3H),1.63(s,6H).LC / MS(ESI+)calcd for C 38 H 35 N5O7([M+H)) + )m / z 674,found 674.
[0854] Example 129: 2-(2,6-dioxadiazin-3-yl)-5-((cis)-3-(4-(2-(4-((5-(1-hydroxyethyl)pyrazin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0855]
[0856] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.41(d,J=1.4Hz,1H),8.29–8.19(m,1H),7.59(d,J=8.3Hz,1H),7.46(d,J=6 .5Hz,1H),7.33–7.22(m,2H),7.21–7.12(m,2H),7.12–7.04(m,2H),6.95–6.74(m,4H),5.49(d,J=4.7Hz,1H),5.04 (dd,J=12.9,5.4Hz,1H),4.79(dd,J=6.5,4.7Hz,1H),4.50(t,J=6.9Hz,1H),3.78(d,J=7.2Hz,1H),3.14–2.97(m,2 H),2.95–2.81(m,1H),2.63–2.52(m,1H),2.06–1.88(m,3H),1.63(s,6H),1.44–1.33(m,3H).LC / MS(ESI+)calcdfor C 38 H37 N5O7([M+H)) + )m / z 676,found 676.
[0857] Example 130: Synthesis of 5-((cis)-3-(4-(2-(4-(((5-acetylpyrazin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0858]
[0859] The target compound was prepared according to a method similar to that of Example 119. Yield: 80%. 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.65(d,J=25.9Hz,2H),7.59(d,J=8.2Hz,1 H),7.46(d,J=6.4Hz,1H),7.37–7.05(m,6H),6.98–6.72(m,4H),5.04(dd,J=13.2 ,5.2Hz,1H),4.60–4.39(m,1H),3.78(s,1H),3.06(s,2H),2.88(t,J=14.5Hz,1H) ,2.57(d,J=18.9Hz,4H),1.96(d,J=16.5Hz,4H),1.64(s,6H).LC / MS(ESI+)calcd for C 38 H 35 N5O7([M+H)) + )m / z 674,found 674.
[0860] Example 131: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-((trans)-3-(4-(3-(4-((2-(1-hydroxyethyl)pyrimidin-5-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0861]
[0862] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.56(s,2H),7.56(dd,J=20.9,6.8Hz,2H),7.18(d,J=8.7Hz,2H) ,7.09–6.96(m,4H),6.90–6.71(m,4H),5.24(d,J=5.5Hz,1H),5.04(dd,J=12.9,5.4Hz,1H),4.93–4.71( m,2H),4.14(d,J=5.7Hz,1H),2.87(td,J=17.2,15.4,5.3Hz,1H),2.63–2.51(m,3H),2.41(t,J=6.1Hz, 3H),2.01(dq,J=13.7,6.0,5.4Hz,5H),1.40(d,J=6.5Hz,3H),0.56(t,J=7.1Hz,6H).LC / MS(ESI+)calcd for C 40 H 41 N5O7([M+H)) + )m / z 704,found 704.
[0863] Example 132: 5-((trans)-3-(4-(3-(4-(((2-acetylpyrimidin-5-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[0864]
[0865] The target compound was prepared according to a method similar to that of Example 119. Yield: 80%. 1 H NMR (400MHz, DMSO-d6) δ11.03 (s, 1H), 8.68 (s, 2H), 7.56 (dd, J = 20.5, 6.8Hz, 2H), 7.3 3–7.01(m,6H),6.95–6.65(m,4H),5.03(dd,J=13.1,5.5Hz,1H),4.94–4.83(m,1H),4. 14(s,1H),2.97–2.79(m,1H),2.64(s,3H),2.43(q,J=7.3,6.2Hz,2H),2.03(td,J=14 .9,14.0,7.1Hz,5H),1.24(d,J=9.3Hz,4H),0.57(t,J=7.2Hz,6H).LC / MS(ESI+)calcd for C 40 H 39 N5O7([M+H)) +)m / z 702,found 702.
[0866] Example 133: 2-(2,6-dioxadiazin-3-yl)-5-((cis)-3-(4-(3-(4-((2-(1-hydroxyethyl)pyrimidin-5-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0867]
[0868] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.56(s,2H),7.59(d,J=8.3Hz,1H),7.45(d,J=6.4Hz,1H),7.24–7.15(m,2H ),7.10–6.99(m,4H),6.90(d,J=2.0Hz,1H),6.85–6.75(m,3H),5.24(d,J=5.5Hz,1H),5.04(dd,J=12.9,5.4Hz,1H) ,4.87–4.72(m,1H),4.50(p,J=7.0Hz,1H),3.78(p,J=7.5Hz,1H),3.13–2.96(m,2H),2.87(ddd,J=17.2,14.0,5.4 Hz,1H),2.63–2.51(m,2H),2.11–1.85(m,7H),1.40(d,J=6.5Hz,3H),0.56(t,J=7.2Hz,6H).LC / MS(ESI+)calcdfor C 40 H 41 N5O7([M+H)) + )m / z 704, found 704.
[0869] Example 134: 2-(2,6-dioxadiazine-3-yl)-5-((trans)-3-(4-(1-(4-((2-(1-hydroxyethyl)pyrimidin-5-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0870]
[0871] The target compound was prepared according to a method similar to that of Example 118. Yield: 25%. 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),8.56(s,2H),7.56(dd,J=21.7,6.9Hz,2H),7.39–7.28(m,2H),7.27–7.1 7(m,2H),7.04–6.93(m,2H),6.90–6.67(m,4H),5.24(d,J=5.5Hz,1H),5.04(dd,J=12.9,5.4Hz,1H),4.90–4.7 2(m,2H),4.13(d,J=5.1Hz,1H),2.88(ddd,J=19.5,15.3,5.5Hz,1H),2.57(d,J=17.6Hz,3H),2.42(q,J=6.1Hz ,2H),2.23(s,4H),1.99(q,J=4.9,4.2Hz,1H),1.60(t,J=3.8Hz,4H),1.40(d,J=6.6Hz,3H).LC / MS(ESI+)calcd forC 40 H 39 N5O7([M+H)) + )m / z 702,found 702.
[0872] Example 135: 5-((trans)-3-(4-(1-(4-(((2-acetylpyrimidin-5-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0873]
[0874] The target compound was prepared according to a method similar to that of Example 119. Yield: 80%. 1H NMR(400MHz,DMSO-d6)δ11.08(s,1H),8.68(s,2H),7.56(dd,J=19.9,6.8Hz,2H),7.45–7.33(m,2H), 7.23(d,J=8.7Hz,2H),7.16–7.06(m,2H),6.91–6.67(m,4H),5.04(dd,J=12.9,5.4Hz,1H),4.84(dd,J =8.9,3.8Hz,1H),4.12(s,1H),2.96–2.78(m,1H),2.64(s,3H),2.59(d,J=3.5Hz,3H),2.42(q,J=7.5 ,7.0Hz,2H),2.35–2.14(m,4H),1.99(q,J=5.2,4.1Hz,2H),1.62(d,J=6.1Hz,4H).LC / MS(ESI+)calcd for C 40 H 37 N5O7([M+H)) + )m / z 700,found 700.
[0875] Example 136: 5-((4-((8-(4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0876]
[0877] Step 1: Synthesis of tert-butyl butyl (4-((8-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butylcarbamate)
[0878] Dissolve tert-butyl (4-((8-(4-(4-hydroxyphenyl)propyl-2-phenoxy)octyl)oxy)carbamate (264 mg, 0.50 mmol) in 5 mL Cesium carbonate (325 mg, 1.0 mmol) and (2-(1-ethoxyvinyl)pyrimidin-4-yl)methanesulfonate (129 mg, 0.5 mmol) were added to DMF. The mixture was reacted at room temperature for 2 hours. Then, 15 mL of ethyl acetate and 12 mL of water were added, the mixture was stirred, and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 172 mg of the product (4-((8-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butylcarbamate tert-butyl ester, yield: 50%. LC / MS (ESI+) calcd for C 41 H 59 N3O6([M+H)) + )m / e 690.4, found 690.4.
[0879] Step 2: Synthesis of 2-(2,6-dioxopiridine-3-yl)-5-(4-((8-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)isoindoline-1,3-dione
[0880] (4-((8-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)tert-butylcarbamate (170 mg, 0.24 mmol) was dissolved in 4 mL of dichloromethane. The mixture was placed in an ice-water bath, and 1 mL of trifluoroacetic acid was added dropwise. The reaction was maintained at this temperature for 1 hour. The pH was adjusted to alkaline with saturated sodium carbonate aqueous solution. The mixture was extracted with dichloromethane / methanol at a ratio of 10:1, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 130 mg of solid product. Dissolve 65 mg of the product in 5 mL of DMSO, add 5 drops of N,N-diisopropylethylamine and 2-(2,6-dioxadiidine-3-yl)-5-fluoroisoindoline-1,3-dione (48 mg, 0.16 mmol), react overnight at 90 °C, cool, extract with dichloromethane / water, dry, concentrate, and purify by thin-layer chromatography to obtain 23 mg of the product 2-(2,6-dioxadiidine-3-yl)-5-(4-((8-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)isoindoline-1,3-dione, yield: 25%, LC / MS (ESI+) calcd for C 49 H 59N5O8([M+H)) + )m / e 845.4, found 845.4.
[0881] Step 3: Synthesis of 5-((4-((8-(4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxoperidin-3-yl)isoindoline-1,3-dione)
[0882] Dissolve 2-(2,6-dioxadiazine-3-yl)-5-(4-((8-(4-(2-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)isoindoline-1,3-dione (23 mg, 0.027 mmol) in 4 mL of acetone, and add 2 mL of 2N The reaction was carried out in HCl aqueous solution at room temperature for 1.5 hours. Then, 15 mL of ethyl acetate and 12 mL of water were added, the mixture was stirred, and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 10 mg of the product 5-((4-((8-(4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)octyl)oxy)butyl)amino)-2-(2,6-dioxadiazine-3-yl)isoindoline-1,3-dione, yield: 45%. LC / MS (ESI+) calcd for C 47 H 55 N5O8([M+H)) + )m / e 818.4, found 818.4, 1H NMR(400MHz,Chloroform-d)δ8.92(d,J=5.0Hz,1H),8.00(s,1H),7.74(d,J=4.8Hz,1H),7.61(d,J=8.1Hz,1H),7.1 7(d,J=8.6Hz,2H),7.14–7.09(m,2H),6.99(s,1H),6.86(d,J=8.5Hz,2H),6.82–6.74(m,3H),5.25(s,2H),4.92(dd ,J=12.0,5.2Hz,1H),3.91(t,J=6.5Hz,2H),3.45(dt,J=13.3,6.2Hz,4H),3.25(t,J=6.5Hz,2H),2.80(s,5H),2.13 (d,J=5.9Hz,2H),2.01(d,J=4.6Hz,2H),1.74(dd,J=13.7,6.4Hz,6H),1.63(s,6H),1.46–1.41(m,2H),1.26(s,6H).
[0883] Example 137: 5-((4-(2-(4-(3-((2-(2,6-dioxopiridine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)phenyl)prop-2-yl)phenoxy)methyl)-N-methyl-1,2,4-oxadiazole-3-carboxamide
[0884]
[0885] Step 1: Synthesis of tert-butyl (3-(4-(2-(4-hydroxyphenyl)prop-2-yl)phenoxy)propyl)carbamate
[0886] Bisphenol A (17.1 g, 75 mmol) was dissolved in 100 mL of DMF. Anhydrous cesium carbonate (24.4 g, 75 mmol) was added with stirring. N-Boc-3-aminopropyl bromide (11.9 g, 50 mmol) was dissolved in 30 mL of DMF and added dropwise to the reaction system. After the addition was complete, the reaction was carried out at 60 °C for 5 hours. After cooling to room temperature, 150 mL of ethyl acetate and 120 mL of water were added, and the mixture was stirred and extracted. The aqueous layer was back-extracted once with 100 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 12.2 g of tert-butyl 3-(4-(2-(4-hydroxyphenyl)propyl-2-yl)phenoxy)propyl)carbamate, yield: 63%. LC / MS (ESI+) calcd for C 23 H 31 NO4([M+H)) +)m / e 386.2, found386.2.
[0887] Step 2: Synthesis of ethyl 5-((4-(2-(4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)propyl-2-yl)phenoxy)methyl)-1,2,4-oxadiazole-3-carboxylic acid ester
[0888] Dissolve tert-butyl (3-(4-(2-(4-hydroxyphenyl)prop-2-yl)phenoxy)propyl)carbamate (1930 mg, 5.0 mmol) in 15 mL Anhydrous potassium carbonate (1.38 g, 10 mmol) was added to DMF, followed by ethyl 5-(chloromethyl)-1,2,4-oxadiazole-3-carboxylate (953 mg, 5.0 mmol). The mixture was stirred and reacted overnight at room temperature. 35 mL of ethyl acetate and 30 mL of water were added, and the mixture was extracted. The organic layer was back-extracted once with 25 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 1.55 g of ethyl 5-((4-(2-(4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)propyl-2-yl)phenoxy)methyl)-1,2,4-oxadiazole-3-carboxylate, yield: 57%. LC / MS (ESI+) calcd for C 29 H 37 N3O7([M+H)) + )m / e 540.2, found 540.2.
[0889] Step 3: Synthesis of tert-butyl carbamate (3-(4-(2-(4-((3-(methylcarbamoyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propyl-2-yl)phenoxy)propyl)carbamate
[0890] Ethyl 5-((4-(2-(4-(3-((tert-butyloxycarbonyl)amino)propoxy)phenyl)propyl-2-yl)phenoxy)methyl)-1,2,4-oxadiazole-3-carboxylic acid (225 mg, 0.42 mmol) was dissolved in 2 mL of methanol, and 1 mL of 7 mmol / L methylamine alcohol solution was added. The mixture was sealed in a tube at 100 °C for 3 hours, cooled to room temperature, and purified by thin-layer chromatography to obtain 120 mg of tert-butyl (3-(4-(2-(4-((3-(methylcarbamoyl)-1,2,4-oxadiazole-5-yl)methoxy)phenyl)propyl-2-yl)phenoxy)propyl)carbamate, yield: 54%. LC / MS (ESI+) calcd for C 28 H 36 N4O6([M+H)) + )m / e 525.3, found 525.3.
[0891] Step 4: Synthesis of 5-((4-(2-(4-(3-((2-(2,6-dioxadiazol-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)phenyl)prop-2-yl)phenoxy)methyl)-N-methyl-1,2,4-oxadiazole-3-carboxamide
[0892] Dissolve tert-butyl carbamate (120 mg, 0.24 mmol) in 4 mL of dichloromethane in an ice-water bath, add 1 mL of trifluoroacetic acid dropwise, and incubate for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate aqueous solution, extract with a 10:1 dichloromethane / methanol mixture, dry to dryness with anhydrous magnesium sulfate, and concentrate under reduced pressure to dryness. Dissolved in 5 mL of dimethyl sulfoxide, 5 drops of N,N-diisopropylethylamine and 2-(2,6-dioxadiidine-3-yl)-5-fluoroisoindoline-1,3-dione (70 mg, 0.25 mmol) were added. The mixture was reacted overnight at 95 °C, cooled, extracted with dichloromethane / water, dried, concentrated, and purified by thin-layer chromatography to obtain 29 mg of the product 5-((4-(2-(4-(3-((2-(2,6-dioxadiidine-3-yl)-1,3-dioxadiidine-5-yl)amino)propoxy)phenyl)prop-2-yl)phenoxy)methyl)-N-methyl-1,2,4-oxadiazole-3-carboxamide, yield: 18%. LC / MS (ESI+) calcd for C 36 H 36 N6O8([M+H)) + )m / e 681.3, found681.3; 1 H NMR(400MHz,Chloroform-d)δ8.13(s,1H),7.59(d,J=8.3Hz,1H),7.20–7.10(m,4H),7.06( s,1H),6.98(d,J=2.1Hz,1H),6.90–6.85(m,2H),6.84–6.79(m,2H),6.75(dd,J=8.3,2.2Hz ,1H),5.31(s,2H),5.01(s,1H),4.93(dd,J=12.1,5.2Hz,1H),4.09(t,J=5.5Hz,2H),3.47( t,J=6.5Hz,2H),3.04(d,J=5.1Hz,3H),2.93–2.68(m,4H),2.15–2.11(m,2H),1.64(s,6H).
[0893] Example 138: 5-((4-(2-(4-((8-(4-((2-(2,6-dioxadiazine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)butoxy)octoxy)phenyl)propane-2-yl)phenoxy)methyl)-1,2,4-oxadiazole-3-carboxamide
[0894]
[0895] The target compound was prepared using a method similar to that in Example 137. LC / MS (ESI+) calcd for C 44 H 52 N6O9([M+H)) + )m / e 809.4, found 809.4; 1 H NMR (400MHz, Chloroform-d) δ8.07(s,1H),7.61(d,J=8.0Hz,1H),7.17(d,J=8.5Hz,2H),7.11(d,J=8. 6Hz,2H),6.99(d,J=4.9Hz,1H),6.87(d,J=8.6Hz,2H),6.81–6.71(m,3H),5.96(s,1H),5.33(s,2H),4. 96–4.90(m,1H),3.91(t,J=6.5Hz,2H),3.45(dt,J=13.1,6.1Hz,4H),3.30–3.22(m,2H),2.94–2.68(m ,4H),1.78–1.71(m,6H),1.63(s,6H),1.59(d,J=7.9Hz,2H),1.46–1.41(m,2H),1.26(t,J=4.7Hz,6H).
[0896] Example 139: 5-((3-(4-(2-(4-((3-(azacyclobutane-1-carbonyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)-2-(2,6-dioxanidindoline-1,3-dione)
[0897]
[0898] The target compound was prepared using a method similar to that in Example 137. LC / MS (ESI+) calcd for C 38 H 38 N6O8([M+H)) + )m / e 706.3, found 706.3. 1H NMR(400MHz,Chloroform-d)δ8.14(s,1H),7.59(d,J=8.3Hz,1H),7.19–7.10(m,4H),6.98( d,J=2.2Hz,1H),6.91–6.85(m,2H),6.84–6.78(m,2H),6.74(dd,J=8.3,2.2Hz,1H),5.32(s, 2H),5.02–4.89(m,2H),4.60–4.53(m,2H),4.29–4.23(m,2H),4.09(t,J=5.5Hz,2H),3.46( q,J=7.2,5.9Hz,2H),2.93–2.69(m,3H),2.46–2.35(m,2H),2.18–2.07(m,3H),1.63(s,6H).
[0899] Example 140: 2-(2,6-dioxadiazol-3-yl)-5-((3-(4-(2-(4-((3-(pyrrolidine-1-carbonyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0900]
[0901] The target compound was prepared using a method similar to that in Example 137. LC / MS (ESI+) calcd for C 39 H 40 N6O8([M+H)) + )m / e 721.3, found 721.3. 1 H NMR(400MHz,Chloroform-d)δ8.14(s,1H),7.59(d,J=8.3Hz,1H),7.19–7.10(m,4H),6.98(d,J=2. 2Hz,1H),6.92–6.87(m,2H),6.84–6.79(m,2H),6.74(dd,J=8.3,2.2Hz,1H),5.33(s,2H),4.97–4. 89(m,1H),4.41(s,1H),4.09(t,J=5.5Hz,2H),3.77(t,J=6.5Hz,2H),3.69(t,J=6.6Hz,2H),3.51– 3.42(m,2H),2.93–2.69(m,3H),2.17–2.08(m,3H),1.98(dtd,J=9.6,7.0,5.2Hz,4H),1.64(s,6H).
[0902] Example 141: 2-(2,6-dioxadiazin-3-yl)-5-(3-(4-(2-(4-((3-(4-methylpiperazin-1-carbonyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0903]
[0904] The target compound was prepared using a method similar to that in Example 137. LC / MS (ESI+) calcd for C 40 H 43 N7O8([M+H)) + )m / e 750.3, found 750.3. 1 H NMR(400MHz,Chloroform-d)δ8.53(s,1H),7.59(d,J=8.3Hz,1H),7.15(dd,J=8.8,6.9Hz,4H),6.98( d,J=2.2Hz,1H),6.92–6.85(m,2H),6.82(d,J=8.6Hz,2H),6.74(dd,J=8.3,2.2Hz,1H),5.33(s,2H),4 .99(s,1H),4.92(dd,J=12.1,5.2Hz,1H),4.09(t,J=5.5Hz,2H),3.88(s,2H),3.72(s,2H),3.46(q,J =6.3Hz,2H),2.91–2.72(m,3H),2.54(s,3H),2.39(s,3H),2.12(dt,J=10.1,4.8Hz,4H),1.64(s,6H).
[0905] Example 142: 2-(2,6-dioxadiazol-3-yl)-5-((3-(4-(2-(4-((3-(morpholin-4-carbonyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propane-2-yl)phenoxy)propyl)amino)isoindoline-1,3-dione
[0906]
[0907] The target compound was prepared using a method similar to that in Example 137. LC / MS (ESI+) calcd for C 39 H 40 N6O9([M+H)) + )m / e 737.3, found737.3. 1H NMR(400MHz,Chloroform-d)δ8.13(s,1H),7.59(d,J=8.3Hz,1H),7.20–7.10(m,4H), 6.98(d,J=2.1Hz,1H),6.92–6.86(m,2H),6.84–6.79(m,2H),6.75(dd,J=8.3,2.1Hz,1 H),5.33(s,2H),4.97–4.88(m,1H),4.09(t,J=5.5Hz,2H),3.86–3.76(m,4H),3.74–3 .65(m,4H),3.46(t,J=6.4Hz,2H),2.92–2.70(m,4H),2.17–2.07(m,2H),1.64(s,6H).
[0908] Example 143: 5-((4-(2-(4-(3-((2-(2,6-dioxadiazine-3-yl)-1,3-dioxoisoindoline-5-yl)amino)propoxy)phenyl)propane-2-yl)phenoxy)methyl)-1,2,4-oxadiazole-3-carboxamide
[0909]
[0910] The target compound was prepared using a method similar to that in Example 137. LC / MS (ESI+) calcd for C 35 H 36 N6O8([M+H)) + )m / e 666.2, found 666.2. 1 H NMR(400MHz,Chloroform-d)δ8.10(s,1H),7.59(d,J=8.3Hz,1H),7.15(dd,J=8.7 ,6.6Hz,4H),6.98(d,J=2.0Hz,1H),6.92–6.85(m,3H),6.82(d,J=8.8Hz,2H),6.76 –6.72(m,1H),5.33(s,2H),4.93(dd,J=11.9,5.2Hz,1H),4.09(t,J=5.5Hz,2H),3 .47(t,J=6.5Hz,2H),2.93–2.73(m,4H),2.14(d,J=7.4Hz,2H),1.29–1.23(m,6H).
[0911] Example 144: 5-((R)-2-((4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-yl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0912]
[0913] Step 1: Synthesis of (R)-2-((methanesulfonyl)oxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester
[0914] Boc-D-prolyl (1.05 g, 5.0 mmol) was dissolved in 15 mL of dichloromethane, and triethylamine (1.01 g, 10.0 mmol) was added. The mixture was placed in an ice-water bath, and methanesulfonyl chloride (684 mg, 6.0 mmol) was added. The mixture was heated to room temperature and reacted overnight at room temperature. The product was washed with saturated ammonium chloride aqueous solution, then washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 1.22 g of (R)-2-((methanesulfonyl)oxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester.
[0915] Step 2: Synthesis of (R)-2-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester
[0916] Bisphenol A (514 mg, 2.25 mmol) was dissolved in 6 mL of DMF, and anhydrous cesium carbonate (975 mg, 3.0 mmol) was added. Then (R)-2-((methanesulfonyl)oxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester (420 mg, 1.5 mmol) was added. The mixture was reacted at 60 °C for 5 hours, cooled to room temperature, and 15 mL of ethyl acetate and 12 mL of water were added. The mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 200 mg of (R)-2-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester, yield: 33%. LC / MS (ESI+) calcd for C 25 H 33 NO4([M+H)) + )m / e 412.2, found 412.2.
[0917] Step 3: Synthesis of (R)-2-((4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester
[0918] Dissolve (R)-2-((4-(2-(4-hydroxyphenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester (112 mg, 0.27 mmol) in 5 mL Anhydrous cesium carbonate (176 mg, 0.54 mmol) was added to DMF, followed by methyl (2-(1-ethoxyvinyl)pyrimidin-4-yl)methanesulfonate (70 mg, 0.27 mmol). The mixture was reacted at 60 °C for 4 hours, cooled to room temperature, and then 15 mL of ethyl acetate and 12 mL of water were added. The mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 110 mg of (R)-2-((4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester, yield: 71%. LC / MS (ESI+) calcd for C 34 H 43 N3O5([M+H)) + )m / e574.3, found 574.3.
[0919] Step 4: Synthesis of 2-(2,6-dioxadiazin-3-yl)-5-((R)-2-((4-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrrolid-1-yl)isoindoline-1,3-dione
[0920] (R)-2-((4-(2-(4-((2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrrolidine-1-carboxylic acid tert-butyl ester (110 mg, 0.19 mmol) was dissolved in 4 mL of dichloromethane. The mixture was placed in an ice-water bath, and 1 mL of trifluoroacetic acid was added dropwise. The reaction was maintained at this temperature for 1 hour. The pH was adjusted to alkaline with saturated sodium carbonate aqueous solution. The mixture was extracted with dichloromethane / methanol at a ratio of 10:1, dried over anhydrous magnesium sulfate, and concentrated to dryness under reduced pressure. Dissolve in 5 mL DMSO, add 5 drops of N,N-diisopropylethylamine, 2-(2,6-dioxadiidine-3-yl)-5-fluoroisoindoline-1,3-dione (70 mg, 0.25 mmol), react overnight at 90 °C, cool, extract with dichloromethane / water, dry, concentrate, and purify by thin-layer chromatography to obtain 50 mg of the product 2-(2,6-dioxadiidine-3-yl)-5-((R)-2-((4-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrrolidine-1-yl)isoindoline-1,3-dione, yield: 36%, LC / MS (ESI+) calcd for C 42 H 43N5O7([M+H)) + )m / e 730.3, found 730.3.
[0921] Step 5: Synthesis of 5-((R)-2-((4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-yl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0922] Dissolve 50 mg (0.069 mmol) of 2-(2,6-dioxadiazin-3-yl)-5-((R)-2-((4-(2-(1-ethoxyvinyl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)methyl)pyrrolidone-1-yl)isoindoline-1,3-dione in 4 mL of acetone, and add 2 mL of 2N The reaction was carried out in HCl aqueous solution at room temperature for 1.5 hours. Then, 15 mL of ethyl acetate and 12 mL of water were added, the mixture was stirred, and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 20 mg of the product 5-((R)-2-((4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-yl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione, yield: 42%. LC / MS (ESI+) calcd for C 40 H 39 N5O7([M+H)) + )m / e702.8, found 702.8; 1 H NMR(400MHz,Chloroform-d)δ8.91(d,J=5.1Hz,1H),8.08(d,J=14.0Hz,1H),7.73(dd,J=5.1,1.1Hz,1H),7 .66(d,J=8.5Hz,1H),7.20–7.06(m,5H),6.89–6.80(m,3H),6.79–6.73(m,2H),5.24(s,2H),4.94(dd,J=12 .2,5.2Hz,1H),4.29(s,1H),4.01(dd,J=9.2,3.8Hz,1H),3.84(t,J=8.4Hz,1H),3.59(t,J=8.6Hz,1H),3.3 4(q,J=8.6,6.6Hz,1H),2.93–2.83(m,1H),2.80(s,3H),2.79–2.59(m,2H),2.28–2.08(m,5H),1.63(s,6H).
[0923] Example 145: 5-((S)-2-((4-(2-(4-(((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)pyrrolidine-1-yl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0924]
[0925] The target compound was prepared using a method similar to that in Example 144. LC / MS (ESI+) calcd for C 40 H 39 N5O7([M+H)) + )m / e 702.8, found 702.8. 1 H NMR(400MHz,Chloroform-d)δ8.92(d,J=4.9Hz,1H),8.01(d,J=14.6Hz,1H),7.73(s,1H), 7.66(d,J=8.4Hz,1H),7.20–7.03(m,5H),6.84(t,J=9.9Hz,3H),6.77(d,J=8.5Hz,2H),5.2 4(s,2H),4.94(dd,J=12.3,5.2Hz,1H),4.29(s,1H),4.01(dd,J=9.3,3.6Hz,1H),3.84(t,J =8.4Hz,1H),3.59(s,1H),3.34(s,1H),2.93–2.69(m,6H),2.27–2.09(m,5H),1.63(s,6H).
[0926] Example 146: 5-((1r, 4r)-4-((4-(2-(4-((2-acetylpyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)methyl)cyclohexyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[0927]
[0928] The target compound was prepared using a method similar to that in Example 144. LC / MS (ESI+) calcd for C 42 H 43 N5O7([M+H)) + )m / e 730.3, found 730.3. 1H NMR(400MHz,Chloroform-d)δ8.92(s,1H),7.97(s,1H),7.74(s,1H),7.61(d,J=8.1Hz,1H),7.16(dd,J=15.3, 8.6Hz,4H),6.96(s,1H),6.87(d,J=8.5Hz,2H),6.80(d,J=8.7Hz,2H),6.73(d,J=8.3Hz,1H),5.35(t,J=4.9Hz ,2H),5.25(s,2H),4.93(dd,J=12.1,5.5Hz,1H),4.31(t,J=6.7Hz,1H),3.78(d,J=6.1Hz,2H),3.39(s,1H),2. 81(s,4H),2.27–2.15(m,3H),2.01(d,J=6.5Hz,4H),1.42(d,J=6.6Hz,1H),1.26(s,6H),0.87(d,J=7.0Hz,2H).
[0929] Example 147: 5-((4-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)piperidin-1-yl)methyl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0930]
[0931] Step 1: Synthesis of 4-(2-(4-((2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenol
[0932] Dissolve 1.76 g (5.0 mmol) of 4-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenol in 13 mL In DMSO, DIEA (1.95 g, 15 mmol) was added, followed by 2-oxo-6-azaspiro[3.3]heptane hemioxalate (865 mg, 3.0 mmol). The mixture was reacted overnight at 90 °C, cooled to room temperature, and then 30 mL of ethyl acetate and 25 mL of water were added. The mixture was stirred and extracted. The aqueous layer was back-extracted once with 25 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and then stirred for 30 minutes with 10 mL of ethyl acetate. The mixture was filtered, and the filter cake was dried to obtain 1.7 g of 4-(2-(4-((2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenol, yield: 81%. LC / MS (ESI+) calcd for C25 H 27 N3O3([M+H)) + )m / e 418.2, found 418.2.
[0933] Step 2: 4-(4-(2-(4-((2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester
[0934] 4-(2-(4-((2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenol (100 mg, 0.23 mmol) was dissolved in 5 mL of DMF, anhydrous cesium carbonate (325 mg, 1.0 mmol) was added, and 1-N-Boc-4-bromopiperidine (132 mg, 0.5 mmol) was added. The mixture was reacted overnight at 80 °C. Cool to room temperature, add 15 mL ethyl acetate and 12 mL water, stir, extract, and back-extract the aqueous layer with 10 mL ethyl acetate. Combine the organic layers, wash with water and saturated brine respectively, dry with anhydrous sodium sulfate, concentrate under reduced pressure, and purify by thin-layer chromatography to obtain 50 mg of tert-butyl 4-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)piperidine-1-carboxylic acid, yield: 35%. LC / MS (ESI+) calcd for C 35 H 44 N4O5([M+H)) + )m / e 601.3, found601.3.
[0935] Step 3: 5-((4-(4-(2-(4-((2-(2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)piperidin-1-yl)methyl)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0936] 4-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester (50 mg, 0.083 mmol) was dissolved in 4 mL of dichloromethane, placed in an ice-water bath, and 1 mL of trifluoroacetic acid was added. The mixture was kept warm for 1 hour, and the pH was adjusted to alkaline with saturated sodium carbonate aqueous solution. The mixture was extracted with dichloromethane / methanol at a ratio of 10:1, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to dryness. Dissolved in 5 mL acetonitrile, 3 drops of N,N-diisopropylethylamine and 5-(bromomethyl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione (30 mg, 0.09 mmol) were added. The mixture was reacted overnight at 40 °C, cooled, extracted with dichloromethane / water, dried, concentrated, and purified by thin-layer chromatography to obtain the product 5-((4-(4-(2-(4-((2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)piperidin-1-yl)methyl)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[0937] 12mg, yield: 18%. LC / MS (ESI+) calcd for C 44 H 46 N6O7([M+H)) + )m / e 771.3, found771.3; 1 H NMR(400MHz,Chloroform-d)δ8.30(d,J=5.1Hz,1H),8.22(s,1H),7.93(s,1H),7.88 (d,J=4.6Hz,1H),7.17–7.06(m,4H),6.86–6.74(m,5H),4.99(dd,J=12.3,5.2Hz,1H) ,4.94(s,2H),4.86(s,4H),4.41(s,1H),4.29(s,4H),3.84(s,1H),2.97–2.68(m,5H ),2.54(s,1H),2.17(dt,J=10.6,6.6Hz,2H),1.94(s,3H),1.62(s,6H),1.26(s,2H).
[0938] Example 148: 5-((3-(4-(2-(4-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)azabut-1-yl)methyl)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0939]
[0940] The target compound was prepared using a method similar to that in Example 147. LC / MS (ESI+) calcd for C 42 H 42 N6O7([M+H)) + )m / e 743.3, found 743.3. 1 H NMR(400MHz,Chloroform-d)δ8.30(d,J=5.0Hz,1H),8.27(s,1H),7.88(s,3H),7. 12(dd,J=8.8,2.1Hz,4H),6.86–6.78(m,3H),6.68–6.61(m,2H),4.98(dd,J=12.2, 5.3Hz,1H),4.94(s,2H),4.89(d,J=6.3Hz,1H),4.86(s,4H),4.29(s,4H),4.11(s, 1H),4.04(s,2H),3.40(s,2H),2.96–2.69(m,4H),2.19–2.11(m,1H),1.61(s,6H).
[0941] Example 149: 5-((R)-1-(4-(2-(4-((2-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)-3-methylbutane-2-yl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0942]
[0943] Step 1: Synthesis of (R)-(1-(4-(2-(4-((2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)-3-methylbutane-2-yl)carbamate tert-butyl
[0944] Dissolve 140 mg (0.34 mmol) of 4-(2-(4-((2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenol in 5 mL In DMF, cesium carbonate (330 mg, 1.02 mmol) and (R)-2-((tert-butyloxycarbonyl)amino)-3-methylbutylmethanesulfonate (191 mg, 0.68 mmol) were added, and the mixture was reacted overnight at 100 °C. After cooling to room temperature, 15 mL of ethyl acetate and 12 mL of water were added, and the mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 150 mg of (R)-(1-(4-(2-(4-((2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)-3-methylbutane-2-yl)carbamate, yield: 73%. LC / MS (ESI+) calcd for C 35 H 46 N4O5([M+H)) + )m / e 603.3, found 603.3.
[0945] Step 2: Synthesis of 5-((R)-1-(4-(2-(4-((2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)-3-methylbutane-2-yl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0946] (R)-(1-(4-(2-((2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)-3-methylbutane-2-yl)tert-butyl carbamate (80 mg, 0.13 mmol) was dissolved in 4 mL of dichloromethane. The mixture was placed in an ice-water bath, and 1 mL of trifluoroacetic acid was added dropwise. The reaction was maintained at this temperature for 1 hour. The pH was adjusted to alkaline with saturated sodium carbonate solution. The mixture was extracted with dichloromethane / methanol at a ratio of 10:1, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 60 mg of the product. This product was dissolved in 5 mL of DMSO, and 3 drops of N,N-diisopropylethylamine were added. 6-Dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (40 mg, 0.15 mmol) was reacted overnight at 90 °C, cooled, extracted with dichloromethane / water, dried, concentrated, and purified by thin-layer chromatography to obtain product 5-((R)-1-(4-(2-(4-((2-(2-(2-oxy-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)prop-2-yl)phenoxy)-3-methylbutane-2-yl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione 3 mg, yield: 3%, LC / MS (ESI+) calcd for C 43 H 46 N6O7([M+H)) + )m / e 759.3, found 759.3; 1 H NMR(400MHz,Chloroform-d)δ8.28(s,1H),8.15(s,1H),7.60(d,J=8.2Hz,1H),7.11(d,J=8.4Hz,4H),7.03(s,1H),6.98(s,1H),6.82–6.75(m,5H),5. 02(s,2H),4.93(s,1H),4.87(s,4H),4.56(s,4H),4.05(s,2H),3.63(s,1H) ,2.89–2.76(m,3H),2.13(s,1H),1.62(s,6H),1.06(dd,J=6.7,3.3Hz,6H).
[0947] Example 150: 5-((S)-1-(4-(2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)-3-methylbutane-2-yl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0948]
[0949] The target compound was prepared using a method similar to that in Example 149. LC / MS (ESI+) calcd for C 43 H 46 N6O7([M+H)) + )m / e 759.3, found 759.3.
[0950] Example 151: 5-((1-(4-(2-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)propane-2-yl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0951]
[0952] The target compound was prepared using a method similar to that in Example 149. LC / MS (ESI+) calcd for C 41 H 42 N6O7([M+H)) + )m / e 731.3, found 731.3. 1 H NMR(400MHz,Chloroform-d)δ8.31(d,J=4.7Hz,1H),8.11(d,J=14.2Hz,1H),7.62(d,J= 8.3Hz,1H),7.13(d,J=8.5Hz,4H),7.02(d,J=2.1Hz,1H),6.91(s,1H),6.80(t,J=8.9Hz, 5H),4.99(s,2H),4.96–4.91(m,1H),4.86(s,4H),4.45(s,4H),4.02(s,2H),3.97(d,J=5 .3Hz,1H),2.94–2.66(m,4H),2.12(d,J=5.3Hz,1H),1.63(s,6H),1.41(d,J=6.0Hz,3H).
[0953] Example 152: 5-((1R)-2-(4-(2-(2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclohexyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[0954]
[0955] The target compound was prepared using a method similar to that in Example 149. LC / MS (ESI+) calcd for C44 H 46 N6O7([M+H)) + )m / e 771.3, found 771.3.
[0956] Example 153: 5-(((1s, 4s)-4-(4-(2-(4-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenoxy)cyclohexyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[0957]
[0958] The target compound was prepared using a method similar to that in Example 149. LC / MS (ESI+) calcd for C 44 H 46 N6O7([M+H)) + )m / e 771.3, found 771.3. 1 H NMR(400MHz,Chloroform-d)δ8.31(d,J=5.0Hz,1H),8.08(s,1H),7.61(d,J=8.3Hz,1H),7.18–7 .09(m,4H),6.97(d,J=2.2Hz,1H),6.86–6.77(m,5H),6.74(dd,J=8.3,2.2Hz,1H),4.94(s,2H), 4.94–4.89(m,1H),4.86(s,4H),4.51(d,J=11.9Hz,2H),4.30(s,4H),3.50(s,1H),2.93–2.68(m ,3H),2.16–2.06(m,2H),2.01(d,J=5.5Hz,1H),1.89(s,2H),1.72(d,J=9.8Hz,4H),1.26(s,6H).
[0959] Example 154: 5-((1-(4-(2-(4-(4-((2-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-4-yl)methoxy)phenyl)propane-2-yl)phenyl)azacyclobutane-3-yl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0960]
[0961] The target compound was prepared using a method similar to that in Example 149. LC / MS (ESI+) calcd for C 41 H41 N7O6([M+H)) + )m / e 728.3, found728.3; 1 H NMR(400MHz,Chloroform-d)δ8.30(d,J=5.1Hz,1H),8.13(s,1H),7.65(d,J=8.2Hz,1H),7.17–7 .07(m,4H),6.92(d,J=2.1Hz,1H),6.86–6.79(m,3H),6.75(dd,J=8.3,2.2Hz,1H),6.46–6.38(m, 2H),5.02(d,J=6.5Hz,1H),4.94(s,2H),4.92(d,J=5.4Hz,1H),4.86(s,4H),4.45(q,J=5.7Hz,1 H),4.31(s,6H),3.68(dd,J=7.6,4.6Hz,2H),2.92–2.69(m,3H),2.15–2.08(m,1H),1.62(s,6H).
[0962] Example 155: 5-((1s, 3s)-3-(4-(2-(4-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxapyridin-3-yl)isoindoline-1,3-dione
[0963]
[0964] Step 1: Synthesis of 6-(2-chloropyrimidin-4-yl)-2-oxa-6-azaspirocyclic[3.3]heptane
[0965] 2,4-Dichloropyrimidine (1.19 g, 8.0 mmol) was dissolved in 20 mL, and 2-oxo-6-azaspiro[3.3]heptane hemioxalate (577 mg, 2.0 mmol) was added. N,N-diisopropylethylamine (1.03 g, 8.0 mmol) was added, and the mixture was reacted at room temperature for 3 hours. The solution was concentrated to dryness under reduced pressure, and purified by thin-layer chromatography to obtain 490 mg of 6-(2-chloropyrimidin-4-yl)-2-oxa-6-azaspiro[3.3]heptane. Yield: 58%. LC / MS (ESI+) calcd for C9H 10 ClN3O([M+H)) + )m / e 212.0, found212.0.
[0966] Step 2: Synthesis of ((1s,3s)-3-(4-(2-(4-((4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0967] Dissolve tert-butyl carbamate (90 mg, 0.23 mmol) in 5 mL of water. Anhydrous potassium carbonate (64 mg, 0.46 mmol) and 6-(2-chloropyrimidin-4-yl)-2-oxa-6-azaspirocyclic[3.3]heptane (72 mg, 0.34 mmol) were added to DMF and reacted overnight at 100 °C. After cooling to room temperature, 15 mL of ethyl acetate and 12 mL of water were added, stirred, and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 75 mg of the product ((1s, 3s)-3-(4-(2-(4-((4-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate, yield: 57%, LC / MS (ESI+) calcd for C 33 H 40 N4O5([M+H)) + )m / e 573.3, found 573.3.
[0968] Step 3: Synthesis of 5-((1s, 3s)-3-(4-(2-(4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxapyridin-3-yl)isoindoline-1,3-dione
[0969] Dissolve ((1s, 3s)-3-(4-(2-(4-((4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate (75 mg, 0.13 mmol) in 4 mL of dichloromethane. In an ice-water bath, add 1.5 mL of trifluoroacetic acid and keep the reaction at this temperature for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate aqueous solution. Extract with dichloromethane / methanol at a ratio of 10:1. Dry under anhydrous magnesium sulfate and concentrate under reduced pressure to dryness. Dissolved in 5 mL DMSO, 5 drops of N,N-diisopropylethylamine and 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (45 mg, 0.16 mmol) were added. The mixture was reacted overnight at 93 °C, cooled, extracted with dichloromethane / water, dried, concentrated, and purified by thin-layer chromatography to obtain 10 mg of the product 5-((1s,3s)-3-(4-(2-(4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione. Yield: 16%. LC / MS (ESI+) calcd for C 41 H 40 N6O7([M+H)) + )m / e 729.3, found 729.3; 1 H NMR(400MHz,Chloroform-d)δ8.12(s,1H),7.98(d,J=5.8Hz,1H),7.62(d,J=8.3Hz,1H),7.24–7.2 0(m,2H),7.18–7.14(m,2H),7.07–7.04(m,2H),6.92(d,J=2.2Hz,1H),6.74–6.70(m,3H),5.92(d, J=5.9Hz,1H),4.93(dd,J=12.2,5.3Hz,1H),4.85(s,4H),4.51(t,J=6.8Hz,1H),4.26(s,4H),3.77 (t,J=8.3Hz,1H),3.17–3.08(m,2H),2.95–2.68(m,4H),2.17–2.04(m,3H),1.66(d,J=2.8Hz,6H).
[0970] Example 156: 5-((1r, 3r)-3-(4-(2-(4-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxapyridin-3-yl)isoindoline-1,3-dione
[0971]
[0972] The target compound was prepared using a method similar to that in Example 155. LC / MS (ESI+) calcd for C 41 H 40 N6O7([M+H)) + )m / e 729.3, found 729.3.
[0973] Example 157: 2-(2,6-dioxadiazin-3-yl)-5-((1s,3s)-3-(4-(4-((5-fluoro-4-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0974]
[0975] The target compound was prepared using a method similar to that in Example 155. LC / MS (ESI+) calcd for C 41 H 39 FN6O7([M+H)) + )m / e 747.3, found 747.3. 1 H NMR(400MHz,Chloroform-d)δ8.06(s,1H),7.76(d,J=3.6Hz,1H),7.62(d,J=8.3Hz,1H),7.24 –7.19(m,2H),7.19–7.13(m,2H),7.06–7.01(m,2H),6.92(d,J=2.2Hz,1H),6.72(dd,J=9.0,2 .5Hz,3H),4.93(dd,J=12.1,5.2Hz,1H),4.85(s,4H),4.77(s,1H),4.51(t,J=6.8Hz,1H),4.4 3(s,4H),3.77(s,1H),3.18–3.07(m,2H),2.93–2.66(m,3H),2.16–2.03(m,3H),1.66(s,6H).
[0976] Example 158: 2-(2,6-dioxadiazin-3-yl)-5-((1s,3s)-3-(4-(4-((5-fluoro-2-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrimidin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0977]
[0978] The target compound was prepared using a method similar to that in Example 155. LC / MS (ESI+) calcd for C 41 H 39 FN6O7([M+H)) + )m / e 747.3, found 747.3. 1 H NMR(400MHz,Chloroform-d)δ8.12–8.04(m,2H),7.62(d,J=8.2Hz,1H),7.24(s,2H),7. 18–7.11(m,2H),7.08(t,J=6.5Hz,2H),6.92(d,J=2.1Hz,1H),6.77–6.69(m,3H),4.93(d d,J=12.0,5.3Hz,1H),4.79(s,4H),4.54(q,J=7.0Hz,1H),4.12(s,4H),3.79(d,J=9.4H z,2H),3.19–3.08(m,2H),2.93–2.71(m,3H),2.11(dd,J=10.4,4.7Hz,3H),1.69(s,6H).
[0979] Example 159: 5-((1s, 3s)-3-(4-(2-(4-((6-(2-oxo-6-azaspirocyclic[3.3]heptane-6-yl)pyrazin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[0980]
[0981] The target compound was prepared using a method similar to that in Example 155. LC / MS (ESI+) calcd for C 41 H 40 N6O7([M+H)) + )m / e729.3, found 729.3. 1H NMR(400MHz,Chloroform-d)δ8.07(s,1H),7.62(d,J=8.2Hz,1H),7.46(d,J=2.1Hz,2H),7.25–7 .20(m,2H),7.17–7.12(m,2H),7.05–6.99(m,2H),6.92(d,J=2.1Hz,1H),6.76–6.70(m,3H),4.9 3(dd,J=12.1,5.2Hz,1H),4.84(s,4H),4.77(d,J=6.0Hz,1H),4.53(t,J=6.8Hz,1H),4.19(s,4H ),3.78(d,J=6.8Hz,1H),3.18–3.09(m,2H),2.93–2.70(m,3H),2.16–2.04(m,3H),1.67(s,6H).
[0982] Example 160: 5-((1r, 3r)-3-(4-(2-(4-(2-oxa-6-azaspirocyclic[3.3]heptane-6-yl)-1,3,5-triazin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0983]
[0984] The target compound was prepared using a method similar to that in Example 155. LC / MS (ESI+) calcd for C 40 H 39 N7O7([M+H)) + )m / e 730.3, found 730.3. 1 H NMR(400MHz,Chloroform-d)δ8.35(s,1H),8.07(s,1H),7.63(d,J=8.3Hz,1H),7.26–7.23(m,2H),7 .18–7.13(m,2H),7.07–7.02(m,2H),6.89(d,J=2.1Hz,1H),6.73–6.67(m,3H),4.96–4.90(m,1H),4 .89–4.86(m,1H),4.85(d,J=2.5Hz,5H),4.33(d,J=21.5Hz,4H),4.22(d,J=6.9Hz,1H),2.92–2.74( m,3H),2.70(dd,J=13.2,5.9Hz,2H),2.40(dt,J=13.6,6.3Hz,2H),2.16–2.08(m,1H),1.67(s,6H).
[0985] Example 161: 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(2-(4-(2-hydroxypropane-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0986]
[0987] Step 1: Synthesis of methyl 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-4-carboxylic acid
[0988] 200 mg (0.5 mmol) of tert-butyl carbamate ((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propyl-2-phenoxy)cyclobutyl)carbamate was dissolved in 5 mL of DMF. Anhydrous potassium carbonate (138 mg, 1.0 mmol) was added, followed by stirring. Methyl 2-chloropyrimidine-4-carboxylic acid (86 mg, 0.5 mmol) was added, and the mixture was reacted overnight at room temperature. 15 mL of ethyl acetate and 12 mL of water were added, and the mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 190 mg of methyl 2-(4-(2-(4-((1r,3r)-3-((tert-butyloxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-4-carboxylic acid, yield: 71%. LC / MS (ESI+) calcd for C 30 H 35 N3O6([M+H)) + )m / e 534.2, found 534.2.
[0989] Step 2: Synthesis of ((1r,3r)-3-(4-(2-(4-((4-(2-hydroxypropan-2-yl)pyrimidin-2-yl)oxy)phenyl)propan-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[0990] Methyl 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-4-carboxylic acid ester (190 mg, 0.35 mmol) was dissolved in 5 mL of anhydrous tetrahydrofuran under argon protection and cooled in an ice-water bath. 0.6 mL of the solution was then added dropwise. After adding 3NMeMgBr solution dropwise, the mixture was kept at this temperature for 1.5 hours. The reaction was quenched with saturated ammonium chloride aqueous solution. 15 mL of dichloromethane and 10 mL of water were added, and the mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of dichloromethane. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 60 mg of tert-butyl carbamate ((1r,3r)-3-(4-(2-(4-((4-(2-hydroxypropane-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate, yield: 32%). LC / MS (ESI+) calcd for C 31 H 39 N3O5([M+H)) + )m / e 534.2, found 534.2.
[0991] Step 3: Synthesis of 2-(2,6-dioxopiridine-3-yl)-5-((1r,3r)-3-(4-(2-(4-(2-hydroxypropan-2-yl)pyrimidin-2-yl)oxy)phenyl)propan-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0992] Dissolve tert-butyl carbamate (60 mg, 0.11 mmol) in 4 mL of dichloromethane in an ice-water bath, add 1.5 mL of trifluoroacetic acid, and incubate for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate aqueous solution, extract with dichloromethane / methanol at a ratio of 10:1, dry with anhydrous magnesium sulfate, and concentrate under reduced pressure to dryness. Dissolve in 5 mL DMSO, add 5 drops of N,N-diisopropylethylamine, 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (45 mg, 0.16 mmol), react overnight at 93 °C, cool, extract with dichloromethane / water, dry, concentrate, and purify by thin-layer chromatography to obtain 12 mg of the product 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(2-(4-(2-hydroxypropane-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione, yield: 16%, LC / MS (ESI+) calcd for C 39 H 39N5O7([M+H)) + )m / e 690.2, found 690.2; 1 H NMR(400MHz,Chloroform-d)δ8.51(d,J=5.1Hz,1H),8.06(s,1H),7.63(d,J=8.3Hz,1H),7.28(d,J =2.2Hz,1H),7.25(d,J=3.1Hz,1H),7.17(d,J=8.8Hz,2H),7.14–7.06(m,3H),6.90(d,J=2.1Hz,1H) ,6.71(dd,J=9.5,2.4Hz,3H),4.93(dd,J=12.2,5.2Hz,1H),4.88(d,J=11.1Hz,1H),4.27–4.19(m, 1H),2.94–2.65(m,6H),2.41(dt,J=12.9,6.1Hz,2H),2.15–2.08(m,1H),1.68(s,6H),1.53(s,6H).
[0993] Example 162: 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(2-(4-((6-(2-hydroxypropane-2-yl)pyrazin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[0994]
[0995] The target compound was prepared using a method similar to that in Example 161. LC / MS (ESI+) calcd for C 39 H 39 N5O7([M+H)) + )m / e 690.2, found 690.2. 1H NMR(400MHz,Chloroform-d)δ8.42(s,1H),8.24(s,1H),8.04(s,1H),7.64(d,J=8.3Hz,1H),7.27(s,1 H),7.25(d,J=3.1Hz,1H),7.18–7.11(m,2H),7.07–7.02(m,2H),6.90(d,J=2.1Hz,1H),6.75–6.68(m, 3H),4.93(dd,J=12.2,5.3Hz,1H),4.90–4.83(m,1H),4.77(s,1H),4.23(d,J=4.6Hz,1H),2.94–2.74( m,3H),2.74–2.66(m,2H),2.41(dt,J=12.9,6.0Hz,2H),2.16–2.09(m,1H),1.68(s,6H),1.54(s,6H).
[0996] Example 163: 5-((1r, 3r)-3-(4-(2-(2-(4-((1H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[0997]
[0998] Step 1: Synthesis of ((1r,3r)-3-(4-(2-(4-(((2-bromopyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate tert-butyl
[0999] Dissolve tert-butyl carbamate (200 mg, 0.5 mmol) in 5 mL of water. DMF was added, along with anhydrous cesium carbonate (325 mg, 1.0 mmol), and 4-fluoro-2-bromopyridine (106 mg, 0.6 mmol) was added with stirring. The mixture was reacted at 80 °C for 4 hours, cooled to room temperature, and then 15 mL of ethyl acetate and 12 mL of water were added. The mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 240 mg of tert-butyl carbamate ((1r, 3r)-3-(4-(2-(4-((2-bromopyridine-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate, yield: 87%. LC / MS (ESI+) calcd for C 29 H 33 BrN2O4([M+H]+ )m / e 553.1, found 553.1.
[1000] Step 2: Synthesize tert-butyl cyclobutylcarbamate and tert-butyl cyclobutylcarbamate.
[1001]
[1002] Pd2(dba)3 (19 mg, 0.02 mmol) and the ligand (26 mg, 0.055 mmol) were added to a single-necked round-bottom flask, followed by 1 mL of toluene. The mixture was stirred at 120 °C for 3 minutes under argon protection to prepare a pre-catalyst, which was then cooled to room temperature. Tert-butyl carbamate (125 mg, 0.22 mmol) was dissolved in 3 mL of toluene, and anhydrous potassium phosphate and 2H triazole were added. The mixture was then reacted at 120 °C overnight under argon protection, followed by argon protection. The mixture was cooled to room temperature, and 15 mL of ethyl acetate and 12 mL of water were added. The mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The combined organic layers were washed with water and saturated brine, respectively, and dried over anhydrous sodium sulfate. The solution was concentrated to dryness under pressure, and then purified by thin-layer chromatography to obtain 65 mg of ((1r,3r)-3-(4-(2-(4-(2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutylcarbamate tert-butyl ester and 45 mg of ((1r,3r)-3-(4-(2-(4-(2-(1H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutylcarbamate tert-butyl ester. The overall yield was 90%. LC / MS (ESI+) calcd for C 31 H 35 N5O4([M+H)) + )m / e 542.2, found542.2.
[1003] Step 3: Synthesis of 5-(((1r,3r)-3-(4-(2-(4-((2-(1H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxoperidin-3-yl)isoindoline-1,3-dione
[1004]
[1005] ((1r,3r)-3-(4-(2-(4-(2-(1H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutylcarbamate tert-butyl ester (45 mg, 0.083 mmol) was dissolved in 4 mL of dichloromethane. The mixture was placed in an ice-water bath, and 1.5 mL of trifluoroacetic acid was added. The reaction was maintained at this temperature for 1 hour. The pH was adjusted to alkaline with saturated sodium carbonate aqueous solution. The mixture was extracted with dichloromethane / methanol at a ratio of 10:1, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to dryness. Dissolve in 5 mL DMSO, add 5 drops of N,N-diisopropylethylamine, 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (30 mg, 0.11 mmol), react overnight at 93 °C, cool, extract with dichloromethane / water, dry, concentrate, and purify by thin-layer chromatography to obtain 20 mg of the product 5-(((1r,3r)-3-(4-(2-(4-((2-(1H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione, yield: 17%, LC / MS (ESI+) calcd for C 39 H 35 N7O6([M+H)) + )m / e 698.2, 1 H NMR(400MHz,Chloroform-d)δ8.58(s,1H),8.34(d,J=5.7Hz,1H),8.04(s,1H),7.81(s,1H),7.69 (d,J=2.3Hz,1H),7.64(d,J=8.0Hz,1H),7.30(d,J=8.6Hz,2H),7.17(d,J=8.5Hz,2H),7.06–7.00 (m,2H),6.93(dd,J=5.8,2.3Hz,1H),6.91(s,1H),6.73(t,J=8.1Hz,3H),4.93(dd,J=12.2,5.2Hz ,1H),4.88(s,1H),4.24(s,1H),2.94–2.66(m,5H),2.42(s,2H),2.17–2.08(m,1H),1.70(s,6H).
[1006] Example 164: 5-(((1r, 3r)-3-(4-(2-(4-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindoline-1,3-dione
[1007]
[1008] Dissolve tert-butyl cyclobutylcarbamate (65 mg, 0.12 mmol) in 4 mL of dichloromethane in an ice-water bath, add 1.5 mL of trifluoroacetic acid, and incubate for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate aqueous solution, extract with dichloromethane / methanol at a ratio of 10:1, dry with anhydrous magnesium sulfate, and concentrate under reduced pressure to dryness. Dissolve in 5 mL DMSO, add 5 drops of N,N-diisopropylethylamine, 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (40 mg, 0.14 mmol), react overnight at 93 °C, cool, extract with dichloromethane / water, dry, concentrate, and purify by thin-layer chromatography to obtain 20 mg of the product 5-(((1r,3r)-3-(4-(2-(4-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione, yield: 24%, LC / MS (ESI+) calcd for C 39 H 35 N7O6([M+H)) + )m / e 698.2, 1 H NMR(400MHz,Chloroform-d)δ8.43(d,J=5.7Hz,1H),8.06(s,1H),7.88(d,J=1.3Hz,2H),7. 66–7.59(m,2H),7.30(d,J=8.2Hz,2H),7.17(d,J=8.5Hz,2H),7.04(d,J=8.3Hz,2H),6.90( d,J=1.8Hz,1H),6.88–6.83(m,1H),6.77–6.67(m,3H),4.95–4.91(m,1H),4.88(s,1H),4.2 5(s,1H),2.94–2.65(m,5H),2.48–2.36(m,2H),2.12(dd,J=14.2,6.7Hz,1H),1.70(s,6H).
[1009] Example 165: 5-(((1r, 3r)-3-(4-(2-((4-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindole-1,3-dione
[1010]
[1011] The target compound was prepared using a method similar to that in Example 164. LC / MS (ESI+) calcd for C 39 H 35 N7O6([M+H)) + )m / e 698.2, found 698.2. 1 H NMR(400MHz,Chloroform-d)δ8.92(d,J=2.7Hz,1H),8.35(dd,J=8.9,2.8Hz,1H),8.07(s,1H),7.83(s,2H),7.62(d ,J=8.3Hz,1H),7.28(d,J=2.1Hz,1H),7.26(s,1H),7.20–7.15(m,2H),7.09–7.04(m,2H),7.01(d,J=8.9Hz,1H),6. 89(d,J=2.1Hz,1H),6.71(dq,J=10.4,2.7,2.2Hz,3H),4.93(dd,J=12.1,5.2Hz,1H),4.90–4.83(m,1H),4.22(td,J =7.7,3.8Hz,1H),2.98–2.57(m,6H),2.40(dt,J=12.8,6.3Hz,2H),2.12(ddd,J=10.4,5.0,2.7Hz,1H),1.68(s,6H).
[1012] Example 166: 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(2-(4-(4-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1013]
[1014] Step 1: Synthesis of tert-butyl carbamate ((1r,3r)-3-(4-(2-(4-((4-cyanopyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate
[1015] Dissolve tert-butyl carbamate (320 mg, 0.8 mmol) in 5 mL of water. DMF was added to anhydrous potassium carbonate (221 mg, 1.6 mmol), followed by the addition of 2-fluoro-4-cyanopyrimidine (140 mg, 1.0 mmol) under stirring. The mixture was reacted at 66 °C for 5 hours, cooled to room temperature, and then 15 mL of ethyl acetate and 12 mL of water were added. The mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 390 mg of tert-butyl carbamate ((1r, 3r)-3-(4-(2-(4-((4-cyanopyrimidine-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate, yield: 97%. LC / MS (ESI+) calcd for C 29 H 32 N4O4([M+H)) + )m / e 501.2, found 501.2.
[1016] Step 2: Synthesis of ((1r,3r)-3-(4-(2-(4-((4-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[1017] Dissolve tert-butyl carbamate (390 mg, 0.78 mmol) in 5 mL of ethanol, add 50% aqueous hydroxylamine (106 mg, 1.6 mmol), reflux for 1 hour, cool to room temperature, filter, wash the filter cake with a small amount of ethyl acetate, and dry to obtain a white solid product. Dissolved in 3 mL pyridine, cooled in an ice-water bath, acetyl chloride (173 mg, 2.2 mmol) was added dropwise. After the addition was complete, the mixture was stirred for 10 minutes, the ice-water bath was removed, and the mixture was heated to 105 °C and reacted overnight. The mixture was concentrated to dryness under reduced pressure, and purified by thin-layer chromatography to obtain 235 mg of the product ((1r,3r)-3-(4-(2-(4-((4-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate, yield: 54%, LC / MS (ESI+) calcd for C 31 H 35 N5O5([M+H)) + )m / e 558.2, found 558.2.
[1018] Step 3: Synthesis of 2-(2,6-dioxopiridine-3-yl)-5-((1r,3r)-3-(4-(2-(4-(4-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1019] Dissolve tert-butyl carbamate (230 mg, 0.42 mmol) in 4 mL of dichloromethane in an ice-water bath, add 1.5 mL of trifluoroacetic acid, and incubate for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate solution, extract with dichloromethane / methanol at a ratio of 10:1, dry with anhydrous magnesium sulfate, and concentrate under reduced pressure to dryness. Dissolve in 5 mL DMSO, add 8 drops of N,N-diisopropylethylamine, 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (152 mg, 0.55 mmol), react overnight at 93 °C, cool, extract with dichloromethane / water, dry, concentrate, and purify by thin-layer chromatography to obtain 60 mg of the product 2-(2,6-dioxadiazin-3-yl)-5-((1r,3r)-3-(4-(2-(4-(4-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione, yield: 20%, LC / MS (ESI+) calcd for C 39 H 35 N7O7([M+H)) + )m / e 714.2, found 714.2; 1 H NMR(400MHz,Chloroform-d)δ8.69(d,J=4.8Hz,1H),8.01(s,1H),7.74(d,J=4.7Hz,1H ),7.63(d,J=8.0Hz,1H),7.28(d,J=8.4Hz,2H),7.16(dd,J=16.4,8.4Hz,4H),6.90(s, 1H),6.71(d,J=8.2Hz,3H),4.93(dd,J=12.0,5.2Hz,1H),4.87(s,1H),4.24(s,1H),2. 93–2.72(m,5H),2.72(s,3H),2.41(d,J=10.1Hz,2H),2.16–2.08(m,1H),1.69(s,6H).
[1020] Example 167: 2-(2,6-dioxopyridin-3-yl)-5-(((1r,3r)-3-(4-(2-((4-(2-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1021]
[1022] The target compound was prepared using a method similar to that in Example 166. LC / MS (ESI+) calcd for C 40 H 35 N6O7([M+H)) + )m / e 713.2, found 713.2. 1 H NMR(400MHz,Chloroform-d)δ8.62(d,J=5.2Hz,1H),8.14(s,1H),7.68(d,J=2.0Hz,1H),7.62(d,J=8.2 Hz,1H),7.29(d,J=8.5Hz,2H),7.17(d,J=8.4Hz,2H),7.01(d,J=8.4Hz,2H),6.95(d,J=4.9Hz,1H),6.88 (d,J=2.0Hz,1H),6.71(dd,J=11.6,7.5Hz,3H),4.93(dd,J=12.2,5.3Hz,1H),4.88(s,1H),4.22(d,J=4. 9Hz,1H),2.95–2.69(m,5H),2.68(s,3H),2.41(dt,J=12.8,6.0Hz,2H),2.17–2.08(m,1H),1.69(s,6H).
[1023] Example 168: 5-(((1r, 3r)-3-(4-(2-(4-((4-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[1024]
[1025] The target compound was prepared using a method similar to that in Example 164. LC / MS (ESI+) calcd for C 39 H 35 N7O6([M+H)) + )m / e 698.2, found 698.2. 1H NMR(400MHz,Chloroform-d)δ8.31(d,J=5.6Hz,1H),7.99(s,1H),7.89(s,2H),7.78–7.72(m,1H),7.63( d,J=8.3Hz,1H),7.59(d,J=1.7Hz,1H),7.29(s,1H),7.18(d,J=8.7Hz,2H),7.08(d,J=8.5Hz,2H),6.90(d ,J=2.1Hz,1H),6.71(dd,J=8.6,2.0Hz,3H),4.93(dd,J=12.1,5.2Hz,1H),4.87(s,1H),4.23(d,J=4.8Hz, 1H),2.93–2.78(m,2H),2.78–2.65(m,3H),2.41(dt,J=12.9,6.2Hz,2H),2.15–2.09(m,1H),1.69(s,6H).
[1026] Example 169: 5-(((1r, 3r)-3-(4-(2-(4-((4-(1H-1,2,3-triazol-1-yl)pyridin-2-yl)oxy)phenyl)propane-2-ylphenoxy)cyclobutyl)amino)-2-(2,6-dioxopyridin-3-yl)isoindoline-1,3-dione
[1027]
[1028] The target compound was prepared using a method similar to that in Example 163. LC / MS (ESI+) calcd for C 39 H 35 N7O6([M+H)) + )m / e 698.2, found 698.2. 1H NMR(400MHz,Chloroform-d)δ8.34(d,J=5.2Hz,1H),8.09(s,1H),8.01(s,1H),7.89(s,1H),7.63(d,J=8.3H z,1H),7.44(d,J=5.1Hz,1H),7.34(s,1H),7.28(d,J=8.6Hz,2H),7.18(d,J=8.7Hz,2H),7.08(d,J=8.4Hz,2 H),6.90(d,J=2.0Hz,1H),6.72(d,J=8.6Hz,3H),4.93(dd,J=12.1,5.2Hz,1H),4.88(s,1H),4.23(d,J=5.2H z,1H),2.94–2.74(m,3H),2.74–2.66(m,2H),2.41(dt,J=12.6,6.1Hz,2H),2.16–2.08(m,1H),1.69(s,6H).
[1029] Example 170: 5-(((1r, 3r)-3-(4-(2-(4-((4-(2H-1,2,3-triazol-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxanidin-3-yl)isoindole-1,3-dione
[1030]
[1031] The target compound was prepared using a method similar to that in Example 164. LC / MS (ESI+) calcd for C 38 H 34 N8O6([M+H)) + )m / e 699.2, found 699.2. 1 H NMR(400MHz,Chloroform-d)δ8.62(d,J=5.4Hz,1H),8.06(s,1H),7.97(s,2H),7.74(d,J =5.5Hz,1H),7.63(d,J=8.3Hz,1H),7.31–7.27(m,2H),7.21–7.11(m,4H),6.90(d,J=2.1H z,1H),6.75–6.68(m,3H),4.93(dd,J=12.2,5.2Hz,1H),4.87(d,J=5.1Hz,1H),4.27–4.19 (m,1H),2.93–2.67(m,5H),2.41(dt,J=12.8,6.0Hz,2H),2.16–2.08(m,1H),1.69(s,6H).
[1032] Example 171: 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(2-(4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1033]
[1034] Step 1: Synthesis of 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-4-carboxylic acid
[1035] 300 mg (0.75 mmol) of tert-butyl ((1r,3r)-3-(4-(2-(4-hydroxyphenyl)propyl-2-phenoxy)cyclobutyl)carbamate was dissolved in 5 mL of DMF. Anhydrous cesium carbonate (500 mg, 1.5 mmol) was added, followed by stirring. Methyl 2-chloropyrimidine-4-carboxylic acid (130 mg, 0.75 mmol) was added, and the mixture was reacted overnight at 85 °C. After cooling to room temperature, the pH was adjusted to 5.0 with citric acid aqueous solution. 15 mL of ethyl acetate was added, and the mixture was stirred and extracted. The aqueous layer was back-extracted once with 10 mL of ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 350 mg of the product 2-(4-(2-(4-((1r,3r)-3-((tert-butyloxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-4-carboxylic acid, yield: 90%.
[1036] Step 2: Synthesis of ((1r,3r)-3-(4-(2-(4-((4-(5-methyl-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)tert-butyl carbamate
[1037] 2-(4-(2-(4-((1r,3r)-3-((tert-butoxycarbonyl)amino)cyclobutoxy)phenyl)propane-2-yl)phenoxy)pyrimidine-4-carboxylic acid (350 mg, 0.61 mmol) was dissolved in 10 mL of dichloromethane, and N,N-diisopropylethylamine (142 mg, 1.1 mmol) was added. Under an ice-water bath, HOBT (119 mg, 0.88 mmol) was added, and the mixture was stirred for 5 minutes. Acetylhydrazine (65 mg, 0.88 mmol) and EDCI (210 mg, 1.1 mmol) were added, and the mixture was reacted overnight at room temperature. The product was washed with water, dried over anhydrous magnesium sulfate, concentrated to dryness, and purified by thin-layer chromatography to obtain the product. Dissolved in 10 mL dichloromethane, triethylamine (122 mg, 1.22 mmol) and p-toluenesulfonyl chloride (139 mg, 0.73 mmol) were added. The mixture was reacted overnight at room temperature, washed with water, and purified by thin-layer chromatography to obtain 200 mg of the product ((1r, 3r)-3-(4-(2-(4-((4-(5-methyl-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)carbamate, yield: 59%. LC / MS (ESI+) calcd for C 31 H 35 N5O5([M+H)) + )m / e 558.2, found 558.2.
[1038] Step 3: Synthesis of 2-(2,6-dioxopiridine-3-yl)-5-(((1r,3r)-3-(4-(2-(4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1039] Dissolve tert-butyl carbamate (200 mg, 0.37 mmol) in 4 mL of dichloromethane in an ice-water bath, add 1.5 mL of trifluoroacetic acid, and incubate for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate solution, extract with dichloromethane / methanol at a ratio of 10:1, dry with anhydrous magnesium sulfate, and concentrate under reduced pressure to dryness. Dissolved in 5 mL DMSO, 10 drops of N,N-diisopropylethylamine and 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (111 mg, 0.40 mmol) were added. The mixture was reacted overnight at 93 °C, cooled, extracted with dichloromethane / water, dried, concentrated, and purified by thin-layer chromatography to obtain 50 mg of the product 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(2-(4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione. Yield: 19%. LC / MS (ESI+) calcd for C 39 H 35 N7O7([M+H)) + )m / e714.2, 1 H NMR(400MHz,Chloroform-d)δ8.71(d,J=5.0Hz,1H),8.21(s,1H),7.87(d,J=5.0Hz,1H),7.62(d ,J=8.3Hz,1H),7.34–7.27(m,2H),7.22–7.16(m,2H),7.16–7.10(m,2H),6.89(d,J=2.1Hz,1H),6 .77–6.66(m,3H),4.93(dd,J=12.1,5.3Hz,1H),4.87(dt,J=6.8,2.9Hz,1H),4.23(d,J=9.4Hz,1H ),2.93–2.69(m,5H),2.68(s,3H),2.41(dt,J=12.6,6.2Hz,2H),2.16–2.08(m,1H),1.69(s,6H).
[1040] Example 172: 2-(2,6-dioxopyridin-3-yl)-5-(((1r,3r)-3-(4-(2-(4-((2-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1041]
[1042] The target compound was prepared using a method similar to that in Example 171. LC / MS (ESI+) calcd for C 40 H 36 N6O7([M+H)) + )m / e 713.2, found 713.2. 1 H NMR(400MHz,Chloroform-d)δ8.60(s,1H),8.05(s,1H),7.76(s,1H),7.64(d,J=8 .1Hz,1H),7.30(d,J=8.1Hz,2H),7.17(d,J=8.4Hz,2H),7.01(d,J=8.0Hz,3H),6.9 0(s,1H),6.73(t,J=7.9Hz,3H),4.93(dd,J=12.2,5.2Hz,1H),4.89(s,1H),4.24( s,1H),2.94–2.68(m,6H),2.66(s,3H),2.42(s,2H),2.12(dd,J=13.8,6.6Hz,1H).
[1043] Example 173: 2-(2,6-dioxadiazin-3-yl)-5-(((1s,3s)-3-(4-(2-(4-((4-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1044]
[1045] The target compound was prepared using a method similar to that in Example 171. LC / MS (ESI+) calcd for C 39 H 35 N7O7([M+H)) + )m / e 714.2, found 714.2. 1H NMR(400MHz,Chloroform-d)δ8.69(d,J=4.9Hz,1H),8.08(s,1H),7.74(d,J=5.0Hz,1H),7. 62(d,J=8.3Hz,1H),7.31–7.27(m,2H),7.21–7.10(m,4H),6.92(d,J=2.1Hz,1H),6.78–6.6 9(m,3H),5.30(s,1H),4.93(dd,J=12.1,5.2Hz,1H),4.52(p,J=6.9Hz,1H),3.78(p,J=7.6H z,1H),3.19–3.08(m,2H),2.94–2.73(m,3H),2.72(s,3H),2.17–2.04(m,3H),1.68(s,6H).
[1046] Example 174: 2-(2,6-dioxopyridin-3-yl)-5-(((1s,3s)-3-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-4-yl)oxy)phenyl)propane-2-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1047]
[1048] The target compound was prepared using a method similar to that in Example 171. LC / MS (ESI+) calcd for C 40 H 36 N6O7([M+H)) + )m / e 713.2, found 713.2. 1H NMR (400MHz, Chloroform-d) δ8.61(d,J=5.6Hz,1H),8.16(s,1H),7.67(d,J=2.5Hz,1H),7.62(d,J=8.3Hz,1H),7. 28(d,J=8.8Hz,2H),7.20–7.13(m,2H),7.03–6.98(m,2H),6.94(dd,J=5.7,2.5Hz,1H),6.91(d,J=2.1Hz,1H),6.7 8–6.74(m,2H),6.72(dd,J=8.3,2.2Hz,1H),4.93(dd,J=12.2,5.3Hz,1H),4.80(s,1H),4.53(p,J=6.8Hz,1H),3.8 2–3.72(m,1H),3.18–3.08(m,2H),2.91–2.72(m,3H),2.68(s,3H),2.12(ddt,J=9.1,6.7,3.2Hz,3H),1.69(s,6H).
[1049] Example 175: 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(3-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1050]
[1051] Step 1: Synthesis of ((1r,3r)-3-(4-(3-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)carbamate tert-butyl
[1052] Dissolve tert-butyl carbamate (320 mg, 0.59 mmol) in 5 mL of anhydrous methanol in an ice-water bath. Add sodium borohydride (45 mg, 1.2 mmol) and incubate for 20 min. Add 25 mL of ethyl acetate and 20 mL of water, stir, extract, and reuse the aqueous phase for 2 minutes. Back-extraction with 0 mL ethyl acetate was performed once, the organic layers were combined, washed with 10 mL saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography to obtain 220 mg of the product ((1r,3r)-3-(4-(3-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)carbamate, yield: 68%, LC / MS (ESI+) calcd for C 32H 41 N3O5([M+H)) + )m / e 548.3, found 548.3.
[1053] Step 2: Synthesis of 2-(2,6-dioxopiridine-3-yl)-5-(((1r,3r)-3-(4-(3-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1054] Dissolve tert-butyl carbamate (220 mg, 0.40 mmol) in 4 mL of dichloromethane in an ice-water bath, add 1.5 mL of trifluoroacetic acid, and incubate for 1 hour. Adjust the pH to alkaline with saturated sodium carbonate aqueous solution, extract with dichloromethane / methanol at a ratio of 10:1, dry with anhydrous magnesium sulfate, and concentrate under reduced pressure to dryness. Dissolved in 5 mL DMSO, 15 drops of N,N-diisopropylethylamine and 2-(2,6-dioxadiazin-3-yl)-5-fluoroisoindoline-1,3-dione (170 mg, 0.6 mmol) were added. The mixture was reacted overnight at 94 °C, cooled, extracted with dichloromethane / water, dried, concentrated, and purified by thin-layer chromatography to obtain 120 mg of the product 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(3-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione. Yield: 42%. LC / MS (ESI+) calcd for C 40 H 41 N5O7([M+H)) + )m / e 704.3, found 704.3; 1H NMR(400MHz,Chloroform-d)δ8.12(s,1H),7.62(dd,J=8.3,4.1Hz,2H),7.26–7.17(m,3H),7.1 3–7.04(m,4H),6.89(d,J=2.1Hz,1H),6.74–6.65(m,3H),5.14(d,J=6.7Hz,1H),4.93(dd,J=12 .1,5.3Hz,1H),4.86(s,1H),4.20(d,J=12.6Hz,1H),2.93–2.74(m,3H),2.73–2.67(m,2H),2.4 1(dd,J=12.8,6.5Hz,2H),2.08(q,J=7.4Hz,6H),1.57(d,J=6.4Hz,3H),0.64(t,J=7.2Hz,6H).
[1055] Example 176: 5-(((1r, 3r)-3-(4-(3-(4-((6-acetyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[1056]
[1057] 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(3-(4-((6-(1-hydroxyethyl)pyridazin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione (55 mg, 0.078 mmol) was dissolved in 5 mL of anhydrous dichloromethane, and then Dysmartin reagent (40 mg, 0.094 mmol) was added. Stirred overnight at room temperature, filtered, concentrated the filtrate under reduced pressure to dryness, and purified by thin-layer chromatography to obtain 38 mg of the product 5-(((1r,3r)-3-(4-(3-(4-(((6-acetylpyridin-3-yl)oxy)phenyl)pentane-3-yl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione, yield: 69%. LC / MS (ESI+) calcd for C 40 H 39 N5O7([M+H)) + )m / e 702.3, 1H NMR(400MHz,Chloroform-d)δ8.15(d,J=9.1Hz,1H),8.12(s,1H),7.63(d,J=8.3Hz,1H),7.26–7.22 (m,3H),7.16–7.07(m,4H),6.90(d,J=1.9Hz,1H),6.71(td,J=5.7,2.9Hz,3H),4.93(dd,J=12.1,5.2 Hz,1H),4.88(d,J=4.2Hz,1H),4.29–4.20(m,1H),2.93–2.82(m,2H),2.81(s,3H),2.76(d,J=5.3Hz ,1H),2.74–2.67(m,2H),2.41(dt,J=12.8,6.3Hz,2H),2.09(q,J=7.5Hz,6H),0.65(t,J=7.2Hz,6H).
[1058] Example 177: 5-(((1r, 3r)-3-(4-(1-(4-(((5-acetylpyrazin-2-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)-2-(2,6-dioxadiazin-3-yl)isoindoline-1,3-dione
[1059]
[1060] The target compound was prepared using a method similar to that in Example 175. LC / MS (ESI+) calcd for C 40 H 37 N5O7([M+H)) + )m / e 700.3, found 700.3. 1H NMR(400MHz,Chloroform-d)δ8.78(d,J=1.3Hz,1H),8.36(d,J=1.4Hz,1H),8.11(s,1H),7.63(d,J=8.3Hz,1 H),7.36–7.29(m,2H),7.23–7.16(m,2H),7.08–7.01(m,2H),6.89(d,J=2.1Hz,1H),6.70(dd,J=8.6,2.3Hz,3 H),4.96–4.91(m,1H),4.87–4.84(m,1H),4.27–4.18(m,1H),2.93–2.74(m,3H),2.74–2.71(m,1H),2.69(d, J=4.3Hz,1H),2.67(s,3H),2.43–2.35(m,2H),2.27(t,J=10.0Hz,4H),2.16–2.08(m,1H),1.74–1.70(m,4H).
[1061] Example 178: 2-(2,6-dioxadiazin-3-yl)-5-(((1r,3r)-3-(4-(1-(4-((5-(1-hydroxyethyl)pyrazin-2-yl)oxy)phenyl)cyclopentyl)phenoxy)cyclobutyl)amino)isoindoline-1,3-dione
[1062]
[1063] The target compound was prepared using a method similar to that in Example 176. LC / MS (ESI+) calcd for C 40 H 39 N5O7([M+H)) + )m / e 702.3, found 702.3. 1H NMR(400MHz,Chloroform-d)δ8.29(s,1H),8.13(d,J=19.4Hz,2H),7.63(d,J=8.2Hz,1H),7.33–7.27(m,2H),7 .19(d,J=8.7Hz,2H),7.06–6.98(m,2H),6.89(d,J=2.0Hz,1H),6.69(dd,J=7.4,4.7Hz,3H),4.94(dq,J=11.3,5 .8,5.2Hz,2H),4.85(s,1H),4.22(s,1H),2.93–2.78(m,2H),2.76(d,J=4.9Hz,1H),2.70(dd,J=11.1,4.5Hz,2 H),2.38(dd,J=13.3,6.3Hz,2H),2.28(d,J=5.8Hz,4H),2.15–2.09(m,1H),1.72(s,4H),1.54(d,J=6.4Hz,3H).
[1064] Example 179: 2-(2,6-dioxadiazin-3-yl)-5-(1-(4-(2-(4-((2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl)oxy)phenyl)propane-2-yl)phenyl)-1,6-diazospiro[3.3]heptane-6-yl)isoindoline-1,3-dione
[1065]
[1066] The target compound was prepared using a method similar to that in Example 149. LC / MS (ESI+) calcd for C 40 H 36 N8O6([M+H)) + )m / e 725.3, found 725.3. 1H NMR(400MHz,Chloroform-d)δ8.59(s,2H),8.09(s,1H),7.69(d,J=8.2Hz,1H),7.32–7.27(m,2H), 7.14–7.05(m,2H),7.02–6.95(m,2H),6.84(d,J=2.1Hz,1H),6.59(dd,J=8.3,2.2Hz,1H),6.54–6. 46(m,2H),4.95(dd,J=12.2,5.3Hz,1H),4.70(d,J=9.4Hz,2H),4.08(d,J=9.4Hz,2H),3.80(t,J=6...
Claims
1. A compound of formula I, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof: Among them, TB is the target recognition / binding part, L is the linking part, and U is the ubiquitin protease recognition / binding part; the three parts are connected by chemical bonds; The TB part is a structure shown in formula II-A or II-B: TB part The part is selected from any of the following structures: in, A is none, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and 5-6 membered heteroaromatic ring; Among them, R 1 , R 2 are independently selected from the group consisting of: anhydrous, hydrogen, halogen, cyano, amino, hydroxy, C1-C6 alkoxy, C1-C6 alkylamino, C1-C6 alkylthiol, C1-C6 alkylsulfone, C1-C6 alkylsulfoxide, C1-C6 alkylcarbonyl, C1-C6 alkylaminocarbonyl, -NR 3 R 4 , -CR a R 3 R 4 、-NR 3 -CO-R 4 、-CO-NR 3 R 4 、-NR 3 -SO 2 -R 4 、-SO 2 -NR 3 R 4 、-CO-R 3 、-SO-R 3 、-SO 2 -R 3 , -CR 3 =CH 2 、-OR 3 、-SR 3 , substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclopropylamino, cyclobutylamino, 1-hydroxymethylcyclopropylamino, cyclopropanoyl, 1-hydroxycyclopropyl, azetidinyl acyl, tetrahydropyrrolyl acyl, azetidinyl, piperidine, morpholine, piperazine, N-methylpiperazine, N-ethylpiperazine, N-cyclopropylpiperazine, 2-methylpiperazine, 3-methylpiperazine, 2,2-dimethylpiperazine, 3,3-dimethylpiperazine, 2,3-dimethylpiperazine, N-methyl-1,2-oxadiazolyl, N 1 -1,2,3-triazolyl, N 2 -1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,2-oxazolyl, 1,3-oxazolyl, 1,2,3-oxadiazolyl, 1,3,5-oxadiazolyl, 1,2-thiooxazolyl, 1,3-thiooxazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,5-thiadiazolyl, N 2 -4-fluoro-1,2,3-triazolyl, N 2 -4-methyl-1,2,3-triazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyridinyl, 2-methyl-1,3,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, cyclopentyl butyryl, 1-methyl-1,2-oxadiazolyl, 1,2-oxadiazolyl, 1,3-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 3,5-dimethyl-1,2-oxadiazolyl, tetrahydropyrrolyl, 1,3,4-thiadiazolyl, 3-methyl-1,2,4-thiadiazolyl, hexahydropyridinyl, 1,3-thiazolyl, R 1 , R 2 Can be connected into a ring; Wherein, the substituted substituent is R a , R 3 , R 4 , the R a ,R 3 ,R 4 R is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 alkylamino, C1-C6 alkylsulfone, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclyl, substituted or unsubstituted phenylacyl, sulfonyl; a , R 3 , R 4 Any two of them can be linked to form a 3-8 membered ring; the substituted substituent is selected from halogen, amine, hydroxyl, and hydroxyl-substituted C1-6 alkyl; Among them, G 1 ,G 2 Each of them is independently connected to A through a chemical bond; 1 Select from none, -(CH 2 ) y -、-(CH 2 ) m -CR g1 R g2 -、-(CH 2 ) m -CO-,O,S,SO,SO 2 ,NR g1 ; G 2 Select from none, -(CH 2 ) n -CR g3 R g4 -、-(CH 2 ) n -O-,O,S,SO,SO 2 ,NR g2 ; Wherein y, m, n are integers from 0 to 3; R g1 , R g2 , R g3 , R g4 are independently selected from hydrogen, C1-C6 alkyl, halogen, hydroxyl; R g1 and R g2 , R g3 and R g4 Can be linked into a ring; when G1 and G2 are both absent, X is directly connected to A through a chemical bond; Wherein, X is selected from -N-, -NR 5 -, -O-, -S-, -CO-, -SO-, -SO 2 -、-CONR 5 -、-NR 5 CO-, -CH-, -CHR 5 -、-CR 5 R 5’ -; said R 5 ,R 5’ Each is independently selected from H, C1-C6 alkyl; Wherein, the above-mentioned U part is a structure shown in formula IU: In formula IU, The part is selected from any of the following structures: U 1 , U 2 , U 3 , U 4 All are CH; or some of them are N or CX 0 , the rest are CH, X 0 is a halogen; In formula IU, The structure of the part is as follows: R m is hydrogen or methyl; Wherein, the above L part is a structure shown in formula XA: Where n2 is 0 or 1; R y1 , R y2 R are independently selected from hydrogen or C1-C3 alkyl; w1 , R w2 are independently selected from hydrogen or halogen substituted or unsubstituted C1-C3 alkyl; or R y1 With R y2 connected to form a 3-4 membered saturated carbon ring; or R w1 With R w2 connected to form a 3-4 membered saturated carbon ring; or R y2 With R w2 Connect to form a 3-4 membered saturated carbon ring.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: R y1 , R y2 are independently selected from hydrogen or methyl; R w1 , R w2 are independently selected from hydrogen, methyl, chlorine-substituted or unsubstituted propyl; or R y1 With R y2 connected to form a 3-membered saturated carbon ring; or R w1 With R w2 connected to form a 3-4 membered saturated carbon ring; or R y2 With R w2 Connect to form a 4-membered saturated carbon ring.
3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The L part is any of the following structures:
4. A compound of formula I, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof: Among them, TB is the target recognition / binding part, L is the linking part, and U is the ubiquitin protease recognition / binding part; the three parts are connected by chemical bonds; The TB part is a structure shown in formula II-A or II-B: TB part The part is selected from any of the following structures: in, A is none, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and 5-6 membered heteroaromatic ring; Among them, R 1 , R 2 are independently selected from the group consisting of: anhydrous, hydrogen, halogen, cyano, amino, hydroxy, C1-C6 alkoxy, C1-C6 alkylamino, C1-C6 alkylthiol, C1-C6 alkylsulfone, C1-C6 alkylsulfoxide, C1-C6 alkylcarbonyl, C1-C6 alkylaminocarbonyl, -NR 3 R 4 , -CR a R 3 R 4 、-NR 3 -CO-R 4 、-CO-NR 3 R 4 、-NR 3 -SO 2 -R 4 、-SO 2 -NR 3 R 4 、-CO-R 3 、-SO-R 3 、-SO 2 -R 3 , -CR 3 =CH 2 、-OR 3 、-SR 3 , substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclopropylamino, cyclobutylamino, 1-hydroxymethylcyclopropylamino, cyclopropanoyl, 1-hydroxycyclopropyl, azetidinyl acyl, tetrahydropyrrolyl acyl, azetidinyl, piperidine, morpholine, piperazine, N-methylpiperazine, N-ethylpiperazine, N-cyclopropylpiperazine, 2-methylpiperazine, 3-methylpiperazine, 2,2-dimethylpiperazine, 3,3-dimethylpiperazine, 2,3-dimethylpiperazine, N-methyl-1,2-oxadiazolyl, N 1 -1,2,3-triazolyl, N 2 -1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,2-oxazolyl, 1,3-oxazolyl, 1,2,3-oxadiazolyl, 1,3,5-oxadiazolyl, 1,2-thiooxazolyl, 1,3-thiooxazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,5-thiadiazolyl, N 2 -4-fluoro-1,2,3-triazolyl, N 2 -4-methyl-1,2,3-triazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyridinyl, 2-methyl-1,3,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, cyclopentyl butyryl, 1-methyl-1,2-oxadiazolyl, 1,2-oxadiazolyl, 1,3-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 3,5-dimethyl-1,2-oxadiazolyl, tetrahydropyrrolyl, 1,3,4-thiadiazolyl, 3-methyl-1,2,4-thiadiazolyl, hexahydropyridinyl, 1,3-thiazolyl, R 1 , R 2 Can be connected into a ring; Wherein, the substituted substituent is R a , R 3 , R 4 , the R a ,R 3 ,R 4 R is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 alkylamino, C1-C6 alkylsulfone, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclyl, substituted or unsubstituted phenylacyl, sulfonyl; a , R 3 , R 4 Any two of them can be linked to form a 3-8 membered ring; the substituted substituent is selected from halogen, amine, hydroxyl, and hydroxyl-substituted C1-6 alkyl; Among them, G 1 ,G 2 Each of them is independently connected to A through a chemical bond; 1 Select from none, -(CH 2 ) y -、-(CH 2 ) m -CR g1 R g2 -、-(CH 2 ) m -CO-,O,S,SO,SO 2 ,NR g1 ; G 2 Select from none, -(CH 2 ) n -CR g3 R g4 -、-(CH 2 ) n -O-,O,S,SO,SO 2 ,NR g2 ; Wherein y, m, n are integers from 0 to 3; R g1 , R g2 , R g3 , R g4 are independently selected from hydrogen, C1-C6 alkyl, halogen, hydroxyl; R g1 and R g2 , R g3 and R g4 Can be linked into a ring; when G1 and G2 are both absent, X is directly connected to A through a chemical bond; Wherein, X is selected from -N-, -NR 5 -, -O-, -S-, -CO-, -SO-, -SO 2 -、-CONR 5 -、-NR 5 CO-, -CH-, -CHR 5 -、-CR 5 R 5’ -; said R 5 ,R 5’ Each is independently selected from H, C1-C6 alkyl; Wherein, the above-mentioned U part is a structure shown in formula IU: In formula IU, The part is selected from any of the following structures: U 1 , U 2 , U 3 , U 4 All are CH; or some of them are N or CX 0 , the rest are CH, X 0 is a halogen; In formula IU, The structure of the part is as follows: R m is hydrogen or methyl; Wherein, the above L part is selected from one of the following structures:
5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: A is a heteroaromatic ring, G 1 , G 2 is not nothing, and the TB portion of the compound has a structure as shown in Formula III-A: where k 1 , k 2 , k 3 , k 4 , k 5 are independently selected from CH or N, but not both CH.
6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: G 1 -CH 2 -, G 2 -CH 2 -or-CH 2 CH 2 -, the TB portion of the compound has a structure as shown in Formula IV-A or IV-B: where k 1 , k 2 , k 3 , k 4 are independently selected from CH or N, but not both CH.
7. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: A is a heteroaromatic ring, G 2 The compound TB has a structure as shown in Formula VA: Among them, G 1 Not for nothing; Or the compound TB part has a structure as shown in formula VB:
8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: A is a 6-membered heteroaromatic ring, G 2 The TB portion of the compound has a structure as shown in Formula VI-A: Among them, G 1 Not for nothing; 1 、z 2 、z 3 、z 4 、z 5 are independently selected from CH or N, and are not CH at the same time; Or, the compound TB has a structure as shown in Formula VI-B: Among them, z 1 、z 2 、z 3 、z 4 、z 5 are independently selected from CH or N, and are not CH at the same time.
9. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: A is a 5-membered heteroaromatic ring, G 2 For None: The TB portion of the compound has a structure as shown in Formula VII-A: Among them, G 1 Not for nothing; x 1 、x 2 、x 3 、x 4 are independently selected from CH, N, O or S, and are not CH at the same time; Or, the compound TB has a structure as shown in Formula VII-B: Among them, x 1 、x 2 、x 3 、x 4 are independently selected from CH, N, O or S, and are not CH at the same time.
10. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: A is a 5-membered heteroaromatic ring and a 6-membered heteroaromatic ring, G 2 The compound TB has a structure as shown in Formula VIII-A: Among them, p 1 、p 2 、p 3 、p 4 、p 5 、p 6 、p 7 、p 8 are independently selected from CH, N, O or S, and p 1 、p 2 、p 3 、p 4 At least one of them is not CH, p 2 、p 3 、p 5 、p 6 、p 7 、p 8 At least one of them is not CH.
11. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: A is none, G 1 , G 2 For none, R 1 is hydrogen, R 2 is nothing, X is -O-, and the TB portion of the compound has a structure as shown in Formula IX-A:
12. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The compound TB part of which The part has any of the following structures, where X, x 1 ,x 2 Each independently selected from -N-, -NR 5 -, -O-, -S-, -CO-, -SO-, -SO 2 -、-CONR 5 -、-NR 5 CO-, -CH-, -CHR 5 -、-CR 5 R 5’ -; said R 5 ,R 5’ Each independently selected from H, C1-C6 alkyl:
13. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The compound TB part of which The section has the following structure: or hydroxyl.
14. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: In the TB portion of the compound, R 1 ,R 2 Each is independently selected from hydrogen, trifluoromethyl or any of the following structures: Wherein, q, r, s, and t are independently selected from integers of 0-5; Among them, D 1 ,D 2 are independently selected from -O-, -S-, -SO-, -SO 2 -、-NR 6 -、-NCOR 6 -、-NSO 2 R 7 -、-CR 6 X 1 -、-CR 6 R 7 -; where R 6 , R 7 are independently selected from H, halogen, hydroxy, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino or R 6 , R 7 Connect into a ring; Among them, X 1 For-OR 8 -、-NR 8 R 9 -、-NCOR 8 -、-NSO 2 R 9 -、-CR 8 R 9 -; where R 8 , R 9 are independently selected from H, substituted or unsubstituted C1-C6 alkyl, C3-C6 cycloalkyl; or R 8 and R 9 They can be connected to each other to form a ring; the substituted substituent is a hydroxyl group or an amino group.
15. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: In the TB portion of the compound, R 1 ,R 2 Each of the following structures is independently selected from hydrogen, trifluoromethyl or any of the following structures: methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, amino, methylamino, ethylamino, propylamino, isopropylamino, cyclopropylamino, cyclobutylamino, hydroxyethylamino, 1-hydroxymethylcyclopropylamino, N,N-dimethylamino, N,N-diethylamino, formyl, acetyl, propionyl, isopropylamino, cyclopropionyl, 1-hydroxymethyl, 1 -hydroxyethyl, 1-hydroxypropyl, 1-hydroxyisopropyl, 1-hydroxycyclopropyl, aminoacyl, N-methylaminoacyl, N-ethylaminoacyl, N,N-dimethylacyl, azetidinyl acyl, tetrahydropyrrolyl acyl, methoxyacyl, ethoxyacyl, azetidinyl, tetrahydropyrrole, piperidine, morpholine, piperazine, N-methylpiperazine, N-ethylpiperazine, N-cyclopropylpiperazine, 2-methylpiperazine, 3-methylpiperazine, 2,2-dimethylpiperazine, 3,3-dimethylpiperazine, 2,3-dimethylpiperazine, 16. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: TB part of which R 1 ,R 2 are independently selected from any of the following structures: hydrogen, fluorine, chlorine, bromine, iodine, methyl, amide, substituted or unsubstituted 1,2-oxadiazole, 1,3-oxadiazole, N-methyl-1,2-oxadiazole, N 1 -1,2,3-triazolyl, N 2 -1,2,3-triazolyl, 1,3,4-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,2-oxazolyl, 1,3-oxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,5-oxadiazolyl, 1,2-thiooxazolyl, 1,3-thiooxazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,5-thiadiazolyl, N 2 -4-Fluoro-1,2,3-triazolyl, N 2 -4-methyl-1,2,3-triazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl; the substituted substituents are halogen, hydroxyl, amino, C1-C6 alkoxy, C1-C6 alkylamino, cyano, amide, C1~C6 alkyl, C3-C6 cycloalkyl.
17. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: TB part of which R 1 ,R 2 Each of the following structures is independently selected: hydrogen, amino, methylamino, dimethylamino, methylthio, methanesulfonyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyridyl, fluorine, iodine, 2-methyl-1,3,4-oxadiazolyl, cyano, 5-methyl-1,2,4-oxadiazolyl, 1-hydroxyethyl, 1-hydroxypropyl, acetyl, propionyl, cyclopropanoyl, cyclobutanoyl, isopropanoyl, 1-hydroxyisopropyl, 1-hydroxyisobutyl, methoxyacyl, ethoxyacyl, 1-hydroxy methyl, methoxy, ethoxy, cyclopropyloxy, aminoacyl, N-methylaminoacyl, 1-methyl-1,2-oxadiazolyl, 1,2-oxadiazolyl, 1,3-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 3,5-dimethyl-1,2-oxadiazolyl, tetrahydropyrrolyl, 1,3,4-thiadiazolyl, 3-methyl-1,2,4-thiadiazolyl, hexahydropyridinyl, carboxyl, 1,3-thiazolyl, -NHCN, Wherein, R' is methyl, ethyl or cyclopropyl, R" is hydrogen or methyl; R"' and R"" are independently selected from: hydrogen, methyl, ethyl, or R"' and R"" are connected to form a methyl-substituted or unsubstituted 4-6 membered heterocyclic ring.
18. The compound according to claim 17, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: R 1 , R 2 Not for 19. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The compound TB part of which A section has any of the following structures:
20. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The TB portion is selected from any of the following structures:
21. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The U part is any of the following structures:
22. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof, Features: The U part is any of the following structures:
23. The following compound, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof:
24. A drug, It is characterized in that The invention relates to a preparation prepared by taking the compound described in any one of claims 1 to 23, or its pharmaceutically acceptable salt, or its tautomer, or its mixture as the active ingredient and adding pharmaceutically acceptable excipients.
25. Use of the compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a mixture thereof in the preparation of a protein degradation targeted chimera of an androgen receptor, wherein the androgen receptor is a mutant androgen receptor, and the protein degradation targeted chimera is a drug for treating a disease regulated by the androgen receptor, wherein the disease is drug-resistant cancer.
26. The use according to claim 25, It is characterized in that The protein degradation targeting chimera can target and recognize / bind to androgen receptor.
27. The use according to claim 25, It is characterized in that The protein degradation targeting chimera is capable of degrading androgen receptor.
28. The use according to claim 25, It is characterized in that The mutant androgen receptor includes a splice mutant androgen receptor and a point mutant androgen receptor.
29. The use according to claim 28, It is characterized in that The mutant androgen receptor is a spliced mutant androgen receptor AR-v7.
30. The use according to claim 25, It is characterized in that The cancer is an androgen receptor positive cancer.
31. The use according to claim 30, It is characterized in that The cancer is prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, endometrial cancer or salivary gland cancer.
Citation Information
Patent Citations
Ether compound and use thereof
CN111247138A
Regulating chimeric antigen receptors
CN111386263A
A class of difunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors, and application thereof
CN111825657A
Aromatic amine protein degradation chimeric compound targeting AR and BET and application
CN111944012A
Compounds and methods for treating diseases
CN116323570A
